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Preamble
It is important that the medical profession play a significant
role in critically evaluating the use of diagnostic procedures
and therapies as they are introduced and tested in the
detection, management, or prevention of disease states. Rig-
orous and expert analysis of the available data documenting
absolute and relative benefits and risks of those procedures
and therapies can produce helpful guidelines that improve the
effectiveness of care, optimize patient outcomes, and favor-
ably affect the overall cost of care by focusing resources on
the most effective strategies.
The American College of Cardiology (ACC) Foundation
and the American Heart Association (AHA) have jointly
engaged in the production of such guidelines in the area of
cardiovascular disease since 1980. The ACC/AHA Task
Force on Practice Guidelines, whose charge is to develop,
update, or revise practice guidelines for important cardiovas-
cular diseases and procedures, directs this effort. Writing
committees are charged with the task of performing an
assessment of the evidence and acting as an independent
group of authors to develop, update, or revise written recom-
mendations for clinical practice.
Experts in the subject under consideration have been
selected from both organizations to examine subject-specific
data and write guidelines. The process includes additional
representatives from other medical practitioner and specialty
groups when appropriate. Writing committees are specifically
charged to perform a formal literature review, weigh the
strength of evidence for or against a particular treatment or
procedure, and include estimates of expected health outcomes
where data exist. Patient-specific modifiers, comorbidities,
and issues of patient preference that may influence the choice
of particular tests or therapies are considered, as well as
frequency of follow-up and cost-effectiveness. When avail-
able, information from studies on cost will be considered;
however, review of data on efficacy and clinical outcomes
will constitute the primary basis for preparing recommenda-
tions in these guidelines.
The ACC/AHA Task Force on Practice Guidelines makes
every effort to avoid any actual, potential, or perceived
conflicts of interest that may arise as a result of an industry
relationship or personal interest of the writing committee.
Specifically, all members of the writing committee, as well as
peer reviewers of the document, were asked to provide
disclosure statements of all such relationships that may be
perceived as real or potential conflicts of interest. Writing
committee members are also strongly encouraged to declare a
previous relationship with industry that may be perceived as
relevant to guideline development. If a writing committee
member develops a new relationship with industry during
their tenure, they are required to notify guideline staff in
writing. The continued participation of the writing committee
member will be reviewed. These statements are reviewed by
the parent task force, reported orally to all members of the
writing committee at each meeting, and updated and reviewed
by the writing committee as changes occur. Please refer to the
methodology manual for ACC/AHA guideline writing com-
mittees, available on the ACC and AHA World Wide Web
sites (http://www.acc.org/qualityandscience/clinical/manual/
manual_I.htm and http://circ.ahajournals.org/manual/), for
further description of the policy on relationships with indus-
try. Please see Appendix I for author relationships with
industry and Appendix II for peer reviewer relationships with
industry that are pertinent to these guidelines.
These practice guidelines are intended to assist healthcare
providers in clinical decision making by describing a range of
generally acceptable approaches for the diagnosis, manage-
ment, and prevention of specific diseases or conditions. These
guidelines attempt to define practices that meet the needs of
most patients in most circumstances. Clinical decision mak-
ing should consider the quality and availability of expertise in
the area where care is provided. These guideline recommen-
dations reflect a consensus of expert opinion after a thorough
review of the available, current scientific evidence and are
intended to improve patient care.
Patient adherence to prescribed and agreed on medical
regimens and lifestyles is an important aspect of treatment.
Prescribed courses of treatment in accordance with these
recommendations will only be effective if they are followed.
Because lack of patient understanding and adherence may
adversely affect treatment outcomes, physicians and other
healthcare providers should make every effort to engage the
patient in active participation with prescribed medical regi-
mens and lifestyles.
If these guidelines are used as the basis for regulatory or
payer decisions, the ultimate goal is quality of care and
serving the patient’s best interests. The ultimate judgment
regarding care of a particular patient must be made by the
healthcare provider and the patient in light of all of the
circumstances presented by that patient. There are circum-
stances in which deviations from these guidelines are
appropriate.
The guidelines will be reviewed annually by the ACC/AHA
Task Force on Practice Guidelines and will be considered
current unless they are updated, revised, or sunsetted and
withdrawn from distribution. The executive summary and rec-
ommendations are published in the October 23, 2007, issue of
the Journal of the American College of Cardiology and October
23, 2007, issue of Circulation. The full text-guidelines are
e-published in the same issue of the journals noted above, as well
as posted on the ACC (www.acc.org) and AHA (www.ameri-
canheart.org) Web sites. Copies of the full text and the executive
summary are available from both organizations.
Sidney C. Smith, Jr, MD, FACC, FAHA
Chair, ACC/AHA Task Force on Practice Guidelines
Alice K. Jacobs, MD, FACC, FAHA,
Vice Chair, ACC/AHA Task Force on Practice Guidelines
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1. Definition of the Problem
1.1. Purpose of These Guidelines
These guidelines are intended for physicians and nonphysi-
cian caregivers who are involved in the preoperative, opera-
tive, and postoperative care of patients undergoing noncar-
diac surgery. They provide a framework for considering
cardiac risk of noncardiac surgery in a variety of patient and
surgical situations. The writing committee that prepared these
guidelines strove to incorporate what is currently known
about perioperative risk and how this knowledge can be used
in the individual patient.
The tables and algorithms provide quick references for
decision making. The overriding theme of this document is
that intervention is rarely necessary to simply lower the risk
of surgery unless such intervention is indicated irrespective of
the preoperative context. The purpose of preoperative evalu-
ation is not to give medical clearance but rather to perform an
evaluation of the patient’s current medical status; make
recommendations concerning the evaluation, management,
and risk of cardiac problems over the entire perioperative
period; and provide a clinical risk profile that the patient,
primary physician, and nonphysician caregivers, anesthesiol-
ogist, and surgeon can use in making treatment decisions that
may influence short- and long-term cardiac outcomes. No test
should be performed unless it is likely to influence patient
treatment. The goal of the consultation is the optimal care of
the patient.
1.2. Methodology and Evidence
The ACC/AHA Committee to Revise the 2002 Guidelines on
Perioperative Cardiovascular Evaluation for Noncardiac Sur-
gery conducted a comprehensive review of the literature
relevant to perioperative cardiac evaluation published since
the last publication of these guidelines in 2002. Literature
searches were conducted in the following databases: PubMed,
MEDLINE, and the Cochrane Library (including the Co-
chrane Database of Systematic Reviews and the Cochrane
Controlled Trials Register). Searches were limited to the
English language, the years 2002 through 2007, and human
subjects. Related-article searches were conducted in MED-
LINE to find additional relevant articles. Finally, committee
members recommended applicable articles outside the scope
of the formal searches.
Major search topics included perioperative risk, cardiac
risk, noncardiac surgery, intraoperative risk, postoperative
risk, risk stratification, cardiac complication, cardiac evalua-
tion, perioperative care, preoperative evaluation, preoperative
assessment, and intraoperative complications. Additional
searches cross-referenced these topics with the following
subtopics: troponin, myocardial infarction (MI), myocardial
ischemia, Duke activity status index, functional capacity,
dobutamine, adenosine, venous thrombosis, thromboembo-
lism, warfarin, percutaneous transluminal coronary angio-
plasty (PTCA), stent, adrenergic beta agonists, echocardiog-
raphy, anticoagulant, beta blocker, coronary artery bypass
surgery, valve, diabetes mellitus, wound infection, blood
sugar control, normothermia, body temperature changes,
body temperature regulation, hypertension, pulmonary hyper-
tension, anemia, aspirin, arrhythmia, implantable defibrilla-
tor, artificial pacemaker, pulmonary artery catheters, Swan-
Ganz catheter, and platelet aggregation inhibitors.
As a result of these searches, more than 400 relevant, new
articles were identified and reviewed by the committee for the
revision of these guidelines. Using evidence-based method-
ologies developed by the ACC/AHA Task Force on Practice
Guidelines, the committee revised the guidelines text and
recommendations.
All of the recommendations in this guideline revision were
converted from the tabular format used in the 2002 guidelines
to a listing of recommendations that has been written in full
sentences to express a complete thought, such that a recom-
mendation, even if separated and presented apart from the rest
of the document, would still convey the full intent of the
recommendation. It is hoped that this will increase the
reader’s comprehension of the guidelines. Also, the level of
evidence, either an A, B, or C, for each recommendation is
now provided.
The schema for classification of recommendations and
level of evidence are summarized in Table 1, which also
illustrates how the grading system provides an estimate of the
size of treatment effect and an estimate of the certainty of the
treatment effect.
1.3. Epidemiology
The prevalence of cardiovascular disease increases with age,
and it is estimated that the number of persons older than 65
years in the United States will increase 25% to 35% over the
next 30 years (1). Coincidentally, this is the same age group
in which the largest number of surgical procedures is per-
formed (2). Thus, it is conceivable that the number of
noncardiac surgical procedures performed in older persons
will increase from the current 6 million to nearly 12 million
per year, and nearly one fourth of these—major intra-
abdominal, thoracic, vascular, and orthopedic procedures—
have been associated with significant perioperative cardio-
vascular morbidity and mortality.
1.4. Practice Patterns
There are few reliable data available regarding 1) how often a
family physician, general internist, physician extender, special-
ist, or surgeon performs a preoperative evaluation on his or her
own patient without a formal cardiovascular consultation and 2)
how often a formal preoperative consultation is requested from
either a generalist or a subspecialist such as a cardiologist for
different types of surgical procedures and different categories of
patients. The actual patterns of practice with regard to the
practitioner performing the evaluation and utilization of testing
varies widely, suggesting the need to determine which practices
lead to the best clinical and economic outcomes (3). There is an
important need to determine the relative cost-effectiveness of
different strategies of perioperative evaluation. In many institu-
tions, patients are evaluated in an anesthesia preoperative eval-
uation setting. If sufficient information about the patient’s
cardiovascular status is available, the symptoms are stable, and
further evaluation will not influence perioperative management,
a formal consultation may not be required or obtained. This is
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facilitated by communication between anesthesia personnel and
physicians responsible for the patient’s cardiovascular care.
1.5. Financial Implications
The financial implications of risk stratification cannot be
ignored. The need for better methods of objectively measur-
ing cardiovascular risk has led to the development of multiple
noninvasive techniques in addition to established invasive
procedures. Although a variety of strategies to assess and
lower cardiac risk have been developed, their aggregate cost
has received relatively little attention. Given the striking
practice variation and high costs associated with many
evaluation strategies, the development of practice guidelines
based on currently available knowledge can serve to foster
more efficient approaches to perioperative evaluation.
2. General Approach to the Patient
This guideline focuses on the evaluation of the patient undergo-
ing noncardiac surgery who is at risk for perioperative cardiac
morbidity or mortality. In patients with known coronary artery
disease (CAD) or the new onset of signs or symptoms suggestive
of CAD, baseline cardiac assessment should be performed. In
the asymptomatic patient, a more extensive assessment of
history and physical examination is warranted in those individ-
uals 50 years of age or older, because the evidence related to the
determination of cardiac risk factors and derivation of a Revised
Cardiac Risk Index occurred in this population (4). Preoperative
cardiac evaluation must therefore be carefully tailored to the
circumstances that have prompted the evaluation and to the
nature of the surgical illness. Given an acute surgical emergency,
preoperative evaluation might have to be limited to simple and
critical tests, such as a rapid assessment of cardiovascular vital
signs, volume status, hematocrit, electrolytes, renal function,
urine analysis, and ECG. Only the most essential tests and
interventions are appropriate until the acute surgical emergency
is resolved. A more thorough evaluation can be conducted after
surgery. In patients in whom coronary revascularization is not an
option, it is often not necessary to perform a noninvasive stress
test. Under other, less urgent circumstances, the preoperative
cardiac evaluation may lead to a variety of responses, including
cancellation of an elective procedure.
2.1. Role of the Consultant
If a consultation is requested, then it is important to identify
the key questions and ensure that all of the perioperative
caregivers are considered when providing a response. Several
studies suggest that such an approach is not always taken. A
multiple-choice survey regarding the purposes and utility of
cardiology consultations was sent to randomly selected New
York metropolitan area anesthesiologists, surgeons, and car-
diologists (5). There was substantial disagreement on the
importance and purposes of a cardiology consultation; for
instance, intraoperative monitoring, “clearing the patient for
surgery,” and advising as to the safest type of anesthesia were
regarded as important by most cardiologists and surgeons but
as unimportant by anesthesiologists. In addition, the charts of
55 consecutive patients aged more than 50 years who re-
ceived preoperative cardiology consultations were examined
to determine the stated purpose of the consultation, recom-
mendations made, and concordance by surgeons and anesthe-
siologists with cardiologists’ recommendations. Of the cardi-
ology consultations, 40% contained no recommendations
other than “proceed with case,” “cleared for surgery,” or
“continue current medications.” A review of 146 medical
consultations suggests that the majority of such consultations
give little advice that truly impacts either perioperative
management or outcome of surgery (6). In only 5 consulta-
tions (3.4%) did the consultant identify a new finding; 62
consultations (42.5%) contained no recommendations.
Once a consultation has been obtained, the consultant
should review available patient data, obtain a history, and
perform a physical examination that includes a comprehen-
sive cardiovascular examination and elements pertinent to the
patient’s problem and the proposed surgery. The consultant
must not rely solely on the question that he or she has been
asked to answer but must provide a comprehensive evaluation
of the patient’s risk. The consultation may have been re-
quested for an ECG anomaly, chest pain, or arrhythmia that
may have been thought to be indicative of CAD but that the
consultant may determine is noncardiac in origin or benign,
therefore requiring no further evaluation. In contrast, the
consultation may lead to a suspicion of previously unsus-
pected CAD or heart failure (HF) in a patient scheduled for an
elective procedure, which justifies a more extensive evalua-
tion (7–9). A critical role of the consultant is to determine the
stability of the patient’s cardiovascular status and whether the
patient is in optimal medical condition, within the context of
the surgical illness. The consultant may recommend changes
in medication, suggest preoperative tests or procedures, or
propose higher levels of postoperative care. In some in-
stances, an additional diagnostic cardiac evaluation is neces-
sary on the basis of the results of the initial preoperative test.
In general, preoperative tests are recommended only if the
information obtained will result in a change in the surgical
procedure performed, a change in medical therapy or moni-
toring during or after surgery, or a postponement of surgery
until the cardiac condition can be corrected or stabilized.
Before suggesting an additional test, the consultant should
feel confident that the information will have the potential to
affect treatment. Redundancy should be avoided.
The consultant must also bear in mind that the periopera-
tive evaluation may be the ideal opportunity to effect the
long-term treatment of a patient with significant cardiac
disease or risk of such disease. The referring physician and
patient should be informed of the results of the evaluation and
implications for the patient’s prognosis. The consultant can
also assist in planning for follow-up, such as suggesting
additional therapies known to reduce long-term cardiovascu-
lar risk or setting up an office appointment. It is the
cardiovascular consultant’s responsibility to ensure clarity of
communication, such that findings and impressions will be
incorporated effectively into the patient’s overall plan of care.
This ideally would include direct communication with the
surgeon, anesthesiologist, and other physicians, as well as
frank discussion directly with the patient and, if appropri-
ate, the family. The consultant should not use phrases such
as “clear for surgery.” As is expected for good medical
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care in general, clear documentation in the medical record
is appropriate.
2.2. History
A history is crucial to the discovery of cardiac and/or
comorbid diseases that would place the patient in a high
surgical risk category. The history should seek to identify
serious cardiac conditions such as unstable coronary syn-
dromes, prior angina, recent or past MI, decompensated HF,
significant arrhythmias, and severe valvular disease (Table
2). It should also determine whether the patient has a prior
history of a pacemaker or implantable cardioverter defibril-
lator (ICD) or a history of orthostatic intolerance. Modifiable
risk factors for coronary heart disease (CHD) should be
recorded, along with evidence of associated diseases, such as
peripheral vascular disease, cerebrovascular disease, diabetes
mellitus, renal impairment, and chronic pulmonary dis-
ease. In patients with established cardiac disease, any
recent change in symptoms must be ascertained. Accurate
recording of current medications used, including herbal
and other nutritional supplements, and dosages is essential.
Use of alcohol, tobacco, and over-the-counter and illicit
drugs should be documented.
The history should also seek to determine the patient’s
functional capacity (Table 3). An assessment of an individu-
al’s capacity to perform a spectrum of common daily tasks
has been shown to correlate well with maximum oxygen
uptake by treadmill testing (11). A patient classified as high
risk owing to age or known CAD but who is asymptomatic
and runs for 30 minutes daily may need no further evaluation.
In contrast, a sedentary patient without a history of cardio-
vascular disease but with clinical factors that suggest in-
creased perioperative risk may benefit from a more extensive
preoperative evaluation (8,9,13,14). The preoperative consul-
tation may represent the first careful cardiovascular evalua-
tion for the patient in years or, in some instances, ever. For
example, inquiry regarding symptoms suggestive of angina or
anginal equivalents such as dyspnea or HF may establish or
suggest these diagnoses for the first time.
2.3. Physical Examination
A cardiovascular examination should include an assessment
of vital signs (including measurement of blood pressure in
both arms), carotid pulse contour and bruits, jugular venous
pressure and pulsations, auscultation of the lungs, precordial
palpation and auscultation, abdominal palpation, and exami-
nation of the extremities for edema and vascular integrity.
The presence of an implanted pacemaker or ICD can also be
confirmed by physical examination. More detailed observa-
tions will be dictated by specific circumstances. The follow-
ing points are worth emphasizing:
The general appearance provides invaluable evidence re-
garding the patient’s overall status. Cyanosis, pallor, dyspnea
during conversation or with minimal activity, Cheyne-Stokes
respiration, poor nutritional status, obesity, skeletal deformi-
ties, tremor, and anxiety are just a few of the clues of
underlying disease or CAD that can be recognized by the
skilled physician.
In patients with acute HF, rales and chest X-ray evidence
of pulmonary congestion correlate well with elevated pulmo-
nary venous pressure. However, in patients with chronic HF,
these findings may be absent. An elevated jugular venous
pressure or a positive hepatojugular reflux are more
reliable signs of hypervolemia in these patients (15,16).
Peripheral edema is not a reliable indicator of chronic HF
unless the jugular venous pressure is elevated or the
hepatojugular test is positive.
An examination of the carotid and other arterial pulses is
essential. The presence of associated vascular disease should
heighten suspicion of occult CAD. Cardiac auscultation will
often provide useful clues to underlying cardiac disease.
When present, a third heart sound at the apical area suggests
a failing left ventricle (LV), but its absence is not a reliable
indicator of good ventricular function (16). If a murmur is
present, the clinician will need to decide whether or not it
represents significant valvular disease. Detection of signifi-
cant aortic stenosis is of particular importance because this
lesion poses a higher risk for noncardiac surgery (17).
Significant mitral stenosis or regurgitation increases the risk
of HF. Aortic regurgitation and mitral regurgitation may be
minimal, yet they predispose the patient to infective endocar-
ditis should bacteremia occur after surgery. Recommenda-
Table 2. Active Cardiac Conditions for Which the Patient
Should Undergo Evaluation and Treatment Before Noncardiac
Surgery (Class I, Level of Evidence: B)
Condition Examples
Unstable coronary syndromes Unstable or severe angina* (CCS class
III or IV)†
Recent MI‡
Decompensated HF (NYHA
functional class IV; worsening or
new-onset HF)
Significant arrhythmias High-grade atrioventricular block
Mobitz II atrioventricular block
Third-degree atrioventricular heart
block
Symptomatic ventricular arrhythmias
Supraventricular arrhythmias (including
atrial fibrillation) with uncontrolled
ventricular rate (HR greater than 100
bpm at rest)
Symptomatic bradycardia
Newly recognized ventricular
tachycardia
Severe valvular disease Severe aortic stenosis (mean pressure
gradient greater than 40 mm Hg,
aortic valve area less than 1.0 cm2, or
symptomatic)
Symptomatic mitral stenosis
(progressive dyspnea on exertion,
exertional presyncope, or HF)
CCS indicates Canadian Cardiovascular Society; HF, heart failure; HR, heart
rate; MI, myocardial infarction; NYHA, New York Heart Association.
*According to Campeau (10).
†May include stable angina in patients who are unusually sedentary.
‡The American College of Cardiology National Database Library defines
recent MI as more than 7 days but less than or equal to 1 month (within 30
days).
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tions for endocarditis prophylaxis have been published else-
where (18) (see Section 3.5 Valvular Heart Disease).
2.4. Comorbid Diseases
The consultant must evaluate the cardiovascular system
within the framework of the patient’s overall health. Associ-
ated conditions often heighten the risk of anesthesia and may
complicate cardiac management. The most common of these
conditions are discussed below.
2.4.1. Pulmonary Disease
The presence of either obstructive or restrictive pulmonary
disease places the patient at increased risk of developing
perioperative respiratory complications. Hypoxemia, hyper-
capnia, acidosis, and increased work of breathing can all lead
to further deterioration of an already compromised cardiopul-
monary system. If significant pulmonary disease is suspected
by history or physical examination, determination of func-
tional capacity, response to bronchodilators, and/or evalua-
tion for the presence of carbon dioxide retention through
arterial blood gas analysis may be justified. If there is
evidence of infection, appropriate antibiotics are critical.
Steroids and bronchodilators may be indicated, although the
risk of producing arrhythmia or myocardial ischemia by beta
agonists must be considered. Recommendations for preoper-
ative chest radiographs can be found elsewhere (19).
2.4.2. Diabetes Mellitus
A variety of metabolic diseases may accompany cardiac
disease. Diabetes mellitus is the most common. Its presence
should heighten suspicion of CAD, particularly because CAD
and myocardial ischemia are more likely in patients with
diabetes mellitus (20–22). Lee et al identified insulin therapy
for diabetes mellitus as a significant risk factor for cardiac
morbidity (4). Older patients with diabetes mellitus are more
likely to develop HF postoperatively than those without
diabetes mellitus even after adjustment for treatment with
angiotensin-converting enzyme (ACE) inhibitors (23). Man-
agement of blood glucose levels in the perioperative period
may be difficult. Fragile patients with diabetes mellitus need
careful treatment with adjusted doses or infusions of short-
acting insulin based on frequent blood sugar determinations.
Historically, it has been acceptable to maintain relatively high
glucose levels perioperatively to avoid the attendant risks of
hypoglycemic episodes; however, aggressive perioperative
glucose control in coronary bypass surgery patients by a
continuous, intravenous insulin infusion was found to be
superior to intermittent subcutaneous insulin administration
in significantly reducing postoperative wound infection (24).
A similar benefit is less well established but may be found in
noncardiac surgery (25). A discussion of the perioperative
management of blood glucose concentration can be found in
Section 8.7.
2.4.3. Renal Impairment
Azotemia is commonly associated with cardiac disease and is
associated with an increased risk of cardiovascular events.
Maintenance of adequate intravascular volume for renal
perfusion during diuresis of a patient with HF is often
challenging. Excessive diuresis in combination with initiation
of ACE inhibitors or angiotensin receptor blockers may result
in an increase in blood urea nitrogen and serum creatinine
concentrations. In patients with known vascular disease, a
small increase in blood urea nitrogen and creatinine may
suggest the presence of renal artery stenosis. However, small
increases in blood urea nitrogen and serum creatinine con-
centrations are not an indication to discontinue these drugs,
because they have been shown to improve survival in patients
with HF due to systolic dysfunction. Preexisting renal disease
(preoperative serum creatinine levels 2 mg per dL or greater
Table 3. Estimated Energy Requirements for Various Activities
1 MET
Can you   
Take care of yourself? 4 METs
Can you   
Climb a flight of stairs or walk
up a hill?
4
™™
™™
™™
™™
™™
™™
™™
™™ Eat, dress, or use the toilet?
4
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™
™™ Walk on level ground at 4 mph
(6.4 kph)?
Walk indoors around the
house?
Run a short distance?
Walk a block or 2 on level
ground at 2 to 3 mph (3.2
to 4.8 kph)?
Do heavy work around the house
like scrubbing floors or lifting or
moving heavy furniture?
4 METs Do light work around the
house like dusting or
washing dishes?
Participate in moderate
recreational activities like golf,
bowling, dancing, doubles tennis,
or throwing a baseball or
football?
Greater
than 10
METs
Participate in strenuous sports
like swimming, singles tennis,
football, basketball, or skiing?
kph indicates kilometers per hour; MET, metabolic equivalent; and mph, miles per hour.
*Modified from Hlatky et al (11), copyright 1989, with permission from Elsevier, and adapted from
Fletcher et al (12).
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or reduced glomerular filtration rate) has been identified as a
risk factor for postoperative renal dysfunction and increased
long-term morbidity and mortality compared with patients
without renal disease (26,27). In coronary artery bypass
patients who are more than 70 years old, preoperative
creatinine levels greater than 2.6 mg per dL place the patient
at much greater risk for chronic dialysis postoperatively than
creatinine levels below 2.6 mg per dL (28). Intuitively, one
might extrapolate these findings to those older patients with
comparable creatinine levels who undergo major noncardiac
surgical procedures. One large study has shown that a
preoperative creatinine level greater than 2 mg per dL is a
significant, independent risk factor for cardiac complications
after major noncardiac surgery (4).
Creatinine clearance, another indicator of renal function,
has been used to predict postoperative complications (29,30).
Creatinine clearance incorporates serum creatinine, age, and
weight to provide a more accurate assessment of renal
function than serum creatinine alone. Kertai and colleagues
evaluated 852 subjects undergoing major vascular surgery
and demonstrated an increase in mortality as both serum
creatinine increased and creatinine clearance decreased, with
creatinine clearance providing a more accurate assessment
(29). To date, there has been no validation of this relationship
by other investigators or in a prospective study. The AHA, in
a scientific statement, advocated use of the Modification in
Diet in Renal Disease equation to calculate glomerular
filtration rate to determine kidney function (27).
2.4.4. Hematologic Disorders
Anemia imposes a stress on the cardiovascular system that
may exacerbate myocardial ischemia and aggravate HF (31).
Preoperative transfusion, when used appropriately in patients
with advanced CAD and/or HF, may reduce perioperative
cardiac morbidity. However, with current concern about
transfusion reaction, clerical error, or transmission of com-
municable disease through the use of blood products, a
conservative approach with respect to transfusion is war-
ranted. Hematocrits less than 28% are associated with an
increased incidence of perioperative ischemia and postoper-
ative complications in patients undergoing prostate and vas-
cular surgery (31–33). In the VA National Surgical Quality
Improvement Program database, mild degrees of preoperative
anemia or polycythemia were associated with an increased
risk of 30-day postoperative mortality and cardiac events in
older, mostly male veterans undergoing major noncardiac
surgery (34). The adjusted risk of 30-day postoperative
mortality and cardiac morbidity begins to rise when hemat-
ocrit levels decrease to less than 39% or exceed 51%.
Polycythemia, thrombocytosis, and other conditions that
increase viscosity and hypercoagulability may increase the
risk of thromboembolism or hemorrhage. Appropriate steps
to reduce these risks should be considered and tailored to the
individual patient’s particular circumstances. Current guide-
lines are available that address perioperative transfusion
practices (35).
2.5. Ancillary Studies
The consultant should review all pertinent available labora-
tory data. In the present era of cost containment, the labora-
tory data available may be minimal. Therefore, the consultant
may require additional tests such as blood chemistries and a
chest x-ray on the basis of history and physical examination.
Blood levels of cardiac drugs should be obtained only when
there are specific indications, such as changes in renal function,
a recent change in dose, or symptoms that suggest toxicity.
The ECG is frequently obtained as part of a preoperative
evaluation in all patients over a specific age or undergoing a
specific set of procedures. Section 5.2.1 identifies the indi-
cations for a preoperative ECG based on the available
evidence. An abnormal ECG report is often the reason that
consultation is requested, but if not previously done, an ECG
should be obtained as part of the consultation. Metabolic and
electrolyte disturbances, medications, intracranial disease,
and pulmonary disease, among other things, can alter the
ECG. Conduction disturbances, such as right bundle-branch
block or first-degree atrioventricular block, may lead to
concern but usually do not justify further workup. The same
is often true of asymptomatic ventricular arrhythmias, even in
the presence of structural heart disease (36,37). On the other
hand, subtle ECG clues can point to a clinically silent
condition of major importance.
2.6. Multivariable Indices to Predict
Preoperative Cardiac Morbidity
The basic clinical evaluation obtained by history, physical
examination, and review of the ECG usually provides the
consultant with sufficient data to estimate cardiac risk. In an
attempt to codify those clinical and laboratory factors that
influence outcome, numerous investigators have developed
risk indices over the past 25 years based on multivariable
analyses (17,38–47). Although some authors have suggested
a scoring system that assigns more weight to some factors
than others and sums these to arrive at a composite risk
(17,45,47), most recent articles have suggested simpler crite-
ria (4,38–44). Lee et al derived and validated a “simple
index” for the prediction of cardiac risk for stable patients
undergoing nonurgent major noncardiac surgery (4). Six
independent risk correlates were identified: ischemic heart
disease (defined as history of MI, history of positive treadmill
test, use of nitroglycerin, current complaints of chest pain
thought to be secondary to coronary ischemia, or ECG with
abnormal Q waves); congestive HF (defined as history of HF,
pulmonary edema, paroxysmal nocturnal dyspnea, peripheral
edema, bilateral rales, S3, or X-ray with pulmonary vascular
redistribution); cerebral vascular disease (history of transient
ischemic attack or stroke); high-risk surgery (abdominal
aortic aneurysm or other vascular, thoracic, abdominal, or
orthopedic surgery); preoperative insulin treatment for diabe-
tes mellitus; and preoperative creatinine greater than 2 mg per
dL. Increasing numbers of risk factors correlated with in-
creased risk, yet the risk was substantially lower than de-
scribed in many of the original indices (4). These improve-
ments in outcome most likely reflect selection bias with
respect to who presents for elective surgery, advances in
surgical technique and anesthesia, and advances in the man-
agement of CAD both perioperatively and in general. The
Revised Cardiac Risk Index has become one of the most
widely used risk indices (4).
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2.7. Clinical Assessment
In the original guidelines, the committee chose to segre-
gate clinical risk factors into major, intermediate, and
minor risk factors. There continues to be a group of active
cardiac conditions that when present indicate major clini-
cal risk. The presence of 1 or more of these conditions
mandates intensive management and may result in delay or
cancellation of surgery unless the surgery is emergent
(Table 2). These include
● unstable coronary syndromes,
 unstable or severe angina,
 recent MI,
● decompensated HF,
● significant arrhythmias, and
● severe valvular disease.
Given the increasing use of the Revised Cardiac Risk
Index, the committee chose to replace the intermediate-risk
category with the clinical risk factors from the index, with the
exclusion of the type of surgery, which is incorporated
elsewhere in the approach to the patient. Clinical risk factors
include
● history of ischemic heart disease,
● history of compensated or prior HF,
● history of cerebrovascular disease,
● diabetes mellitus, and
● renal insufficiency (4).
A history of MI or abnormal Q waves by ECG is listed as
a clinical risk factor, whereas an acute MI (defined as at least
1 documented MI 7 days or less before the examination) or
recent MI (more than 7 days but less than or equal to 1 month
before the examination) with evidence of important ischemic
risk by clinical symptoms or noninvasive study is an active
cardiac condition. This definition reflects the consensus of the
ACC Cardiovascular Database Committee. In this way, the
separation of MI into the traditional 3- and 6-month intervals
has been avoided (17,48). Current management of MI pro-
vides for risk stratification during convalescence (49). If a
recent stress test does not indicate residual myocardium at
risk, the likelihood of reinfarction after noncardiac surgery is
low. Although there are no adequate clinical trials on which
to base firm recommendations, it appears reasonable to wait
4 to 6 weeks after MI to perform elective surgery.
Minor predictors are recognized markers for cardiovascular
disease that have not been proven to increase perioperative risk
independently, for example, advanced age (greater than 70
years), abnormal ECG (LV hypertrophy, left bundle-branch
block, ST-T abnormalities), rhythm other than sinus, and uncon-
trolled systemic hypertension. The presence of multiple minor
predictors might lead to a higher suspicion of CAD but is not
incorporated into the recommendations for treatment.
2.7.1. Stepwise Approach to Perioperative Cardiac
Assessment
Recommendations for Perioperative Cardiac Assessment
CLASS I
1. Patients who have a need for emergency noncardiac surgery
should proceed to the operating room and continue perioperative
surveillance and postoperative risk stratification and risk factor
management. (Level of Evidence: C)
2. Patients with active cardiac conditions* should be evaluated and
treated per ACC/AHA guidelines and, if appropriate, consider
proceeding to the operating room. (Level of Evidence: B)
3. Patients undergoing low risk surgery are recommended to pro-
ceed to planned surgery.† (Level of Evidence: B)
4. Patients with poor (less than 4 METs) or unknown functional
capacity and no clinical risk factors‡ should proceed with
planned surgery.† (Level of Evidence: B)
CLASS IIa
1. It is probably recommended that patients with functional capacity
greater than or equal to 4 METs without symptoms§ proceed to
planned surgery. (Level of Evidence: B)
2. It is probably recommended that patients with poor (less than 4
METs) or unknown functional capacity and 3 or more clinical
risk factors‡ who are scheduled for vascular surgery consider
testing if it will change management.¶ (Level of Evidence: B)
3. It is probably recommended that patients with poor (less than
4 METs) or unknown functional capacity and 3 or more clinical
risk factors‡ who are scheduled for intermediate risk surgery
proceed with planned surgery with heart rate control.¶ (Level of
Evidence: B)
4. It is probably recommended that patients with poor (less than
4 METs) or unknown functional capacity and 1 or 2 clinical risk
factors‡ who are scheduled for vascular or intermediate risk
surgery proceed with planned surgery with heart rate control.¶
(Level of Evidence: B)
CLASS IIb
1. Noninvasive testing might be considered if it will change manage-
ment for patients with poor (less than 4 METs) or unknown
functional capacity and 3 or more clinical risk factors‡ who are
scheduled for intermediate risk surgery. (Level of Evidence: B)
2. Noninvasive testing might be considered if it will change manage-
ment for patients with poor (less than 4 METs) or unknown
functional capacity and 1 or 2 clinical risk factors‡ who are
scheduled for vascular or intermediate risk surgery. (Level of
Evidence: B)
Figure 1 presents, in algorithmic form, a framework for
determining which patients are candidates for cardiac testing.
The clinician must consider several interacting variables and
give them appropriate weight. Since publication of the
perioperative cardiovascular evaluation guidelines in 2002
(50), several new randomized trials and cohort studies have
*See Table 2 for active clinical conditions. †See Class III recommen-
dations in section 5.2.3. Noninvasive Stress Testing in full text guideline.
‡Clinical risk factors include: ischemic heart disease, compensated or
prior heart failure, diabetes mellitus, renal insufficiency, and cerebrovas-
cular disease. §See Table 3 for estimated MET level equivalent.
Noninvasive testing may be considered before surgery in specific
patients with risk factors if it will change management. ¶Consider
perioperative beta-blockade (see Table 12) for populations in which this
has been shown to reduce cardiac morbidity/mortality.
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led to modification of the original algorithm. Given the
availability of this evidence, the writing committee chose to
include the level of the recommendations and strength of
evidence for each of the pathways.
Step 1: The consultant should determine the urgency of
noncardiac surgery. In many instances, patient- or surgery-
specific factors dictate an obvious strategy (eg, emergency
surgery) that may not allow for further cardiac assessment or
treatment. In such cases, the consultant may function best by
providing recommendations for perioperative medical man-
agement and surveillance. Selected postoperative risk strati-
fication is often appropriate in patients with elevated risk for
long-term coronary events who have never had such an
assessment before. This is usually initiated after the patient
has recovered from blood loss, deconditioning, and other
postoperative complications that might confound interpreta-
tion of noninvasive test results.
Step 2: Does the patient have 1 of the active cardiac
conditions in Table 2? If not, proceed to step 3. In patients
being considered for elective noncardiac surgery, the pres-
ence of unstable coronary disease, decompensated HF, or
severe arrhythmia or valvular heart disease usually leads to
cancellation or delay of surgery until the cardiac problem has
been clarified and treated appropriately. Examples of unstable
coronary syndromes include previous MI with evidence of
important ischemic risk by clinical symptoms or noninvasive
study, unstable or severe angina, and new or poorly con-
trolled ischemia-mediated HF. Many patients in these circum-
stances are referred for coronary angiography to assess
further therapeutic options. Depending on the results of the
test or interventions and the risk of delaying surgery, it may
be appropriate to proceed to the planned surgery with
maximal medical therapy.
Step 3: Is the patient undergoing low-risk surgery? Many
procedures are associated with a combined morbidity and
mortality rate less than 1% (see Section 4), even in high-risk
patients. Additionally, mortality on the day of surgery, for
most ambulatory surgical procedures, is actually lower than
mortality on day 30, which suggests that the incremental risk
of ambulatory surgery is negligible or may be protective (51).
Figure 1. Cardiac evaluation and care algorithm for noncardiac surgery based on active clinical conditions, known cardiovascular dis-
ease, or cardiac risk factors for patients 50 years of age or greater. *See Table 2 for active clinical conditions. †See Class III recom-
mendations in Section 5.2.3. Noninvasive Stress Testing. ‡See Table 3 for estimated MET level equivalent. §Noninvasive testing may
be considered before surgery in specific patients with risk factors if it will change management. Clinical risk factors include ischemic
heart disease, compensated or prior heart failure, diabetes mellitus, renal insufficiency, and cerebrovascular disease. ¶Consider periop-
erative beta blockade (see Table 12) for populations in which this has been shown to reduce cardiac morbidity/mortality. ACC/AHA
indicates American College of Cardiology/American Heart Association; HR, heart rate; LOE, level of evidence; and MET, metabolic
equivalent.
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Therefore, interventions based on cardiovascular testing in
stable patients would rarely result in a change in manage-
ment, and it would be appropriate to proceed with the planned
surgical procedure.
Step 4: Does the patient have a functional capacity greater
than or equal to 4 METs, without symptoms? Functional
status has been shown to be reliable for perioperative and
long-term prediction of cardiac events (52–56). In highly
functional asymptomatic patients, management will rarely be
changed based on the results of any further cardiovascular
testing. It is therefore appropriate to proceed with the planned
surgery. In patients with known cardiovascular disease or at
least 1 clinical risk factor, perioperative heart rate control with
beta blockade appears appropriate as outlined in Section 7.2.
If the patient has not had a recent exercise test, functional
status can usually be estimated from the ability to perform
activities of daily living (55). Functional capacity can be
expressed as metabolic equivalents (METs); the resting or
basal oxygen consumption (VO2) of a 70-kg, 40-year-old man
in a resting state is 3.5 mL per kg per min, or 1 MET. For this
purpose, functional capacity has been classified as excellent
(greater than 10 METs), good (7 to 10 METs), moderate (4 to
6 METs), poor (less than 4 METs), or unknown. Multiples of
the baseline MET values provide a uniform terminology
across different exercise protocols to express aerobic de-
mands for specific activities. Maximum and submaximum
levels of work differ per unit of time according to the exercise
protocol used. Thus, 6 minutes of a Naughton protocol is not
equivalent to 6 minutes on a standard Bruce protocol in terms
of work performed and energy expended. The predicted MET
level for a certain activity is influenced by the degree of
conditioning and genetic predisposition. Perioperative cardiac
and long-term risks are increased in patients unable to meet a
4-MET demand during most normal daily activities (55). In 1
series of 600 consecutive patients undergoing major noncar-
diac procedures, perioperative myocardial ischemia and car-
diovascular events were more common in patients who
reported poor exercise tolerance (inability to walk 4 blocks or
climb 2 flights of stairs), even after adjustment for baseline
characteristics known to be associated with increased risk
(55). The likelihood of a serious complication occurring was
inversely related to the number of blocks that could be
walked (P0.006) or flights of stairs that could be climbed
(P0.01). Examples of leisure activities associated with less
than 4 METs are slow ballroom dancing, golfing with a cart,
playing a musical instrument, and walking at a speed of
approximately 2 to 3 mph. Activities that require more than 4
METs include moderate cycling, climbing hills, ice skating,
roller blading, skiing, singles tennis, and jogging. The Duke
Activity Status Index contains questions that can be used to
estimate the patient’s functional capacity (11,52). Use of the
Duke Activity Status Index or other activity scales (53) and
knowledge of the METs levels required for physical activi-
ties, as listed above and described in Table 3, provide the
clinician with a relatively easy set of questions to estimate
whether a patient’s functional capacity will be less than or
greater than 4 METs. At activity levels less than 4 METs,
specific questions to establish risk gradients are less reliable.
Furthermore, a clinical questionnaire only estimates func-
tional capacity and does not provide as objective a measure-
ment as exercise treadmill testing or arm ergometry. Other
activity scales have been advocated, including the Specific
Activity Scale (57).
Step 5: If the patient has poor functional capacity, is
symptomatic, or has unknown functional capacity, then the
presence of clinical risk factors will determine the need for
further evaluation. If the patient has no clinical risk factors,
then it is appropriate to proceed with the planned surgery, and
no further change in management is indicated.
If the patient has 1 or 2 clinical risk factors, then it is
reasonable to either proceed with the planned surgery, with
heart rate control with beta blockade, or consider testing if it
will change management. Two studies in vascular surgery
patients with 1 to 2 clinical risk factors were unable to
demonstrate any difference in outcome in the group who
proceeded with the planned surgery with good medical
management or tight heart rate control, but there are circum-
stances in which the clinician may change aspects of care
based on the results of the test (58,59).
In patients with 3 or more clinical risk factors, the
surgery-specific cardiac risk is important. The surgery-
specific cardiac risk (Table 4) of noncardiac surgery is related
to 2 important factors. First, the type of surgery itself may
identify a patient with a greater likelihood of underlying heart
disease and higher perioperative morbidity and mortality.
Perhaps the most extensively studied example is vascular
surgery, in which underlying CAD is present in a substantial
portion of patients. If the patient is undergoing vascular
surgery, testing should only be considered if it will change
management. Other types of surgery may be associated with
similar risk to vascular surgery but have not been studied
extensively. For nonvascular surgery, the degree of hemody-
namic cardiac stress dictates the surgery-specific risk. De-
pending on the noncardiac surgical procedure, it may be
associated with profound alterations in heart rate, blood
pressure, vascular volume, pain, bleeding, clotting tenden-
Table 4. Cardiac Risk* Stratification for Noncardiac
Surgical Procedures
Risk Stratification Procedure Examples
Vascular (reported cardiac
risk often more than 5%)
Aortic and other major vascular surgery
Peripheral vascular surgery
Intermediate (reported
cardiac risk generally 1%
to 5%)
Intraperitoneal and intrathoracic surgery
Carotid endarterectomy
Head and neck surgery
Orthopedic surgery
Prostate surgery
Low† (reported cardiac
risk generally less than
1%)
Endoscopic procedures
Superficial procedure
Cataract surgery
Breast surgery
Ambulatory surgery
*Combined incidence of cardiac death and nonfatal myocardial infarction.
†These procedures do not generally require further preoperative cardiac
testing.
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cies, oxygenation, neurohumoral activation, and other pertur-
bations. The intensity of these coronary and myocardial
stressors helps determine the likelihood of perioperative
cardiac events. The perioperative morbidity related to the
procedures ranges from 1% to 5%. In these patients who are
considered ready to undergo intermediate-risk surgery, there
are insufficient data to determine the best strategy (proceed-
ing with the planned surgery with tight heart rate control with
beta blockade or further cardiovascular testing if it will
change management).
3. Disease-Specific Approaches
3.1. Coronary Artery Disease
3.1.1. Patients With Known CAD
In some patients, such as those with an acute MI, prior
coronary artery bypass grafting (CABG), coronary angio-
plasty, or a coronary angiogram that shows luminal obstruc-
tions or irregularities, the presence of CAD may be obvious.
On the other hand, many patients without cardiac symptoms
may have severe double- or triple-vessel disease that is not
clinically obvious because the patients may present atypically
or are functionally limited by severe arthritis or peripheral
vascular disease. A subset of patients who are candidates for
revascularization independent of planned noncardiac surgery
may benefit from noninvasive evaluation. In patients with
known CAD, as well as those with previously occult coronary
disease, the questions become 1) What is the amount of
myocardium in jeopardy? 2) What is the ischemic threshold,
ie, the amount of stress required to produce ischemia? 3)
What is the patient’s ventricular function? and 4) Is the
patient on his or her optimal medical regimen? Clarification
of these questions is an important goal of the preoperative
history and physical examination, and selected noninvasive
testing is used to determine the patient’s prognostic gradient
of ischemic response during stress testing() (Table 5). Given
recent evidence regarding the limited value of coronary
revascularization before noncardiac surgery (see Section 7.1),
the indication for preoperative testing is limited to the group
in whom coronary revascularization may be beneficial inde-
pendent of noncardiac surgery.
3.1.2. Influence of Age and Gender
Advanced age is a special risk, not only because of the increased
likelihood of coronary disease but also because of the effects of
aging on the myocardium. The mortality of acute MI increases
dramatically in the aged (69). Intraoperative or perioperative MI
has a higher mortality in the aged (17,44,45).
Gender is important because premenopausal women have a
lower incidence of CAD, and in general, symptomatic CAD
occurs 10 or more years later in women than in men (70).
Women who have premature menopause, such as after
oophorectomy, are an exception to this rule. Women with
diabetes mellitus have an increased risk that is equivalent to
men of the same age. The mortality rate after acute MI is
greater for women than for men, but older age and diabetes
mellitus account for much of this difference (71). Whether or
not other factors such as coronary artery size or different
pathophysiology also contribute to the increased risk in
women is not yet fully understood.
3.2. Hypertension
Numerous studies (17,38,41,44,72,73) have shown that stage
1 or stage 2 hypertension (systolic blood pressure below
180 mm Hg and diastolic blood pressure below 110 mm Hg)
is not an independent risk factor for perioperative cardiovas-
cular complications. However, hypertension is common, and
treatment has been shown to be associated with decreased
rates of death due to stroke and CHD in the nonsurgical
setting. Unfortunately, all too few patients with hypertension
are treated, and fewer yet have their hypertension controlled.
Table 5. Prognostic Gradient of Ischemic Responses During
an ECG-Monitored Exercise Test in Patients With Suspected or
Proven CAD
Risk Level Ischemic Response Gradient
High Ischemia induced by low-level exercise* (less
than 4 METs or heart rate less than 100 bpm or
less than 70% of age-predicted heart rate)
manifested by 1 or more of the following:
Horizontal or downsloping ST depression
greater than 0.1 mV
ST-segment elevation greater than 0.1 mV in
noninfarct lead
Five or more abnormal leads
Persistent ischemic response greater than
3 minutes after exertion
Typical angina
Exercise-induced decrease in systolic blood
pressure by 10 mm Hg
Intermediate Ischemia induced by moderate-level exercise†
(4 to 6 METs or heart rate 100 to 130 bpm 70%
to 85% of age-predicted heart rate) manifested
by 1 or more of the following:
Horizontal or downsloping ST depression
greater than 0.1 mV
Persistent ischemic response greater than 1 to
3 minutes after exertion
Three to 4 abnormal leads
Low No ischemia or ischemia induced at high-level
exercise† (greater than 7 METs or heart rate
greater than 130 bpm greater than 85% of
age-predicted heart rate) manifested by:
Horizontal or downsloping ST depression
greater than 0.1 mV
One or 2 abnormal leads
Inadequate test Inability to reach adequate target workload or
heart rate response for age without an ischemic
response. For patients undergoing noncardiac
surgery, the inability to exercise to at least the
intermediate-risk level without ischemia should
be considered an inadequate test.
bpm indicates beats per min; CAD, coronary artery disease; and MET,
metabolic equivalent.
*Workload and heart rate estimates for risk severity require adjustment for
patient age. Maximum target heart rates for 40- and 80-year-old subjects
taking no cardioactive medication are 180 and 140 bpm, respectively (61–68).
†Based on Weiner et al (61), Morris et al (62), Chaitman (63), Gianrossi et
al (64), Detrano et al (65), Mark et al (66), Mark et al (67), and Gibbons et al
(68).
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Accordingly, the perioperative evaluation is a unique oppor-
tunity to identify patients with hypertension and initiate
appropriate therapy. As a universally measured variable with
a recognized association with CAD, hypertension serves as a
useful marker for potential CAD (74). In addition, several
investigators have demonstrated exaggerated intraoperative
blood pressure fluctuation with associated ECG evidence of
myocardial ischemia in patients with preoperative blood
pressure elevation (75–78). This effect can be modified by
treatment (76–81). Because intraoperative ischemia corre-
lates with postoperative cardiac morbidity (72,82), it follows
that control of blood pressure preoperatively may help reduce
the tendency to perioperative ischemia. Although an elevated
blood pressure on an initial recording in a patient with
previously undiagnosed or untreated hypertension has been
shown to correlate with blood pressure lability under anesthesia
(82,83), the definition of the severity of hypertension rests with
subsequent recordings in a nonstressful environment (74). In
patients undergoing therapy for hypertension, a thorough review
of current medications and dosages, along with awareness of
known intolerance to previously prescribed drugs, is essential.
The physical examination should include a search for target-
organ damage and evidence of associated cardiovascular pathol-
ogy. A funduscopic examination may provide useful data re-
garding the severity and chronicity of hypertension.
The physical examination and simple laboratory tests can
rule out some of the rare but important causes of hyperten-
sion. Further evaluation to exclude secondary hypertension is
rarely warranted before necessary surgery. If pheochromocy-
toma is a serious possibility, surgery should be delayed to
permit its exclusion. A loud abdominal bruit may suggest
renal artery stenosis. A radial to femoral artery pulse delay
suggests coarctation of the aorta, whereas hypokalemia in the
absence of diuretic therapy raises the possibility of
hyperaldosteronism.
If the initial evaluation establishes hypertension as mild or
moderate, and there are no associated metabolic or cardio-
vascular abnormalities, there is no evidence that it is benefi-
cial to delay surgery (84). Several investigators have estab-
lished the value of effective preoperative blood pressure
control among patients with established hypertension
(77,78,81,85), and antihypertensive medications should be
continued during the perioperative period. Particular care
should be taken to avoid withdrawal of beta blockers and
clonidine because of potential heart rate or blood pressure
rebound (see Sections 7.2.1.3 and 7.2.3). In patients unable to
take oral medications, parenteral beta blockers and transder-
mal clonidine may be used. Medication selection and risks
should be assessed on the basis of national guidelines (74).
For stage 3 hypertension (systolic blood pressure greater
than or equal to 180 mm Hg and diastolic blood pressure
greater than or equal to 110 mm Hg), the potential benefits of
delaying surgery to optimize the effects of antihypertensive
medications should be weighed against the risk of delaying
the surgical procedure. With rapidly acting intravenous
agents, blood pressure can usually be controlled within a
matter of several hours. One randomized trial was unable to
demonstrate a benefit to delaying surgery. Weksler and
colleagues studied 989 chronically treated hypertensive pa-
tients who presented for noncardiac surgery with diastolic
blood pressure between 110 and 130 mm Hg who had no
previous MI, unstable or severe angina pectoris, renal failure,
pregnancy-induced hypertension, LV hypertrophy, previous
coronary revascularization, aortic stenosis, preoperative dys-
rhythmias, conduction defects, or stroke (86). The control
group had their surgery postponed, and they remained in the
hospital for blood pressure control, whereas the study patients
received 10 mg of nifedipine delivered intranasally. They
observed no statistically significant differences in postopera-
tive complications, which suggests that this subset of patients
without significant cardiovascular comorbidities can proceed
with surgery despite elevated blood pressure on the day of
surgery. Alternatively, beta blockers appear to be particularly
attractive agents for the treatment of preoperative high blood
pressure. Several reports have shown that the introduction of
preoperative beta-adrenergic blockers leads to effective mod-
ulation of severe blood pressure fluctuations and a reduction
in the number and duration of perioperative coronary ische-
mic episodes (76–81). The preoperative administration of
beta-adrenergic blocking drugs has been shown to decrease
the incidence of postoperative atrial fibrillation (87), and
in patients who have or are at risk for CAD who must
undergo noncardiac surgery, treatment with beta blockers
during hospitalization can reduce mortality and the inci-
dence of cardiovascular complications (88,89). A full
discussion of the benefits and risks of beta blockers can be
found in Section 7.2.1.
Interestingly, patients with preoperative hypertension ap-
pear more likely to develop intraoperative hypotension than
nonhypertensive persons; this is particularly true for patients
taking ACE inhibitors or angiotensin II receptor antagonists
(90). In some patients, this may be related to a decrease in
vascular volume. In 1 report, intraoperative hypotension was
associated with a greater incidence of perioperative cardiac
and renal complications than intraoperative hypertension,
although other studies have not shown this (78,91–96).
Several authors have suggested withholding ACE inhibi-
tors and angiotensin receptor antagonists the morning of
surgery (97–99). Consideration should be given to restart-
ing ACE inhibitors in the postoperative period only after
the patient is euvolemic, to decrease the risk of perioper-
ative renal dysfunction.
3.3. Heart Failure
Heart failure has been identified in several studies as being
associated with a poorer outcome when noncardiac surgery is
performed. In a study by Goldman et al (17), both the
presence of a third heart sound and signs of HF were
associated with a substantially increased risk during noncar-
diac surgery. Detsky et al (45) identified alveolar pulmonary
edema as a significant risk factor, and in the report by
Cooperman et al (47), HF also bestowed a significant risk.
Lee et al also identified HF (defined as the presence of any of
the following: history of congestive HF, pulmonary edema, or
paroxysmal nocturnal dyspnea; physical examination show-
ing bilateral rales or S3 gallop; or chest X-ray showing
pulmonary vascular redistribution) as an independent predic-
tor of risk (4). Every effort must be made to detect unsus-
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pected HF by a careful history and physical examination. If
possible, it is important to identify the cause of HF, because
this may have implications concerning risk of death versus
perioperative HF. For instance, prior HF due to hypertensive
heart disease may portend a different risk than prior HF that
results from CAD.
3.4. Cardiomyopathy
There is little information on the preoperative evaluation of
patients with cardiomyopathy before noncardiac surgery. At
this time, preoperative recommendations must be based on a
thorough understanding of the pathophysiology of the myo-
pathic process. Every reasonable effort should be made
before surgery to determine the cause of the primary myo-
cardial disease. Knowledge of the cause may alter intraoper-
ative and postoperative management of intravenous fluids. In
patients with a history or signs of HF, preoperative
assessment of LV function may be recommended to
quantify the severity of systolic and diastolic dysfunction.
This information is valuable for both intraoperative and
postoperative management. This assessment frequently
includes echocardiography.
Hypertrophic obstructive cardiomyopathy poses special
problems. Reduction of blood volume, decreased systemic
vascular resistance, and increased venous capacitance may
cause a reduction in LV volume and thereby potentially
increase a tendency to outflow obstruction, with potentially
untoward results. Furthermore, reduced filling pressures may
result in a significant fall in stroke volume because of the
decreased compliance of the hypertrophied ventricle. Beta-
adrenergic agonists should be avoided because they may
increase the degree of dynamic obstruction and decrease
diastolic filling. In a relatively small series of 35 patients with
hypertrophic obstructive cardiomyopathy, there were no
deaths or serious ventricular arrhythmias during or immedi-
ately after general surgical procedures; 1 patient had major
vascular surgery (100). In the 22 patients who underwent
catheterization, the mean rest and peak provocable gradients
were 30 and 81 mm Hg, respectively. The only patient who
had a perioperative MI had 2-vessel coronary disease. Sig-
nificant arrhythmias or hypotension that required vasocon-
strictors occurred in 14% and 13% of patients, respectively
(100). In another study, 77 patients with hypertrophic ob-
structive cardiomyopathy who underwent noncardiac surgery
were evaluated. There were no deaths, but these patients had
a significant incidence of adverse cardiac events, frequently
manifested as HF. Independent risk factors for adverse
outcome in all patients included major surgery and increasing
duration of surgery. Echocardiographic features, including
resting outflow tract gradient, were not associated with
adverse cardiac events (101).
3.5. Valvular Heart Disease
Cardiac murmurs are common in patients facing noncardiac
surgery. The consultant must be able to distinguish organic
from functional murmurs, significant from insignificant mur-
murs, and the origin of the murmur to determine which
patients require prophylaxis for endocarditis and which pa-
tients require further quantitation of the severity of the
valvular lesion. We recommend physicians review all of the
available data and use individual clinical judgment when
determining whether to recommend prophylaxis. Specific
recommendations for endocarditis prophylaxis have been
published elsewhere (18).
Severe aortic stenosis poses the greatest risk for noncardiac
surgery (17,102,103). If the aortic stenosis is symptomatic,
elective noncardiac surgery should generally be postponed or
canceled. Such patients require aortic valve replacement
before elective but necessary noncardiac surgery. If the aortic
stenosis is severe but asymptomatic, the surgery should be
postponed or canceled if the valve has not been evaluated
within the year. On the other hand, in patients with severe
aortic stenosis who refuse cardiac surgery or are otherwise
not candidates for aortic valve replacement, noncardiac sur-
gery can be performed with a mortality risk of approximately
10% (104,105). In a database analysis in which severity of
aortic stenosis was not defined, the presence of aortic stenosis
was associated with an increased risk of acute MI (odds ratio
[OR] 1.55) but not death after adjustment for other comor-
bidities (106). If a patient is not a candidate for valve
replacement, percutaneous balloon aortic valvuloplasty may
be reasonable as a bridge to surgery in hemodynamically
unstable adult patients with aortic stenosis who are at high
risk for aortic valve replacement surgery and may be reason-
able in adult patients with aortic stenosis in whom aortic
valve replacement cannot be performed because of serious
comorbid conditions (103,107).
Mitral stenosis, although increasingly rare, is important to
recognize. When stenosis is mild or moderate, the consultant
must ensure control of heart rate during the perioperative
period, because the reduction in diastolic filling period that
accompanies tachycardia can lead to severe pulmonary con-
gestion. Significant mitral stenosis increases the risk of HF.
However, preoperative surgical correction of mitral valve
disease is not indicated before noncardiac surgery unless the
valvular condition should be corrected to prolong survival
and prevent complications that are unrelated to the proposed
noncardiac surgery. When the stenosis is severe, the patient
may benefit from balloon mitral valvuloplasty or open surgi-
cal repair before high-risk surgery (108).
Aortic regurgitation suspected on examination warrants
qualification for long-term follow-up and indicated therapy.
If such qualification is not done, the regurgitation needs to be
identified, and provide appropriate medical treatment. Atten-
tion to volume control and afterload reduction is recom-
mended. In contrast to mitral stenosis, severe aortic regurgi-
tation is not benefited by unusually slow heart rates, which
can increase the volume of regurgitation by increasing the
duration of diastole. Tachycardia thus reduces the time of
regurgitation in severe aortic regurgitation.
Mitral regurgitation has many causes, the 2 most com-
mon being mitral valve prolapse that results from myxo-
matous degeneration and functional mitral regurgitation
that complicates postinfarction LV remodeling. Specific
recommendations regarding perioperative antibiotic pro-
phylaxis for patients with mitral valve prolapse can be
found elsewhere (18).
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Patients with severe mitral regurgitation (often manifested
clinically by an apical holosystolic murmur, a third heart
sound, and a diastolic flow rumble) may benefit from after-
load reduction and administration of diuretics to produce
maximal hemodynamic stabilization before high-risk surgery.
It is also important for the consultant to note even mild
reduction of the LV ejection fraction (LVEF) in patients with
mitral regurgitation, because LVEF may overestimate true
LV performance. In such patients, even a mildly reduced
LVEF may be a sign of reduced ventricular reserve. In
patients with persistent or permanent atrial fibrillation at high
risk for thromboembolism, preoperative and postoperative
therapy with intravenous heparin or subcutaneous low-
molecular-weight heparin may be considered to cover periods
of subtherapeutic anticoagulation (110,111–113). Patients
who have severe symptomatic mitral regurgitation or aortic
insufficiency should be considered for further evaluation.
These topics are discussed in more detail in the AHA/ACC
Valvular Heart Disease guidelines (103).
Patients with a mechanical prosthetic valve are of concern
because of the need for endocarditis prophylaxis (18) when
they undergo surgery that may result in bacteremia and the
need for careful anticoagulation management. The Seventh
American College of Chest Physicians Consensus Confer-
ence on Antithrombotic and Thrombolytic Therapy recom-
mends the following (114): For patients who require mini-
mally invasive procedures (dental work, superficial biopsies),
the recommendation is to briefly reduce the international
normalized ratio (INR) to the low or subtherapeutic range and
resume the normal dose of oral anticoagulation immediately
after the procedure. Perioperative unfractionated heparin
therapy is recommended for patients in whom the risk of
bleeding with oral anticoagulation is high and the risk of
thromboembolism without anticoagulation is also high (me-
chanical valve in the mitral position, Bjork-Shiley valve,
recent [ie, less than 1 year] thrombosis or embolus, or 3 or
more of the following risk factors: atrial fibrillation, previous
embolus at any time, hypercoagulable condition, mechanical
prosthesis, and LVEF less than 30% (115). For patients
between these 2 extremes, physicians must assess the risk and
benefit of reduced anticoagulation versus perioperative hep-
arin therapy.
3.6. Arrhythmias and Conduction Defects
Cardiac arrhythmias and conduction disturbances are not
uncommon findings in the perioperative period (17,39,116),
particularly in the elderly. Both supraventricular and ventric-
ular arrhythmias have been identified as independent risk
factors for coronary events in the perioperative period
(17,116). More recent detailed studies using continuous ECG
monitoring found that asymptomatic ventricular arrhythmias,
including couplets and nonsustained ventricular tachycardia,
were not associated with an increase in cardiac complications
after noncardiac surgery (37). Nevertheless, the presence of
an arrhythmia in the preoperative setting should provoke a
search for underlying cardiopulmonary disease, ongoing
myocardial ischemia or infarction, drug toxicity, or meta-
bolic derangements.
Some cardiac arrhythmias, although relatively benign, may
unmask underlying cardiac problems; for example, atrial
fibrillation and other types of supraventricular arrhythmias
can produce ischemia by increasing myocardial oxygen
demand in patients with coronary disease. Atrial fibrillation is
the most common type of sustained supraventricular
tachycardia, particularly in elderly patients who are likely to
be undergoing surgical procedures. Rarely, arrhythmias, be-
cause of the hemodynamic or metabolic derangements they
cause, may deteriorate into more life-threatening rhythm
disturbances; for example, atrial fibrillation with a rapid
ventricular response in a patient with an accessory bypass
pathway may degenerate into ventricular fibrillation. Ventric-
ular arrhythmias, whether single premature ventricular con-
tractions, complex ventricular ectopy, or nonsustained ven-
tricular tachycardia, usually do not require therapy unless
they result in hemodynamic compromise. Although frequent
ventricular premature beats and nonsustained ventricular
tachycardia are considered risk factors for the development of
intraoperative and postoperative arrhythmias and sustained
ventricular arrhythmias during long-term follow-up, they are
not associated with an increased risk of nonfatal MI or cardiac
death in the perioperative period (36,37). However, patients
who develop sustained and/or nonsustained ventricular
tachycardia during the perioperative period should be referred
to a cardiologist for further evaluation, including an evalua-
tion of their ventricular function and screening for CAD.
Physicians should have a low threshold to institute prophy-
lactic beta-blocker therapy in patients at increased risk of
developing a perioperative or postoperative supraventricular
or ventricular tachyarrhythmia. Several studies suggest
that beta-blocker therapy can reduce mortality and the
incidence of cardiovascular complications (including the
development of arrhythmias) during surgery and for up to
2 years afterward (87– 89,117).
High-grade cardiac conduction abnormalities, such as com-
plete atrioventricular block, if unanticipated, can increase
operative risk and may necessitate temporary or permanent
transvenous pacing. On the other hand, patients with intra-
ventricular conduction delays, even in the presence of a left or
right bundle-branch block, and no history of advanced heart
block or symptoms rarely progress to complete heart block
perioperatively (118). The availability of transthoracic pacing
units makes the decision for temporary transvenous pacing
less critical.
3.7. Implanted Pacemakers and ICDs
Each year, more than 250 000 patients undergo placement of
a permanent pacemaker, and more than 150 000 patients
undergo placement of an ICD. The presence of a pacemaker
or ICD has important implications regarding preoperative,
intraoperative, and postoperative patient management. The
situations in which device malfunction may occur, as well as
the techniques that may be used to prevent them, are
discussed in Section 7.5.
3.8. Pulmonary Vascular Disease and
Congenital Heart Disease
There are no reported studies that specifically assess the
perioperative risk associated with pulmonary vascular disease
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in patients having noncardiac surgery. A number of reports
have evaluated cardiovascular function many years after
surgery for congenital heart disease. Five years after surgery
for ventricular septal defect or patent ductus arteriosus,
pulmonary vasoreactivity often remains abnormal, resulting
in high pulmonary pressures with hypoxia. Such patients may
not tolerate intraoperative or postoperative hypoxia as well as
normal individuals.
Patients with congenital heart disease have also demon-
strated a reduced cardiac reserve during exercise (119).
Postoperative studies of patients with coarctation of the aorta
or tetralogy of Fallot have demonstrated findings consistent
with underlying ventricular dysfunction (120,121). These
observations should be kept in mind when such patients are
evaluated before noncardiac surgery. Patients receiving pri-
mary cardiac repair at a younger age in the present era may be
less prone to postoperative ventricular dysfunction because of
improved surgical techniques.
Although most experts agree that pulmonary hypertension
poses an increased risk for noncardiac surgery, no major
study of this has been performed. The only analogous
situation is labor and delivery for women with Eisenmenger
syndrome due to a congenital intracardiac shunt. Peripartum
mortality was reported to be between 30% and 70% in 1971,
but no recent data exist to clarify whether or not this has
fallen with improvements in care (122). In patients with
severe pulmonary hypertension and a cardiac shunt, systemic
hypotension results in increased right-to-left shunting and
predisposes the patient to development of acidosis, which can
lead to further decreases in systemic vascular resistance. This
cycle must be recognized and treated appropriately.
4. Surgery-Specific Issues
Cardiac complications after noncardiac surgery are a reflec-
tion of factors specific to the patient, the operation, and the
circumstances under which the operation is undertaken. To
the extent that preoperative cardiac evaluation reliably pre-
dicts postoperative cardiac outcomes, it may lead to interven-
tions that lower perioperative risk, decrease long-term mor-
tality, or alter the surgical decision-making process. Such
alterations might include either choosing a lower-risk, less-
invasive procedure or opting for nonoperative management
(eg, recommending an endovascular rather than open opera-
tive approach for a particular aneurysm or occlusive lesion,
electing to follow up rather than operate on a moderate-sized
[4 to 5 cm] infrarenal aortic aneurysm, or choosing nonop-
erative treatment for the disabled claudicant who has no
limb-threatening ischemia). Although different operations are
associated with different cardiac risks, these differences are
most often a reflection of the context in which the patient
undergoes surgery (stability or opportunity for adequate
preoperative preparation), surgery-specific factors (eg,
fluid shifts, stress levels, duration of procedure, or blood
loss), or patient-specific factors (the incidence of CAD
associated with the condition for which the patient is
undergoing surgery).
To the extent that preoperative cardiac evaluation can
identify potentially reducible cardiac risks, interventions
directed at reducing those risks might improve both short-
and long-term cardiac outcomes. The potential for improve-
ment in long-term outcomes is particularly relevant to oper-
ative decision making in patients undergoing surgery directed
at long-term goals. When, for example, surgery in asymp-
tomatic individuals is undertaken with the objective of
prolonging life (eg, elective repair of aortic aneurysm) or
preventing a future stroke (eg, carotid endarterectomy), the
decision to intervene must be made with the expectation that
the patient will live long enough to benefit from the prophy-
lactic intervention.
4.1. Urgency
Mangano (1) determined that cardiac complications are 2 to 5
times more likely to occur with emergency surgical proce-
dures than with elective operations. This finding is not
surprising, because the necessity for immediate surgical
intervention may make it impossible to evaluate and treat
such patients optimally. For instance, collected data have
confirmed that the composite mortality rate for elective repair
of patients with asymptomatic abdominal aortic aneurysms is
significantly lower (3.5%) than that for ruptured aneurysms
(42%) (123). The mortality rate for graft replacements of
symptomatic but intact abdominal aortic aneurysms remains
relatively high (19%) despite the fact that, like elective cases,
they are not associated with antecedent blood loss or hypo-
tension (124). Unfortunately, most true surgical emergencies
(eg, symptomatic abdominal aortic aneurysms, perforated
viscus, or major trauma) do not permit more than a cursory
cardiac evaluation.
In addition, some situations do not lend themselves to
comprehensive cardiac evaluation, although surgical care
may qualify as semielective. In some patients, the impending
danger of the disease is greater than the anticipated periop-
erative risk. Examples include patients who require arterial
bypass procedures for limb salvage or mesenteric revascular-
ization to prevent intestinal gangrene. Patients with malignant
neoplasms also pose a diagnostic and therapeutic dilemma
with respect to preoperative cardiac evaluation, especially
when it is difficult to determine whether the malignancy is
curable before surgical exploration. Each of these situations
illustrates the importance of close communication among
consultant, surgeon, and anesthesiologist to plan an approach
for cardiac assessment that is appropriate for the individual
patient and the underlying disease.
4.2. Surgical Risk
For elective surgery, cardiac risk can be stratified according
to a number of factors, including the magnitude of the
surgical procedure. Backer et al (125) encountered no cardiac
complications after 288 ophthalmologic procedures in 195
patients with a prior history of MI compared with a reinfarc-
tion rate of 6.1% for a number of nonophthalmologic surger-
ies at the same center. Indeed, large-scale studies have
supported the low morbidity and mortality rates in superficial
procedures performed on an ambulatory basis. For example,
Warner et al (126) determined the perioperative (30 day)
incidence of symptomatic MI and cardiac death in 38 500
patients who underwent 45 090 consecutive procedures with
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anesthetics. Fourteen perioperative MIs occurred (0.03%), of
which 2 resulted in death on postoperative day 7 after the
infarction. Two MIs occurred either intraoperatively or within
the first 8 hours, 1 of which was fatal. Using age- and
gender-adjusted annual incidence rates for MIs and sudden
death, the authors predicted that 17.8 MIs should have
occurred among this population during the study period,
which suggests that these events may have occurred indepen-
dent of the procedure. In contrast, Lee and colleagues (4)
reported that major perioperative cardiac events occurred in
1.4% of relatively unselected patients 50 years of age or older
undergoing elective noncardiac surgery that required hospital
admission. In a pooled analysis of prospective studies in
which patients who had or were at risk for cardiac disease
underwent at least 1 measurement of a cardiac enzyme or
cardiac biomarker after surgery, 3.9% experienced a major
perioperative cardiac event (127).
Several large surveys have demonstrated that perioperative
cardiac morbidity is particularly concentrated among patients
who undergo major thoracic, abdominal, or vascular surgery,
especially when they are 70 years of age or older (1,125,128–
130). Ashton et al (38) prospectively studied the incidence of
perioperative MI associated with thoracic, abdominal, uro-
logic, orthopedic, and vascular surgery in a cohort of 1487
men older than 40 years. The highest MI rate (4.1%; OR
10.39, 95% CI: 2.3 to 47.5) occurred in the subset of patients
with an established diagnosis of CAD. Nevertheless, inde-
pendent significant risk factors for infarction also included
age greater than 75 years (OR 4.77, 95% CI: 1.17 to 19.41)
and the need for elective vascular surgery even in the
absence of suspected CAD (adjusted OR 3.72, 95% CI:
1.12 to 12.37). An exception to this assumption is intratho-
racic surgery, notably for pulmonary neoplasm. This group
has a high incidence of tobacco consumption, a notable
risk factor for both lung cancer and atherosclerosis. In
addition, limitations with respect to exercise tolerance can
be due to either CAD, lung disease, or both, which makes
the assessment of CAD more difficult. It is advisable to
have a high index of suspicion of CAD in patients
undergoing intrathoracic surgery.
Few procedure-specific data are available regarding peri-
operative cardiac morbidity in most surgical specialties,
perhaps because advanced age and serious, incidental CAD
are assumed to be distributed randomly within groups of
patients who undergo noncardiac operations in such fields as
general surgery, orthopedics, urology, gynecology, and neu-
rosurgery. As shown by Ashton et al (38) and many others,
however, patients who require vascular surgery appear to
have an increased risk for cardiac complications because 1)
many of the risk factors that contribute to peripheral vascular
disease (eg, diabetes mellitus, tobacco use, and hyperlipid-
emia) are also risk factors for CAD; 2) the usual symptomatic
presentation for CAD in these patients may be obscured by
exercise limitations imposed by advanced age, intermittent
claudication, or both; and 3) major open vascular surgery may
be associated with substantial fluctuations in intravascular/
extravascular fluid volumes, cardiac filling pressures, sys-
temic blood pressure, heart rate, and thrombogenicity (1).
Several studies have attempted to stratify the incidence of
perioperative and long-term mortality and cardiac morbidity
according to the original type of vascular surgery performed.
Using the Medicare National Inpatient Sample from 1994
through 1999, Birkmeyer et al noted that in high-volume
hospitals, the perioperative mortality rates for carotid endar-
terectomy, lower-extremity bypass, and aneurysm surgery
were 1.5%, 4.1%, and 3.9%, respectively (131). In a prospec-
tive series of 53 aortic procedures and 87 infrainguinal bypass
grafts for which operative mortality rates were nearly identi-
cal (9% and 7%, respectively), Krupski et al (132) found that
the risk for fatal/nonfatal MI within a 2-year follow-up period
was 3.5 times higher (21% versus 6%) among patients who
received infrainguinal bypass grafts. This difference probably
is related to the fact that diabetes mellitus (44% versus 11%)
and history of previous MI (43% versus 28%), angina (36%
versus 15%), or HF (29% versus 9%) also were significantly
more prevalent in the infrainguinal bypass group. L’Italien et
al (133) have presented comparable data regarding the peri-
operative incidence of fatal or nonfatal MI and the 4-year
event-free survival rate after 321 aortic procedures, 177
infrainguinal bypass grafts, and 49 carotid endarterectomies.
Slight differences in the overall incidence of MI among the 3
surgical groups, which may have been related to the preva-
lence of diabetes mellitus, were less significant than the
influence of discrete cardiac risk factors (previous MI, an-
gina, HF, fixed or reversible myocardial perfusion imaging
defects, and ST-T depression during stress testing) (133).
Although these and other studies (8) suggest that the
clinical evidence of CAD in a patient who has peripheral
vascular disease appears to be a better predictor of subsequent
cardiac events than the particular type of peripheral vascular
operation to be performed, the introduction of endovascular
alternatives, either alone or in combination with an adjunctive
open surgical procedure, has led to a reduction in all-cause
perioperative mortality and morbidity. For example, the
DREAM (Dutch Randomized Endovascular Aneurysm Man-
agement) trial was a multicenter randomized trial of endo-
vascular abdominal aortic aneurysm repair versus open repair
in which 351 patients were randomized with aneurysms at
least 5 cm in diameter. Patients were enrolled if considered fit
for open repair and if they had suitable anatomy. Initial
results were reported in 2004 (134) and revealed a 30-day
operative mortality rate in favor of endovascular repair (1.7%
for endovascular repair versus 4.7% for open repair, relative
risk [RR] 3.9, 95% CI: 0.9 to 32.9, P0.10). However, 2-year
follow-up (135) demonstrated cumulative survival rates were
not significantly different between the 2 approaches (89.6%
for open repair versus 87.7% for endovascular repair). Sim-
ilar results were noted for the EVAR (EndoVascular Abdom-
inal aortic aneurysm Repair)-1 trial conducted in the United
Kingdom (136,137). Indeed, in a random sample of inpatient
Medicare claims from 2000 to 2003, endovascular abdominal
aortic aneurysm repair increased during this period to 41% of
all elective repairs in the United States, with a decline in
mortality from 5.0% to 3.7% (P less than 0.001) (124).
Likewise, recent clinical trials support the notion that endo-
vascular management of thoracic aneurysms dramatically
reduces all-cause perioperative mortality and morbidity; how-
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ever, the underlying cardiovascular disease may lead to
similar long-term outcomes (138).
Several studies have suggested that variations in surgical
mortality and morbidity are inversely related to hospital
volume. Nonetheless, the relative effect of hospital volume is
procedure-specific, even among relatively complex opera-
tions. Using information from the national Medicare claims
database and the Nationwide Inpatient Sample, Birkmeyer et
al (131) examined the mortality associated with 6 different
types of cardiovascular procedures and 8 types of major
cancer resections between 1994 and 1999. Absolute differ-
ences in adjusted mortality rates between very-low-volume
hospitals and very-high-volume hospitals ranged from more
than 12% for pancreatic resection (16.3% versus 3.8%) to
only 0.2% for carotid endarterectomy (1.7% versus 1.5%).
The absolute differences in adjusted mortality rates between
very-low-volume hospitals and very-high-volume hospitals
were greater than 5% for esophagectomy and pneumonec-
tomy; 2% to 5% for gastrectomy, cystectomy, repair of a
nonruptured abdominal aneurysm, and replacement of an
aortic or mitral valve; and less than 2% for coronary artery
bypass grafting, lower-extremity bypass, colectomy, lobec-
tomy, and nephrectomy (131). In a follow-up report, the
observed associations between hospital volume and operative
mortality for many of these procedures were largely mediated
by surgeon volume (139). Moreover, these investigators have
also noted that the higher operative mortality observed for
black patients across a wide range of surgical procedures is
due in large part to the higher mortality rates at the hospitals
they attend (140).
Some investigators suggest that community-wide quality
improvement initiatives may lead to improvement in care
processes and outcomes. For example, a significant decrease
in the combined event rate (30-day stroke or mortality) for
carotid endarterectomy procedures was observed in a
random sample of Medicare patients in 10 states during
initial (June 1, 1995, to May 31, 1996) and subsequent
(June 1, 1998, to May 31, 1999) reviews. Significant
state-to-state variation was present, however, with a com-
bined event rate for carotid endarterectomy alone that
ranged from 2.7% (Georgia) to 5.9% (Indiana) for all
indications combined, from 4.4% (Georgia) to 10.9%
(Michigan) in patients with recent transient ischemia or
stroke, from 1.4% (Georgia) to 6.0% (Oklahoma) in
patients with no symptoms, and from 3.7% (Georgia) to
7.9% (Indiana) in patients with nonspecific symptoms
(141). Although this may be related to other factors,
quality improvement is likely to be the strongest influence.
Given that the prevalence of CAD contributes substantially
to the perioperative risk of major surgical procedures, at least
some of the differences in surgical outcome from 1 hospital to
another may potentially be related to variations in the degree
to which CAD is recognized and treated appropriately. The
level of this awareness also has implications regarding
survival. In the prospectively randomized Veterans Admin-
istration Trial of Carotid Endarterectomy versus Nonopera-
tive Management for Asymptomatic Carotid Stenosis, for
example, more than 20% of both randomized cohorts died of
cardiac-related complications within a follow-up period of 4
years (142). Historically, Hertzer (9) observed in a selective
review of several thousand open vascular surgical procedures
(carotid endarterectomy, aortic aneurysm resection, and
lower-extremity revascularization) reported in the English
literature from 1970 to 1987 that cardiac complications were
responsible for approximately half of all perioperative deaths
and that fatal events were nearly 5-times more likely to occur
in the presence of standard preoperative indications of CAD.
Furthermore, the late (5-year) mortality rate for patients who
were suspected to have CAD was twice that for patients who
were not (approximately 40% versus 20%). It is intriguing
that in this report, both the perioperative and 5-year mortality
rates for patients who previously had coronary bypass surgery
were similar to the results reported for patients who had no
clinical indications of CAD at the time of peripheral vascular
surgery. Similarly, in the Coronary Artery Surgery Study
(CASS), which included 24 959 participants with known
CAD, prior CABG was associated with reduced cardiac risk
after noncardiac operations involving the thorax, abdomen,
vasculature, and head and neck (postoperative deaths 1.7%
versus 3.3%, MI 0.8% versus 2.7%) (60). Nonetheless, results
from the randomized, prospective Coronary Artery Revascu-
larization Prophylaxis (CARP) trial demonstrated that coro-
nary artery revascularization before elective major vascular
surgery did not improve long-term survival or alter early
postoperative outcomes, including death, MI, and length of
the hospital stay, among patients with stable CAD (143).
However, patients with a stenosis of the left main coronary
artery of greater than 50%, an LVEF of less than 20%, and
severe aortic stenosis were excluded from the trial. In contrast
to the CASS report, the lack of benefit for coronary artery
revascularization in the CARP trial was attributed to a
significant recent increase in use of beta blockers, antiplatelet
agents, ACE inhibitors, and statins (60,143). Indeed, Man-
gano et al and Poldermans et al documented the cardiopro-
tective effect of perioperative beta blockade in substantially
and significantly reducing cardiac morbidity and mortality in
high-risk patients undergoing major vascular surgery (88,89).
However, despite aggressive perioperative medical manage-
ment, the risk of early cardiac morbidity and late mortality
remains significant after major vascular surgery. For exam-
ple, in the CARP trial, the incidence of early MI was 8.4%,
with a median mortality of 23% at 27 months (143).
Patients undergoing major vascular surgery constitute a
particular challenge, because these are high-risk operations in
a patient population with a high prevalence of significant
CAD. There are, however, other surgical procedures for
which the interaction of patient-specific and surgery-specific
factors has been examined. Nonthoracic solid organ trans-
plantation generally represents a high-risk procedure in a
patient with multiple comorbidities. Significant CAD is
common in patients with diabetes mellitus who have end-
stage renal disease. In a study of 176 consecutive patients
undergoing either kidney or kidney-pancreas transplants,
there was a high correlation between adverse postoperative
cardiac events and preoperative documentation of reversible
defects on intravenous dipyridamole myocardial perfusion
imaging in combination with significant CAD on coronary
angiograms: 3 of 27 patients (11.1%) versus 1 of 111 patients
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(0.9%) with a normal dipyridamole myocardial perfusion
imaging (144). Similarly, in a review of 2694 adult renal
transplants performed at the University of Minnesota between
January 1, 1985, and December 31, 1998, there was an
overall incidence of cardiac complications of 6.1%, which
was significantly related to age greater than 50 years and
preexisting cardiac disease (145).
Although the prevalence of CAD is relatively low in
patients with end-stage liver disease who are undergoing liver
transplantation, 2 studies (146,147) have documented the
reliability of dobutamine stress echocardiography (DSE) in
predicting post-transplant cardiac events. Stress echocar-
diography has also been shown to be useful in predicting
cardiac outcomes in patients with advanced obstructive
pulmonary disease who are undergoing lung volume re-
duction surgery (148,149).
As Fleisher and Barash (150) have emphasized, the spe-
cific surgical setting must be considered within any algorithm
regarding preoperative cardiac evaluation. The term “noncar-
diac operation” is exceedingly broad in its definition; it
embraces aging patients with complex technical problems, as
well as younger patients scheduled for straightforward surgi-
cal procedures. As described above, cardiovascular morbidity
and mortality vary not only among procedures but also
among institutions for the same procedure. Therefore, in
assessing the risks and benefits of a perioperative intervention
strategy, risks associated with noncardiac surgery must be
individualized. It is important to remember, however, that the
indications for coronary intervention should not be redefined
simply because a patient who has CAD of marginal signifi-
cance also happens to require a major noncardiac procedure.
Conversely, the long-term implications of severe left main or
triple-vessel disease and diminished LV function are no less
ominous after a minor noncardiac operation than they are in
any other patient situation. In the final analysis, 1 of the
ultimate objectives of the preoperative cardiac assessment is
to exclude the presence of such serious CAD that some form
of direct intervention would be warranted even if no noncar-
diac operation were necessary. In this regard, the presentation
for noncardiac surgery may simply represent the first time
that a patient with overt or suspected CHD has had an
opportunity for cardiovascular assessment.
In summary, the surgical procedures have been classified
as low-risk, intermediate-risk, and vascular surgery. Although
coronary disease is the overwhelming risk factor for periop-
erative morbidity, procedures with different levels of stress
are associated with different levels of morbidity and mortal-
ity. Superficial and ophthalmologic procedures represent the
lowest risk and are rarely associated with excess morbidity
and mortality. Major vascular procedures represent the
highest-risk procedures and are now considered distinctly in
the decision to perform further evaluation because of the
large body of evidence regarding the value of perioperative
interventions in this population (Figure 1). Both endovascular
abdominal aortic aneurysm repair and carotid endarterectomy
should be considered within the intermediate-risk category
distinct from the open vascular surgery procedures on the
basis of preoperative morbidity and mortality rates, but
clinicians should incorporate the similarly poor long-term
survival that accompanies these procedures into their
decision-making processes. Within the intermediate-risk cat-
egory, morbidity and mortality vary depending on the surgi-
cal location and extent of the procedure. Some procedures
may be short, with minimal fluid shifts, whereas others may
be associated with prolonged duration, large fluid shifts, and
greater potential for postoperative myocardial ischemia and
respiratory depression. Therefore, the physician must exer-
cise judgment to correctly assess perioperative surgical risks
and the need for further evaluation.
5. Supplemental Preoperative Evaluation
5.1. Assessment of LV Function
Recommendations for Preoperative Noninvasive
Evaluation of LV Function
CLASS IIa
1. It is reasonable for patients with dyspnea of unknown origin
to undergo preoperative evaluation of LV function. (Level of
Evidence: C)
2. It is reasonable for patients with current or prior HF with
worsening dyspnea or other change in clinical status to un-
dergo preoperative evaluation of LV function if not performed
within 12 months. (Level of Evidence: C)
CLASS IIb
1. Reassessment of LV function in clinically stable patients with
previously documented cardiomyopathy is not well established.
(Level of Evidence: C)
CLASS III
1. Routine perioperative evaluation of LV function in patients is not
recommended. (Level of Evidence: B)
Resting LV function has been evaluated before noncardiac
surgery by radionuclide angiography, echocardiography, and
contrast ventriculography (46,151–160). Of 9 studies that
demonstrated a positive relation between decreased preoper-
ative ejection fraction and postoperative mortality or morbid-
ity, 6 were prospective (151,152,155,158,161,162), and 3
were retrospective (153,154,158).
Halm et al (161) studied a cohort of 339 men either with
documented ischemic heart disease or multiple risk factors
for CHD; 49% had clinically evident vascular disease. An
echocardiographic determination of LVEF less than 40% was
associated with all adverse perioperative outcomes (cardiac
death, nonfatal MI, unstable angina, congestive HF, and
ventricular tachycardia). In multivariable analysis that in-
cluded the clinical risk factors of definite CAD or history of
congestive HF, neither LVEF nor regional wall-motion score
added significant independent value in the prediction of
individual events such as postoperative cardiac death, nonfa-
tal MI, or HF (161).
In a study of 570 patients having transthoracic echocardi-
ography before major noncardiac surgery, Rohde and col-
leagues (162) found that any degree of LV systolic dysfunc-
tion was marginally associated with postoperative MI or
cardiogenic pulmonary edema (OR 2.1, 95% CI: 1.0 to 4.5;
P0.05). The finding of any degree of LV dysfunction had a
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poor sensitivity (43%) and positive predictive value (13%) in
predicting these events, with a specificity of 76% and
negative predictive value of 94%. This finding is concordant
with a subsequent meta-analysis (163) of 8 studies of preop-
erative resting LV function as assessed by radionuclide
angiography. In that study, Kertai et al found that LVEF less
than 35% had a sensitivity of 50% and a specificity of 91% in
the prediction of perioperative nonfatal MI or cardiac death
(163). The greatest risk of complications was observed in
patients with an LVEF at rest of less than 35%. In the
perioperative phase, poor LV systolic or diastolic function is
mainly predictive of postoperative HF and, in critically ill
patients, death. It is noteworthy, however, that resting LV
function was not found to be a consistent predictor of
perioperative ischemic events.
5.2. Assessment of Risk for CAD and
Assessment of Functional Capacity
5.2.1. The 12-Lead ECG
Recommendations for Preoperative Resting 12-Lead
ECG
CLASS I
1. Preoperative resting 12-lead ECG is recommended for patients
with at least 1 clinical risk factor* who are undergoing vascular
surgical procedures. (Level of Evidence: B)
2. Preoperative resting 12-lead ECG is recommended for patients
with known CHD, peripheral arterial disease, or cerebrovascular
disease who are undergoing intermediate-risk surgical proce-
dures. (Level of Evidence: C)
CLASS IIa
1. Preoperative resting 12-lead ECG is reasonable in persons with no
clinical risk factors who are undergoing vascular surgical proce-
dures. (Level of Evidence: B)
CLASS IIb
1. Preoperative resting 12-lead ECG may be reasonable in patients
with at least 1 clinical risk factor who are undergoing
intermediate-risk operative procedures. (Level of Evidence: B)
CLASS III
1. Preoperative and postoperative resting 12-lead ECGs are not
indicated in asymptomatic persons undergoing low-risk surgical
procedures. (Level of Evidence: B)
In patients with established or documented coronary dis-
ease, the resting 12-lead ECG contains important prognostic
information that relates to long-term morbidity and mortality
(164–167). The magnitude and extent of Q waves provide a
crude estimate of LVEF and are a predictor of long-term
mortality (168,169). Horizontal or downsloping ST-segment
depression greater than 0.5 mm, LV hypertrophy with a
“strain” pattern, and left bundle-branch block in patients
with established coronary disease are all associated with
decreased life expectancy (164 –172). In particular, the
presence of LV hypertrophy or ST-segment depression on
a preoperative 12-lead ECG predicts adverse perioperative
cardiac events (173).
The resting 12-lead ECG has been examined both preop-
eratively and postoperatively to evaluate its prognostic value.
To create an index for risk of cardiovascular complications,
Lee and colleagues studied 4135 patients aged 50 years or
older undergoing major noncardiac surgery (4). Major non-
cardiac surgery was defined by an expected hospital length of
stay of at least 2 days. In this cohort, the presence of a
pathological Q wave on the preoperative ECG was associated
with an increased risk of major cardiac complications, de-
fined as an MI, pulmonary edema, ventricular fibrillation,
primary cardiac arrest, or complete heart block. Pathological
Q waves were found in 17% of the patient population.
In contrast to these findings, Liu and colleagues studied the
predictive value of a preoperative 12-lead ECG in 513
patients aged 70 years or older undergoing elective or urgent
noncardiac surgery (174). In this cohort, 75% of the patients
had a baseline ECG abnormality, and 3.7% of the patients
died. The causes of death, in decreasing order, were sepsis,
multisystem organ failure, bowel perforation, stroke, respira-
tory failure, and cardiac complications. Electrocardiographic
abnormalities were not predictive of any outcome, although
no abnormality was examined individually.
The resting 12-lead ECG did not identify increased peri-
operative risk in patients undergoing low-risk surgery (175).
In a study of 18 189 patients at 9 centers undergoing elective
cataract surgery, half of the patients underwent basic testing
that included a 12-lead ECG, complete blood count, and
electrolyte measurement. There was no difference in outcome
between the group that had routine testing versus the group
that did not. The no-testing group was eligible to undergo a
test in response to a specific complaint or physical finding.
Although the optimal time interval between obtaining a
12-lead ECG and elective surgery is unknown, general
consensus suggests that an ECG within 30 days of surgery is
adequate for those with stable disease in whom a preoperative
ECG is indicated.
5.2.2. Exercise Stress Testing for Myocardial Ischemia
and Functional Capacity
The aim of supplemental preoperative testing is to provide an
objective measure of functional capacity, to identify the
presence of important preoperative myocardial ischemia or
cardiac arrhythmias, and to estimate perioperative cardiac
risk and long-term prognosis. Poor functional capacity in
patients with chronic CAD or those convalescing after an
acute cardiac event is associated with an increased risk of
subsequent cardiac morbidity and mortality (62). Decreased
functional capacity may be caused by several factors, includ-
ing inadequate cardiac reserve, advanced age, transient myo-
cardial dysfunction from myocardial ischemia, decondition-
ing, and poor pulmonary reserve.
In evaluating the role of exercise testing to assess patients
undergoing noncardiac procedures, it is useful to summarize
what is known about ECG exercise testing in general. The
sensitivity gradient for detecting obstructive coronary disease
is dependent on severity of stenosis and extent of disease, as
well as the criteria used for a positive test. As many as 50%
*Clinical risk factors include history of ischemic heart disease, history
of compensated or prior HF, history of cerebrovascular disease, diabetes
mellitus, and renal insufficiency.
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of patients with single-vessel coronary disease and adequate
levels of exercise can have a normal exercise ECG (63). The
mean sensitivity and specificity of exercise testing for ob-
structive coronary disease are 68% and 77%, respectively
(64). The sensitivity and specificity are 81% and 66% for
multivessel disease and 86% and 53% for 3-vessel or left
main coronary disease, respectively (65).
Weiner et al (61) studied 4083 medically treated patients in
CASS and identified a high-risk patient subset (12% of the
population) with an annual mortality rate greater than or equal to
5% per year when the exercise workload was less than Bruce
stage I and the exercise ECG showed ST-segment depression
greater than or equal to 1 mm. A low-risk subset (34% of the
population) who were able to complete or do more than Bruce
stage III with a normal exercise ECG had an annual mortality
rate of less than 1% per year over 4 years of follow-up (61).
Similar results have been reported by others (66,67).
Table 6 lists publications in which exercise test results and
perioperative events were reported. In most series, very-high-
risk patients (recent MI, unstable angina, HF, and serious
ventricular arrhythmias) were excluded. McPhail et al (184)
reported on preoperative exercise treadmill testing and supple-
mental arm ergometry in 100 patients undergoing surgery for
peripheral vascular disease or abdominal aortic aneurysm. Of the
100 patients, 30 were able to reach 85% of age-predicted heart
rate maximum, and only 2 had cardiac complications (6%). In
contrast, 70% of the population were unable to reach 85% of
age-predicted heart rate or had an abnormal exercise ECG. In
this group, the cardiac complication rate (MI, death, HF, or
ventricular arrhythmia) was 24% (17 patients).
A peak exercise heart rate greater than 75% of age-
predicted maximum can be expected in approximately half of
all patients who undergo treadmill exercise, with supplemen-
tal arm ergometry when necessary for patients limited by
claudication (177). The frequency of an abnormal exercise
ECG response is dependent on prior clinical history
(177,180). Among patients without a cardiac history and with
a normal resting ECG, approximately 20% to 50% will have
an abnormal exercise ECG. The frequency is greater (35% to
50%) in patients with a prior history of MI or an abnormal
Table 6. Preoperative Exercise Testing Before Major Noncardiac Surgery
Study, Year n
% of
Patients With
Abnormal
Test
Criteria for
Abnormal Test % Events
Prediction of Cardiac
Events
Event Comments
% Positive
Test
% Negative
Test
Peripheral vascular surgery or
abdominal aortic aneurysm
repair
McCabe et al (176), 1981 314 36 STD, CP, or A 38 (15/39) 81 (13/16) 91 (21/23) D, M, I,
H, A
Cutler et al (177), 1981 130 39 STD 7 (9/130) 16 (8/50) 99 (79/80) D, M Less than 75% MPHR
increased risk
Arous et al (178), 1984 808 17 STD NR 21 (19/89) NR D, M
Gardine et al (179), 1985 86 48 STD 11 (2/19) 11 (1/9) 90 (9/10) D, M
von Knorring and Lepantalo
(180), 1986
105 25 STD, A, or CP 3 (3/105) 8 (2/26) 99 (78/79) D, M
Kopecky et al (181), 1986 114 57 Less than
400 kpm
7 (8/110) 13 (8/63) 100
(47/47)
D, M
Leppo et al (182), 1987* 60 28 STD 12 (7/60) 25 (3/12) 92 (44/48) D, M Exercise test results used
to refer patients for
revascularization
Hanson et al (183), 1988 74 57 STD 3 (1/37) 5 (1/19) 100
(18/18)
D, M Arm ergometry
McPhail et al (184), 1988* 100 70 Less than
85% MPHR
19
(19/100)
24 (17/70) 93 (28/30) D, M,
A, F
Less than 85% MPHR;
P0.04; STD; NS
Urbinati et al (185), 1994 121 23 STD 0 0/28 100
(93/93)
D, M Carotid endarterectomy
patients. STD predicted
late death.
Peripheral vascular surgery or
major noncardiac surgery
Carliner et al (186), 1985 200 16 STD 8 (16/200) 16 (5/32) 93
(157/168)
D, M 5 METs (NS)
Numbers in parentheses are number of patients/total number of patients. In references (176, 178, 179, 181, and 183), the total number of patients undergoing
peripheral vascular surgery was less than the total number tested. A indicates cardiac arrhythmia; CP, chest pain; D, death; F, failure; H, hypotension; I, myocardial
ischemia; kpm, kilometers per hour; M, myocardial infarction; MET, metabolic equivalent; MPHR, maximum predicted heart rate; n, number of patients; NR, not
reported; NS, not significant; and STD, exercise-induced electrocardiographic ischemia.
*Studies with prospective collection of postoperative electrocardiogram and cardiac enzymes.
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rest ECG. The risk of perioperative cardiac events and
long-term risk are increased significantly in patients with an
abnormal exercise ECG at low workloads (184,177,178).
In contrast to the above-mentioned studies of patients with
vascular disease, in a general population of patients in which
only 20% to 35% had peripheral vascular disease and who
were undergoing noncardiac surgery, Carliner et al (186)
reported exercise-induced ST-segment depression greater
than or equal to 1 mm in 16% of 200 patients older than 40
years (mean age 59 years) being considered for elective
surgery. Only 2 patients (1%) had a markedly abnormal
(ST-segment depression of 2 mm or more) exercise test. Of
the 32 patients with an abnormal exercise test, 5 (16%) died
or had a nonfatal MI. Of 168 patients with a negative test, 157
(93%) did not die or have an MI. In that series, however, the
results of preoperative exercise testing were not statistically
significant independent predictors of cardiac risk.
Table 5 provides a prognostic gradient of ischemic re-
sponses during an ECG-monitored exercise test as developed
for a general population of patients with suspected or proven
CAD (187). The onset of a myocardial ischemic response at
low exercise workloads is associated with a significantly
increased risk of perioperative and long-term cardiac events.
In contrast, the onset of a myocardial ischemic response at
high exercise workloads is associated with significantly less
risk. The prognostic gradient is also influenced by the age of
the patient, the extent of the coronary disease, the degree of
LV dysfunction, hemodynamic response to exercise, and
presence or absence of chronotropic incompetence. American
College of Cardiology/American Heart Association guide-
lines concerning the indications for and interpretation of
exercise stress testing are available (188).
5.2.3. Noninvasive Stress Testing
Recommendations for Noninvasive Stress Testing Before
Noncardiac Surgery
CLASS I
1. Patients with active cardiac conditions (see Table 2) in whom
noncardiac surgery is planned should be evaluated and treated
per ACC/AHA guidelines† before noncardiac surgery. (Level of
Evidence: B)
CLASS IIa
1. Noninvasive stress testing of patients with 3 or more clinical risk
factors and poor functional capacity (less than 4 METs) who
require vascular surgery‡ is reasonable if it will change manage-
ment. (Level of Evidence: B)
CLASS IIb
1. Noninvasive stress testing may be considered for patients with at
least 1 to 2 clinical risk factors and poor functional capacity (less
than 4 METs) who require intermediate-risk or vascular surgery if
it will change management. (Level of Evidence: B)
CLASS III
1. Noninvasive testing is not useful for patients with no clinical risk
factors undergoing intermediate-risk noncardiac surgery. (Level of
Evidence: C)
2. Noninvasive testing is not useful for patients undergoing low-risk
noncardiac surgery. (Level of Evidence: C)
The 2 main techniques used in preoperative evaluation of
patients undergoing noncardiac surgery who cannot exercise
are to increase myocardial oxygen demand (by pacing or
intravenous dobutamine) and to induce hyperemic responses
by pharmacological vasodilators such as intravenous dipyri-
damole or adenosine. The most common examples presently
in use are DSE and intravenous dipyridamole/adenosine
myocardial perfusion imaging with both thallium-201 and
technetium-99m.
5.2.3.1. Radionuclide Myocardial Perfusion Imaging
Methods
Publications that report the results of stress myocardial
perfusion testing before both vascular and nonvascular sur-
gery are summarized in Table 7. The bulk of the studies
included were prospectively recruited patient studies, a ma-
jority of which involved patients undergoing vascular sur-
gery. Cardiac events in the perioperative period were defined
for the purpose of this table as MI or death due to cardiac
causes, and information about events and scan results had to
be available. These studies have shown that reversible perfu-
sion defects, which reflect jeopardized viable myocardium,
carry the greatest risk of perioperative cardiac death or MI.
The percentage of patients with evidence of ischemic risk
reflected in reversible myocardial perfusion defects ranged
from 23% to 69%. The positive predictive value of reversible
defects for perioperative death or MI ranged from 2% to 20%
in reports that included more than 100 patients. In more
recent publications, the positive predictive value of myocar-
dial perfusion imaging has been decreased significantly. This
is probably related to the fact that in recent years, the results
of preoperative stress nuclear imaging studies have been
actively used to select patients for therapeutic interventions
such as coronary revascularization, as well as to adjust
perioperative medical treatment and monitoring and to select
different surgical procedures. The result is a lower cardiac
event rate in patients with abnormal studies. However,
because of a very high sensitivity of abnormal stress nuclear
imaging studies for detecting patients at risk for perioperative
cardiac events, the negative predictive value of a normal scan
has remained uniformly high at approximately 99% for MI or
cardiac death. Most studies have found that fixed perfusion
defects do not have significant predictive value for perioper-
†ACC/AHA/ESC Guidelines for the Management of Patients With
Atrial Fibrillation (110), ACC/AHA/ACP Guidelines for the Manage-
ment of Patients with Chronic Stable Angina (189), ACC/AHA 2005
Guideline Update for the Diagnosis and Management of Chronic Heart
Failure in the Adult (190), ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction (49), ACC/AHA/ESC
Guidelines for the Management of Patients With Supraventricular Ar-
rhythmias (191), ACC/AHA 2002 Guideline Update for the Management
of Patients With Unstable Angina and Non–ST-Segment Elevation
Myocardial Infarction (192), ACC/AHA 2006 Guidelines for the Man-
agement of Patients With Valvular Heart Disease (103), and ACC/AHA/
ESC Guidelines for the Management of Patients With Ventricular
Arrhythmias and the Prevention of Sudden Cardiac Death (193).
‡Vascular surgery is defined by emergency aortic and other major
vascular surgery and peripheral vascular surgery. See Table 4.
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Table 7. Summary of Studies Examining the Value of Myocardial Perfusion Imaging for Preoperative Assessment of Cardiac Risk
Study, Year n
% of Patients
With Ischemia
Events %
(MI/
Death)
Perioperative Events*
Comments
Ischemia: %
Positive
Predictive
Value
Normal: %
Negative
Predictive
Value
Vascular surgery
Boucher et al (194), 1985 48 33 (16) 6 (3) 19 (3/16) 100 (32/32) First study to define risk of thallium redistribution
Cutler and Leppo (195), 1987 116 47 (54) 10 (11) 20 (11/54) 100 (60/60) Only aortic surgery
Fletcher and Kershaw (196), 1988 67 22 (67) 4 (3) 20 (3/15) 100 (56/56)
Sachs et al (197), 1988 46 31 (14) 4 (2) 14 (2/14) 100 (24/24)
Eagle et al (44), 1989 200 41 (82) 8 (15) 16 (13/82) 98 (61/62) Defined clinical risk
McEnroe et al (198), 1990 95 36 (34) 7 (7) 9 (3/34) 96 (44/46) Fixed defects predict events
Younis et al (199), 1990 111 36 (40) 7 (8) 15 (6/40) 100 (51/51) Included long-term follow-up
Mangano et al (200), 1991 60 37 (22) 5 (3) 5 (1/22) 95 (19/20) Managing physicians blinded to scan result
Strawn and Guernsey (201), 1991 68 N/A 6 (4) N/A 100 (21/21)
Watters et al (202), 1991 26 58 (15) 12 (3) 20 (3/15) 100 (11/11) Included echocardiographic (TEE) studies
Hendel et al (203), 1992 327 51 (167) 9 (28) 14 (23/167) 99 (97/98) Included long-term follow-up
Lette et al (41), 1992 355 45 (161) 8 (30) 17 (28/161) 99 (160/162) Used quantitative scan index
Madsen et al (204), 1992 65 69 (45) 8 (5) 11 (5/45) 100 (20/20)
Brown and Rowen (205), 1993 231 33 (77) 5 (12) 13 (10/77) 99 (120/121) Prognostic utility enhanced by combined scan
and clinical factors
Kresowik et al (206), 1993 170 39 (67) 3 (5) 4 (3/67) 98 (64/65)
Baron et al (207), 1994 457 35 (160) 5 (22) 4 (7/160) 96 (195/203)
NFMI only
Did not analyze for cardiac deaths; no
independent value of scan
Bry et al (208), 1994 237 46 (110) 7 (17) 11 (12/110) 100 (97/97) Cost-effectiveness data included
Koutelou et al (209), 1995 106 44 (47) 3 (3) 6 (3/47) 100 (49/49) Used adenosine/SPECT thallium imaging
Marshall et al (210), 1995 117 47 (55) 10 (12) 16 (9/55) 97 (33/34) Used adenosine thallium and sestamibi; size of
ischemic defect enhanced prognostic utility
Van Damme et al (211), 1997 142 34 (48) 2 (3) N/A N/A Used dobutamine SPECT sestamibi and
echocardiographic imaging; echocardiographic and
nuclear scan prognostic utility was equivalent
Huang et al (212), 1998 106 36 (39) 5 (5) 13 (5/39) 100 (24/24) Dipyridamole thallium SPECT
Cohen et al (213), 2003 153 31 (48) 4 (6) 4 (2/48) 100 (21/21) Dipyridamole SPECT sestamibi imaging;
perioperative and long-term follow-up. Perfusion
defect in the LAD territory was best predictor of
long-term death/MI.
Harafuji et al (214), 2005 302 30 (92) 1.3 (4) 2 (2/92) 100 (210/210) SPECT thallium with adenosine stress in 239
patients; dipyridamole in 63. Summed stress
score greater than or equal to 14 (20-segment
model) best multivariate predictor of events.
Nonvascular surgery†
Camp et al (215), 1990 40 23 (9) 15 (6) 67 (6/9) 100 (23/23) Diabetes mellitus, renal transplant
Iqbal et al (216), 1991 31 41 (11) 11 (3) 27 (3/11) 100 (20/20) Exercise 86%, diabetes mellitus, pancreas transplant
Coley et al (217), 1992 100 36 (36) 4 (4) 8 (3/36) 98 (63/64) Define clinical risk factors in patients with known
or suspected CAD
Shaw et al (218), 1992 60 47 (28) 10 (6) 21 (6/28) 100 (19/19) Used adenosine
Takase et al (219), 1993 53 28 (15) 11 (6) 27 (4/15) 100 (32/32) Patients with documented or suspected CAD;
included rest echocardiogram
Younis et al (220), 1994 161 31 (50) 9 (15) 18 (9/50) 98 (87/89) Intermediate- to high-risk CAD
Stratmann et al (221), 1996 229 29 (67) 4 (10) 6 (4/67) 99 (1/92) Used dipyridamole sestamibi and noted fixed defect
had more prognostic utility than transient defect
Zoghbi et al (222), 2003 87 8 (7) 2 (2) 14 (1/7) 97 (1/79) Liver transplant cohort
Patel et al (223), 2003 174 31 (54) 7 (12) 15 (8/54) 97 (116/120) Renal transplant cohort
All studies except those by Coley et al (217) and Shaw et al (218) acquired patient information prospectively. Only in reports by Mangano et al (200) and Baron
et al (207) were attending physicians blinded to scan results. Patients with fixed defects were omitted from calculations of positive and negative predictive value.
CAD indicates coronary artery disease; LAD, left anterior descending coronary artery; MI, myocardial infarction; n, number of patients who underwent surgery; N/A,
not available; NFMI, nonfatal myocardial infarction; SPECT, single-photon emission computed tomography; and TEE, transesophageal echocardiography.
*Positive and negative predictive values are predictive value (number of patients/total number of patients whose test results indicated either ischemia or a normal scan).
†Studies utilizing pharmacological and/or exercise thallium testing.
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ative cardiac events. Even though patients with fixed defects
in some studies had increased risk compared with patients
with normal images, the risk was significantly lower than in
patients with reversible defects.
Shaw et al (224) conducted a meta-analysis of dipyridam-
ole myocardial perfusion imaging for risk stratification before
elective vascular surgery (10 studies, 1994 patients) that
demonstrated significant prognostic utility for this scinti-
graphic technique. In addition, they noted that the positive
predictive value of perfusion imaging was correlated with the
pretest cardiac risk of the patients. Overall, a reversible
myocardial perfusion defect predicted perioperative
events, and a fixed thallium defect predicted long-term
cardiac events. Semiquantitative analysis of myocardial
perfusion imaging improved the clinical risk stratification
by defining a relationship of increasing risk of cardiac
events as defect size increased.
Importantly, the risk of perioperative cardiac events as a
function of stress nuclear myocardial perfusion imaging is
continuous rather than categorical. Several studies have
shown that the risk of cardiac events increases as the extent of
reversible defects increases (203,205,225). Abnormal imag-
ing studies with a small degree of reversible defect carry a
small risk of cardiac events, whereas the cardiac risk in-
creases significantly as the size of the reversible defect
increases to a moderate degree (20% to 25% of LV mass). A
meta-analysis of studies examining the relationship of peri-
operative cardiac risk and semiquantitative assessment of
reversible defects on dipyridamole myocardial perfusion
imaging in patients undergoing noncardiac vascular surgery
was reported by Etchells and colleagues (226). In 9 studies
comprising 1179 patients, they found that reversible defects
in fewer than 20% of myocardial segments were associated
with a small, nonsignificant increased risk of perioperative
death or MI. Reversible defects that involved more than 20%
of myocardial segments were associated with a significantly
higher risk of perioperative cardiac death or MI that increased
progressively as the extent of reversible defects increased.
Beattie et al (227) conducted a meta-analysis (68 studies)
comparing stress myocardial perfusion imaging versus stress
echocardiography in 10 049 patients at risk for MI before
elective noncardiac surgery. The authors concluded that both
myocardial perfusion imaging and stress echocardiography
detected a moderate-to-large defect in 14% of patients
(likelihood ratio 8.35, 95% CI: 5.6 to 12.45) and that a
moderate-to-large perfusion defect predicted postoperative
MI and death.
Mondillo et al (228) sought to compare the predictive value
of different noninvasive tests in patients scheduled for non-
cardiac surgery. A total of 118 patients were risk stratified
according to clinical markers and LVEF to low-, moderate-,
or high-risk categories and randomly assigned to 1 of 3
noninvasive tests: dipyridamole stress echocardiography, do-
butamine stress echocardiography, or dipyridamole perfusion
scintigraphy. Although the low-risk group was event-free,
10.4% of the moderate-risk group and 24% of the high-risk
group experienced events. Of the clinical risk categories, only
the high-risk category was related to cardiac complications (P
less than 0.05). Multivariable analysis showed the best
predictors of events were the severity and extent of ischemia
(dipyridamole, P less than 0.01; dobutamine, P less than
0.005). Only reversible perfusion defects at scintigraphy were
significantly related to perioperative events. The strongest
predictor of cardiac events was the presence of more than 3
reversible defects (P less than 0.05).
A meta-analysis was performed on 58 studies of 6 preop-
erative noninvasive tests, including studies on myocardial
perfusion scintigraphy (n23), DSE (n8), and dipyridam-
ole stress echocardiography (n4) (163). The summary
receiver operating characteristic curve with the end point of
prediction of perioperative cardiac death and nonfatal MI was
highest with DSE, with a weighted sensitivity of 85% (95%
CI: 74% to 97%) and specificity of 70% (95% CI: 62% to
79%). Although DSE performed better than the other tests,
statistical significance was only reached compared with
myocardial perfusion scintigraphy (relative diagnostic OR:
5.5, 95% CI: 2.0 to 14.9). However, the large majority of the
cited nuclear studies involved older planar imaging technol-
ogy that is generally no longer in use.
The use of techniques to quantify the extent of abnormality
and the current routine use of quantitative gated single-
photon emission computed tomography perfusion imaging to
evaluate LVEF will probably improve the positive predictive
nature of myocardial perfusion imaging. Although there are
relatively few published reports using adenosine myocardial
perfusion imaging in the preoperative risk assessment of
patients before noncardiac surgery, its usefulness appears to
be equivalent to that of dipyridamole. American College of
Cardiology/American Heart Association guidelines concern-
ing indications for and interpretation of stress testing with
myocardial perfusion imaging are available (229).
The need for caution in routine screening with dipyridam-
ole myocardial perfusion imaging of all patients before
vascular surgery has been raised by Baron et al (207). In this
review of patients undergoing elective abdominal aortic
surgery, the presence of definite CAD and age greater than 65
years were better predictors of cardiac complications than
perfusion imaging. Subsequently, several studies have pro-
spectively examined the impact of preoperative cardiac risk
assessment using a methodology that generally followed the
recommendations outlined in prior ACC/AHA preoperative
guidelines. In a report by Vanzetto et al (230), consecutive
patients were evaluated before abdominal aortic surgery. If no
major or fewer than 2 intermediate clinical cardiac risk
factors were present, patients went directly to elective sur-
gery. The authors noted a 5.6% incidence of cardiac events
(death/MI) in those patients with 1 risk factor and a rate of
2.4% in those with no cardiac risk factors. All high-risk
patients (2 or more cardiac risk factors) underwent dipyri-
damole myocardial perfusion single-photon emission com-
puted tomography imaging, and those with a normal scan
(38%) had a cardiac event rate of 2% in contrast to a rate of
23% in 43 patients demonstrating reversible thallium defects.
Bartels et al (54) also reported that patients referred for
elective vascular surgery who had no clinical intermediate or
major clinical risk factors had a 2% incidence of cardiac
events. Those patients with either intermediate risk factors
and a functional capacity of less than 5 METs or high clinical
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risk underwent stress myocardial perfusion imaging or had
intensified medical therapy before elective surgery. Using
this ACC/AHA guideline–influenced approach, the overall
cardiac mortality for the cohort was only 1%, and there were
no significant differences in outcome among patients with
low, intermediate, or high clinical risk. Another report (231)
also used the clinical risk factor parameters to divide vascular
surgery patients into low-, intermediate-, and high-cardiac-
risk groups. Those authors did not include functional capacity
measurements but noted a 0% death or MI rate in the
perioperative period among the low-risk patients.
In summary, stress nuclear myocardial perfusion imaging
has a high sensitivity for detecting patients at risk for
perioperative cardiac events. Perioperative cardiac risk ap-
pears to be directly proportional to the amount of myocar-
dium at risk as reflected in the extent of reversible defects
found on imaging. Because of the overall low positive
predictive value of stress nuclear imaging, it is best used
selectively in patients with a high clinical risk of periop-
erative cardiac events.
5.2.3.2. Dobutamine Stress Echocardiography
Dobutamine stress echocardiography has become the method
of choice for pharmacological stress testing with ultrasound
imaging. With incremental infusion of supratherapeutic doses
of dobutamine, which increases myocardial contractility and
heart rate, significant coronary stenotic disease can be iden-
tified with the induction of LV ischemic regional wall-motion
abnormalities within the distribution of the affected vessels.
The dobutamine infusion is often supplemented with intrave-
nous atropine to optimize chronotropic response to stress. In
patients with suboptimal LV endocardial definition, intrave-
nous contrast imaging for LV opacification is now routinely
used for image enhancement and improved diagnostic inter-
pretation (232).
Several reports have documented the accuracy of DSE to
identify patients with significant angiographic coronary dis-
ease (233–238). The use of DSE in preoperative risk assess-
ment was evaluated in 16 studies, all published since 1991
and identified by a computerized search of the English
language literature (Table 8) (146,149,160,239–251). The
populations predominantly but not exclusively included pa-
tients undergoing peripheral vascular surgical procedures.
Only 2 studies blinded the physicians and surgeons who
treated the patients to the dobutamine stress echocardiogra-
phy results (160,241). In the remaining studies, the results
were used to influence preoperative management, particularly
the decision whether or not to proceed with coronary angiog-
raphy or coronary revascularization before elective surgery.
Each study used similar but not identical protocols. The
definition of a positive and negative test result differed
considerably on the basis of subjective analysis of regional
wall motion (ie, worsening of preexisting wall-motion abnor-
malities was considered by some investigators as a positive
finding and by others as a negative finding). The end points
used to define clinical outcome varied and included both
“soft” (ie, arrhythmia, HF, and ischemia) and “hard” (ie, MI
or cardiac death) perioperative events.
The data indicate that DSE can be performed safely and
with acceptable patient tolerance. The range of positive test
results was 5% to 50%. The predictive value of a positive test
ranged from 0% to 33% for hard events (nonfatal MI or
death). The negative predictive value ranged from 93% to
100%. In the series by Poldermans et al (160), the presence of
a new wall-motion abnormality was a powerful determinant
of an increased risk for perioperative events after multivari-
able adjustment for different clinical and echocardiographic
variables. Several studies have suggested that the extent
of the wall-motion abnormality and/or wall-motion change
at low ischemic thresholds, particularly at a heart rate of
less than 60% of age-predicted maximum (243,247), is
especially important. These findings have been shown to be
predictors of long-term (243,244,252,253) and short-term
(254) outcomes.
Integration of the presence of clinical risk factors such as
ongoing stable angina, prior MI, HF, and diabetes mellitus
with analysis of the ischemic threshold enhances the value of
DSE in predicting perioperative nonfatal MI or death. In a
study by Das et al (247), an ischemic response at 60% or
more of maximal predicted heart rate was associated with
only a 4% event rate if no clinical risk factors were present
versus a 22% event rate in patients with more than 2 risk
factors. The same investigators found a high event rate with
an ischemic threshold of less than 60% of maximal predicted
heart rate (29% in patients with no risk factors compared with
40% in those patients with more than 2 risk factors). In that
study, the only multivariable predictors of perioperative
nonfatal MI or death were ischemic threshold less than 60%
of maximal predicted heart rate (OR: 7.00, 95% CI: 2.8 to
17.6, P0.0001) and congestive HF (OR: 4.66, 95% CI: 1.55
to 14.02, P0.006) (247).
Labib et al (251) investigated the negative predictive value
of preoperative patients who did or did not reach 85% of
maximum predicted heart rate on a DSE test, as well as the
impact of resting wall-motion abnormalities without ischemia
for the prediction of perioperative MI. Of the 429 patients,
16% had a peak heart rate less than 85% of the maximum
predicted (77% of the group undergoing therapy with beta
blockers). Cardiac events were statistically less frequent in
the negative-DSE group than in the positive-DSE group (7 of
397 or 1.8% versus 3 of 32 or 9.4%; P0.03). In the
negative-DSE group, no difference was seen in clinical events
between the maximal and submaximal groups; however,
when resting wall motion was compared in patients who had
a negative DSE (n397), patients with a fixed wall-motion
abnormality at rest had more clinical events than the group
with normal wall motion (7 of 100 or 7% versus 0 of 297
or 0%; P0.0001). Variables associated with postopera-
tive cardiac events (MI or death) included CAD (OR: 5.56,
95% CI: 1.06 to 29.05, P0.035), resting wall-motion
abnormality (OR not available, P less than 0.001), and
resting ejection fraction less than 35% (OR: 13.78, 95%
CI: 2.41 to 78.99, P0.019).
Even in high-risk noncardiac surgery, patients with ische-
mia induced by DSE have a clearly lower (3% to 7%) risk of
perioperative nonfatal MI or death if they are classified as
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moderate to low risk by clinical risk scoring versus a 3- to
5-fold greater risk in those with a high clinical risk score
(4,247,248). This risk may be reduced significantly with
beta-blocker therapy (89,248). In patients at low to interme-
diate clinical risk who are undergoing established and thera-
peutic beta blockade, DSE is unlikely to impact the early
perioperative outcome (248) but contributes to the stratifica-
tion of long-term cardiac risk (253).
Dobutamine stress magnetic resonance imaging has been
used to identify myocardial ischemia in those not well suited
for dobutamine stress transthoracic echocardiography (255–
257). In more than 500 patients across 6 studies, both the
sensitivity and specificity of dobutamine stress magnetic
resonance for appreciating 50% coronary arterial luminal
narrowings have been demonstrated to range between 83%
and 91% (255–260). Results from dobutamine stress mag-
netic resonance are useful for identifying those at risk for the
future occurrence or cardiac death or MI (261). Dobutamine
stress magnetic resonance imaging has been used to assess
perioperative risk in those individuals undergoing noncardiac
surgery (262). In a study of 102 patients with intermediate
clinical predictors of a cardiac event during noncardiac
surgery (262), the presence of inducible ischemia on a
dobutamine stress magnetic resonance stress test was associ-
ated with a 20% incidence of adverse cardiac events (MI,
cardiac death, or perioperative congestive HF) compared with
Table 8. Summary of Studies Examining the Value of Dobutamine Stress Echocardiography for Preoperative Risk Assessment
MI or Death*
Study, Year n
Patients
With
Ischemia, %
Events
(MI/Death) (n) Criteria for Abnormal Test
Positive
Predictive
Value
Negative
Predictive
Value Comments
Lane et al (239), 1991 38 50 8% (3) New WMA 16%
(3/19)
100%
(19/19)
Vascular and general surgery
Lalka et al (240), 1992 60 50 15% (9) New or worsening WMA 23%
(7/30)
93%
(28/30)
Multivariate analysis
Eichelberger et al (241), 1993 75 36 3% (2) New or worsening WMA 7%
(2/27)
100%
(48/48)
Managing physicians blinded to
DSE results
Langan et al (242), 1993 74 24 4% (3) New WMA or ECG changes 17%
(3/18)
100%
(56/56)
Poldermans et al (243), 1993 131 27 4% (5) New or worsening WMA 14%
(5/35)
100%
(96/96)
Multivariate analysis; managing
physicians blinded to DSE
results
Dávila-Román et al (244),
1993
88 23 2% (2) New or worsening WMA 10%
(2/20)
100%
(68/68)
Included long-term follow-up
Poldermans et al (160), 1995 302 24 6% (17) New or worsening WMA 24%
(17/72)
100%
(228/228)
Multivariate analysis
Shafritz et al (245), 997 42 0 2% (1) New or worsening WMA N/A 97%
(41/42)
Plotkin et al (146), 1998 80 8 3% (2) New or worsening WMA, ECG
changes, and/or symptoms of
chest pain or dyspnea
33%
(2/6)
100%
(74/74)
Orthotopic liver transplantation
Ballal et al (246), 1999 233 17 3% (7) New or worsening WMA 0%
(0/39)†
96%
(187/194)
Included long-term follow-up
Bossone et al (149), 1999 46 9 2% (1) New or worsening WMA 25%
(1/4)
100%
(42/42)
Lung volume reduction surgery;
included long-term follow-up
Das et al (246), 2000 530 40 6% (32) New or worsening WMA or
failure to develop hyperdynamic
function
15%
(32/214)
100%
(316/316)
Multivariate analysis;
nonvascular surgery
Boersma et al (248), 2001 1097 20 4% (44) New or worsening WMA 14%
(30/222)
98%
(861/875)
Major vascular surgery;
multivariate analysis; long-term
follow-up
Morgan et al (249), 2002 78 5 0% (0) Undefined 0%
(0/4)
100%
(100%)
High-risk noncardiac surgery in
one third of patients
Torres et al (250), 2002 105 47 10% (10) New or worsening WMA 18%
(9/49)
98%
(55/56)
Multivariate analysis; vascular
surgery in 82% of patients;
long-term follow-up
Labib et al (251), 2004 429 7 2% (10) New or worsening WMA 9%
(3/32)
98%
(390/397)
Vascular surgery in 30% of
patients
DSE indicates dobutamine stress echocardiogram; MI, myocardial infarction; n, number of patients who underwent surgery; and WMA, wall-motion abnormality.
*Numbers in parentheses refer to number of patients/total in group.
†Intervening revascularization in 9 ischemic patients (23%).
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a 2% incidence in those without inducible ischemia
(P0.004).
This difference was significant (P0.04) after adjustment
for age greater than 70 years, diabetes mellitus, the presence
of stable angina before testing, a history of HF, LVEF, or a Q
wave on the resting ECG. As shown with other noninvasive
imaging techniques, dobutamine stress magnetic resonance
results do not provide incremental prognostic information
in individuals with preoperative clinical data indicating a
low risk for sustaining a cardiac event during noncardiac
surgery (262).
An early meta-analysis (224) has suggested that DSE is
superior to dipyridamole-thallium stress testing in the predic-
tion of perioperative cardiac events during vascular surgery.
Subsequent large, prospective, individual studies directly
comparing stress echocardiography and nuclear imaging in
the context of risk stratification for noncardiac surgery,
however, have been lacking (263,264).
A recent, much larger meta-analysis by Beattie and col-
leagues (227). re-examined the predictive value of pharma-
cological stress testing with echocardiography versus nuclear
perfusion scintigraphy. This study did not differentiate be-
tween the type of pharmacological stressor used, nor was
there a subgroup analysis with regard to the type of noncar-
diac surgery. The meta-analysis included 25 studies of stress
echocardiography (3373 patients) and 50 studies of stress
nuclear perfusion imaging (6827 patients). Five studies of
dipyridamole stress echocardiography were included with
those that used dobutamine stress. Perioperative MI and death
were the only end-point events considered. In this analysis,
the likelihood ratio, defined as sensitivity/1-specificity, of a
perioperative cardiac event with a positive stress echocardio-
gram was more than twice that of a positive stress nuclear
perfusion study (likelihood ratio 4.09, 95% CI: 3.21 to 6.56
versus 1.83, 95% CI: 1.59 to 2.10; P0.001). The finding
of a moderate to large ischemic abnormality by either
pharmacological stress imaging modality was highly pre-
dictive of perioperative MI or death (likelihood ratio 8.35,
95% CI: 5.6 to 12.45), but such an abnormality was
detected in only approximately 15% of all patients tested
by either method (227).
5.2.3.3. Stress Testing in the Presence of Left
Bundle-Branch Block
The tachycardia induced during exercise and conceivably
also during dobutamine infusion may result in reversible
septal defects even in the absence of left anterior descending
artery disease in some patients. This response is unusual with
either dipyridamole or adenosine stress testing. Conse-
quently, the specificity of exercise myocardial perfusion
imaging in the presence of left bundle-branch block is low
(reported to be 33%), and overall diagnostic accuracy varies
from 36% to 60% (265,266). In contrast, the use of vasodi-
lators in such patients has a sensitivity of 98%, a specificity
of 84%, and a diagnostic accuracy of 88% to 92% (267–269).
Comparison of DSE to exercise thallium-201 SPECT imag-
ing for the diagnosis of LAD coronary disease in the setting
of left bundle-branch block has also found pharmacologic
stress to be superior to exercise, with diagnostic accuracies of
92% versus 69% respectively (270). Again these findings
were primarily due to the low specificity of exercise perfu-
sion imaging (42%) compared to DSE (92%), despite high
sensitivities of 100% and 91% respectively (270). In a study
by Mairesse et al (271), dobutamine stress testing with
imaging by echocardiography and perfusion scintigraphy
were directly compared in 24 patients with left bundle-branch
block. For the detection of LAD ischemia, the diagnostic
sensitivity of DSE was similar to perfusion imaging (83%
versus 75%), with identical specificities (92%) and equivalent
diagnostic accuracies (87% versus 83%) respectively. In the
presence of left bundle-branch block, the diagnostic accuracy
of perfusion scintigraphy in detection of CAD in other
coronary distributions ranged from 42% to 75% compared to
79% with DSE (271).
Pharmacologic stress testing with either perfusion scintig-
raphy or DSE is hence preferred over exercise stress testing
for the preoperative evaluation of CAD in patients with left
bundle-branch block. Furthermore, exercise should not be
combined with dipyridamole in such patients, and synthetic
catecholamines will also yield false-positive results (272).
5.2.4. Ambulatory ECG Monitoring
The predictive value of preoperative ST changes on 24- to
48-hour ambulatory ECG monitoring for cardiac death or MI
in patients undergoing vascular and nonvascular surgery has
been reported by several investigators. The frequency of
abnormal ST-segment changes observed in 869 patients
reported in 7 series was 25% (range 9% to 39%) (42,273–
277). The positive and negative predictive values for
perioperative MI and cardiac death are shown in Table 9.
In 2 studies, preoperative ST changes had a predic-
tive value similar to dipyridamole myocardial perfusion
imaging (275,278).
Although the test has been shown to be predictive of
cardiac morbidity, there are several limitations. Differences
in the study protocols (24 versus 48 hour, ambulatory versus
in-hospital monitoring) may account for the variability in the
predictive value of the test. Preoperative ambulatory ECG
monitoring for ST-segment changes cannot be performed in a
significant percentage of patients because of baseline ECG
changes. The test, as currently used, only provides a binary
outcome and therefore cannot further stratify the high-risk
group in order to identify the subset for whom coronary
angiography should be considered (278).
5.3. Recommendations: If a Test Is Indicated,
Which Test?
In most ambulatory patients, the test of choice is exercise
ECG testing, which can both provide an estimate of func-
tional capacity and detect myocardial ischemia through
changes in the ECG and hemodynamic response. Although
treadmill exercise stress testing in patients with abdominal
aortic aneurysms would cause concern with regard to induced
rupture, there is evidence that it can be performed safely in
this population. In a series of more than 250 patients with an
abdominal aortic aneurysm greater than 4 cm (including 97
that were 6 cm or greater) who underwent treadmill exercise,
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only a single patient developed subacute aneurysm rupture 12
hours after testing, which was repaired successfully (279).
In patients with important abnormalities on their resting
ECG (eg, left bundle-branch block, LV hypertrophy with
“strain” pattern, or digitalis effect), stress cardiac imaging
should be considered. As discussed with left bundle-branch
block, exercise myocardial perfusion imaging has an unac-
ceptably low specificity because of septal perfusion defects
that are not related to CAD. For these patients, pharmaco-
logic stress myocardial perfusion scintigraphy or dobuta-
mine stress echocardiography is recommended over exer-
cise stress imaging.
In patients unable to perform adequate exercise, a nonex-
ercise stress test should be considered. In this case, pharma-
cological stress testing with adenosine, dipyridamole, or
dobutamine myocardial perfusion imaging testing and dobu-
tamine echocardiography are commonly used tests. Intrave-
nous dipyridamole and adenosine should be avoided in
patients with significant bronchospasm, critical carotid occlu-
sive disease, or a condition that prevents their being with-
drawn from theophylline preparations or other adenosine
antagonists. Dobutamine should not be used as a stressor in
patients with serious arrhythmias, severe hypertension, or
hypotension. For patients in whom echocardiographic image
quality is likely to be poor, a myocardial perfusion study is
more appropriate. Soft tissue attenuation can also be a
problem with myocardial perfusion imaging, although recent
development of attenuation correction for acquisition and
analysis has been very helpful in reducing this issue. If there
is an additional question about valvular dysfunction, the
echocardiographic stress test is favored. In many instances,
either stress perfusion or stress echocardiography is appro-
priate. The expertise of the practitioner’s available stress
laboratory resources in identifying severe coronary disease is
as important as the particular type of stress test ordered.
The current evidence does not support the use of an
ambulatory ECG as the only diagnostic test to refer patients
for coronary angiography, but it may be useful in rare
circumstances to direct medical therapy. In general, indica-
tions for preoperative coronary angiography are similar to
those identified for the nonoperative setting.
6. Implications of Guidelines and Other
Risk Assessment Strategies for Costs
and Outcomes
The decision to recommend further testing or treatment for
the individual patient being considered for noncardiac sur-
gery ultimately becomes a balancing act between the esti-
mated probabilities of effectiveness versus risk. The proposed
benefit, of course, is the possibility of identifying and/or
treating advanced but relatively unsuspected CAD that might
result in significant cardiac morbidity or mortality either
perioperatively or in the long term. In the process of further
screening and treatment, the risks from the tests and treat-
ments themselves may offset or even exceed the potential
benefit of evaluation. Furthermore, the cost of screening and
treatment strategies must be considered. Although physicians
should be concerned with improving the clinical outcome of
their patients, cost is an appropriate consideration when
different evaluation and treatment strategies are available that
cannot be distinguished from one another in terms of clinical
outcome.
Froehlich et al (280) compared test utilization and outcome
for aortic surgery patients before and after implementation of
the ACC/AHA preoperative assessment guidelines at their
center using a comprehensive educational program. They
demonstrated dramatic reductions in stress testing after im-
plementation of the guidelines, mostly with nuclear imaging
(88% to 47%), cardiac catheterization (24% to 11%), coro-
nary revascularization (24% to 2%), and overall preoperative
costs ($1087 to $171). At the same time, perioperative
outcome was actually improved as the death/MI rate fell from
11% to 4%. Of note, implementation of the guidelines had the
greatest impact in the preoperative evaluation of clinically
Table 9. Predictive Value of Preoperative ST-Segment Changes Detected by Ambulatory Monitoring for Perioperative Myocardial
Infarction and Cardiac Death After Major Vascular Surgery
Study, Year n
Patients With
Abnormal Test, %
Criteria for
Abnormal Test
Perioperative Events, % (n/N)
Comments
Positive
Predictive Value*
Negative
Predictive Value
Raby et al (276), 1989 176 18 A 10% (3/32) 1% (1/144) 24 to 48 hours during
ambulation
Pasternack et al (277), 1989 200 39 A 9% (7/78) 2% (2/122)
Mangano et al (42), 1990 144 18 A,B 4% (1/26) 4% (5/118) Immediately before
surgery
Fleisher and Barash (150), 1992 67 24 A,B 13% (2/16) 4% (2/51) Immediately before
surgery
McPhail et al (275), 1993 100 34 A 15% (5/34) 6% (4/66)
Kirwin et al (274), 1993 96 9 A 11% (1/9) 16% (14/87) Definition of MI based on
enzymes only
Fleisher et al (278), 1995 86 23 A,B 10% (2/20) 3% (2/66) Quantitative monitoring
not predictive
A indicates 1 mm of ST-segment depression; B, 2 mm of ST-segment elevation; MI, myocardial infarction; and n, number of patients.
*Positive predictive value for postoperative cardiac events.
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low-risk patients. This study supports the ACC/AHA guide-
line approach of clinical assessment of risk followed by
selective testing with stress nuclear myocardial perfusion
imaging in higher-risk subgroups of patients, and they con-
firm that cardiac patients at low clinical risk can typically
undergo elective surgery with a low event rate without further
testing. The approach of selective testing, based on an
understanding of test performance, a clinical patient assess-
ment, and the potential impact of test results on clinical
decision making, is supported as leading to appropriateness of
testing, as outlined in the ACC Foundation/American Society
of Nuclear Cardiology proposed method for evaluating the
appropriateness of cardiovascular imaging (281).
Formal decision and cost-effectiveness analyses of the
value of preoperative cardiac evaluation have been published
and have yielded highly varied results (208,282,283). These
models were created before the publication of the CARP trial
and the DECREASE (Dutch Echocardiographic Cardiac Risk
Evaluation Applying Stress Echocardiography)-II trial and
assumed that coronary revascularization had benefits in
clinical populations that differed from center to center;
therefore, it is difficult to determine the exact risks of
aggressive screening and treatments versus the benefits in
terms of risk reduction. Additionally, the models all demon-
strate that the optimal strategy depends on the mortality rates
for both cardiac procedures and noncardiac surgeries in the
clinically relevant range. One model, which did not support a
strategy incorporating coronary angiography and revascular-
ization, used lower mortality rates than those used or reported
in the other studies (282,283,284). Therefore, the use of any
decision and cost-effectiveness model in a specific situation
depends on the comparability of local mortality rates to those
of the model.
One report suggested that the cost of a selected coronary
screening approach, as described in the present guidelines,
was as low as $214 per patient (285). Resource utilization and
costs of preoperative evaluation also decreased in patients
undergoing elective abdominal aortic surgery in the period of
implementation for the initial version of these guidelines
compared with historical controls, whereas outcomes were
similar (280). Several publications have shown a cost per year
of life saved for this selected screening strategy of less than
$45 000 when applied to patients undergoing vascular sur-
gery (286,287). However, none of these studies included a
strategy of selected screening followed by aggressive beta-
blocker treatment in high-risk individuals, as described by
Poldermans and colleagues (89).
Available data suggest that implementation of various
strategies of beta blockade in patients undergoing major
vascular surgery is cost-effective and even cost-saving from
the perspective of a short-term provider. Fleisher et al (288)
used decision analytic techniques to compare 5 different
strategies for implementing beta blockade in patients under-
going abdominal aortic aneurysm surgery. These ranged from
1) no routine beta blockade to 2) oral bisoprolol 7 days
preoperatively followed by perioperative intravenous meto-
prolol and oral bisoprolol, 3) immediate preoperative atenolol
with postoperative intravenous then oral atenolol, 4) intraop-
erative esmolol with conversion to intravenous and then oral
atenolol in the immediate postoperative period, and 5) intra-
operative and postoperative (at 18 hours) esmolol followed
by atenolol. Using Medicare costs as a proxy, they found that
the institution of an oral beta blocker a minimum of 7 days
before surgery was associated with a cost savings of approx-
imately $500 from the hospital’s perspective; that is, beta
blockade was associated with both better outcomes and lower
cost. All other strategies tested were cost saving, but to a
lesser degree. Of note, this decision analysis did not include
the performance of any screening tests or the costs of such
testing. Schmidt et al (289) estimated the impact of a clinical
practice guideline for perioperative beta blockers at a medical
center in western Massachusetts in high-risk patients with 2
or more cardiac risk factors or known CAD. Using effective-
ness data for beta-blocker treatment from Mangano et al (88),
they estimated that full use of beta blockers in eligible
patients could result in 62 to 89 fewer deaths annually at a
cost of approximately $33 000 to $40 000. Prophylactic beta
blockade also represents an excellent strategy in patients for
whom coronary revascularization for long-term benefit is not
a serious consideration.
7. Perioperative Therapy
7.1. Preoperative Coronary Revascularization
With CABG or Percutaneous Coronary
Intervention
(All of the Class I indications below are consistent with the
ACC/AHA 2004 Guideline Update for Coronary Artery
Bypass Graft Surgery.)
CLASS I
1. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have significant left main coro-
nary artery stenosis. (Level of Evidence: A)
2. Coronary revascularization before noncardiac surgery is useful
in patients with stable angina who have 3-vessel disease.
(Survival benefit is greater when LVEF is less than 0.50.) (Level
of Evidence: A)
3. Coronary revascularization before noncardiac surgery is useful in
patients with stable angina who have 2-vessel disease with signifi-
cant proximal LAD stenosis and either EF less than 0.50 or demon-
strable ischemia on noninvasive testing. (Level of Evidence: A)
4. Coronary revascularization before noncardiac surgery is recom-
mended for patients with high-risk unstable angina or non–ST-
segment elevation MI.§ (Level of Evidence: A)
5. Coronary revascularization before noncardiac surgery is recom-
mended in patients with acute ST-elevation MI. (Level of Evidence: A)
CLASS IIa
1. In patients in whom coronary revascularization with PCI is appro-
priate for mitigation of cardiac symptoms and who need elective
§High-risk unstable angina/non–ST-segment elevation MI patients
were identified as those with age greater than 75 years, accelerating
tempo of ischemic symptoms in the preceding 48 hours, ongoing rest
pain greater than 20 minutes in duration, pulmonary edema, angina with
S3 gallop or rales, new or worsening mitral regurgitation murmur,
hypotension, bradycardia, tachycardia, dynamic ST-segment change
greater than or equal to 1 mm, new or presumed new bundle-branch
block on ECG, or elevated cardiac biomarkers, such as troponin.
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noncardiac surgery in the subsequent 12 months, a strategy of
balloon angioplasty or bare-metal stent placement followed by 4
to 6 weeks of dual-antiplatelet therapy is probably indicated.
(Level of Evidence: B)
2. In patients who have received drug-eluting coronary stents and
who must undergo urgent surgical procedures that mandate the
discontinuation of thienopyridine therapy, it is reasonable to
continue aspirin if at all possible and restart the thienopyridine as
soon as possible. (Level of Evidence: C)
CLASS IIb
1. The usefulness of preoperative coronary revascularization is not
well established in high-risk ischemic patients (e.g., abnormal
dobutamine stress echocardiograph with at least 5 segments of
wall-motion abnormalities). (Level of Evidence: C)
2. The usefulness of preoperative coronary revascularization is not
well established for low-risk ischemic patients with an abnormal
dobutamine stress echocardiograph (segments 1 to 4). (Level of
Evidence: B)
CLASS III
1. It is not recommended that routine prophylactic coronary revas-
cularization be performed in patients with stable CAD before
noncardiac surgery. (Level of Evidence: B)
2. Elective noncardiac surgery is not recommended within 4 to 6
weeks of bare-metal coronary stent implantation or within 12
months of drug-eluting coronary stent implantation in patients
in whom thienopyridine therapy, or aspirin and thienopyridine
therapy, will need to be discontinued perioperatively. (Level of
Evidence: B)
3. Elective noncardiac surgery is not recommended within 4
weeks of coronary revascularization with balloon angioplasty.
(Level of Evidence: B)
7.1.1. Rationale for Surgical Coronary Revascularization
To understand the value of preoperative evaluation, it is
important to understand the pathophysiology of perioperative
cardiac morbidity. This topic has been reviewed elsewhere
(290). Ellis et al (291) analyzed the coronary angiograms of
63 patients undergoing major nonthoracic vascular surgery in
a case-control study that indirectly supported benefit from
preoperative coronary bypass surgery and found that a coro-
nary occlusion proximal to viable myocardium was associ-
ated with a higher rate of perioperative MI and death, which
raises the question of whether revascularizing coronary oc-
clusions might not reduce the frequency of these adverse
events. However, in that study, the number of mild,
“nonobstructive” lesions was also associated with MI and
death. This is consistent with studies that show that the
most severe stenoses may not always be responsible for MI
and that coronary thrombosis frequently occurs at the site
of milder stenoses. Thus, preoperative revascularization of
severe stenoses may not reduce perioperative ischemic
complications (292).
7.1.2. Preoperative CABG
Until recently, all of the evidence regarding the value of
surgical coronary revascularization was derived from cohort
studies in patients who presented for noncardiac surgery after
successful cardiac surgery. There are now several randomized
trials that have assessed the overall benefit of prophylactic
coronary bypass surgery to lower perioperative cardiac risk of
noncardiac surgery, the results of which can be applied to
specific subsets of patients and will be discussed later.
There have been several cohort studies published. In 1984,
results of preoperative coronary angiography were reported in
a large series of 1001 patients under consideration for elective
vascular surgical procedures at the Cleveland Clinic (293).
Severe CAD was identified by routine coronary angiography
in 251 patients who met contemporary indications for CABG.
In the 216 patients who underwent CABG, the mortality rate
after CABG was 5.3%, with a subsequent mortality rate of
1.5% after vascular surgery. In the entire cohort of 1001
patients, operative deaths with vascular surgery occurred in 1
(1.4%) of 74 patients with normal coronary arteries, in 5
(1.8%) of 278 patients with mild to moderate CAD, in 9
(3.6%) of 250 patients with advanced but compensated CAD,
and in 6 (14%) of 44 patients with severe, uncorrected, or
inoperable CAD (294).
Eagle et al analyzed 3368 patients in the CASS database
who underwent noncardiac surgery during more than 10 years
of follow-up after entry in the CASS study (60). Patients
undergoing urologic, orthopedic, breast, and skin operations
had a very low mortality rate, less than 1%, regardless of
whether they had undergone prior CABG for CAD. However,
patients undergoing thoracic, abdominal, vascular, and head
and neck surgery had a much higher risk of death and MI in
the 30 days after the surgical procedure. In the subset of
patients undergoing these higher-risk surgical procedures,
patients who had undergone prior CABG had a lower risk of
death (1.7% versus 3.3%, P0.03) and nonfatal MI (0.8%
versus 2.7%, P0.002) than patients without prior CABG.
Prior CABG before noncardiac surgery demonstrated the
most benefit among patients with multivessel CAD and those
with more severe angina. These data indicate that patients
undergoing low-risk procedures are unlikely to derive benefit
from CABG before low-risk surgery but suggest that patients
with multivessel disease and severe angina undergoing high-
risk surgery might well benefit from revascularization before
noncardiac surgery.
Prior to the publication of randomized trials to address this
issue, several authors used decision analysis and evaluation of
claims databases to determine the value of coronary revascu-
larization before noncardiac surgery. In an attempt to balance
the potential risks versus benefits of CABG before vascular
surgery, the additional short-term risks and long-term benefits
should be understood. Long-term benefits of such strategies
were not incorporated into 2 decision models (282,283) that
demonstrated that the value of coronary revascularization
before noncardiac surgery depended on local mortality rates
for both CABG and noncardiac surgery. If the long-term
benefits had been included, the value of preoperative coro-
nary revascularization would have been increased. For in-
stance, the European Coronary Surgery Study Group (295)
has reported interesting findings in a small subset of 58
patients with peripheral vascular disease within a much larger
series of 768 men who were randomly assigned to receive
either coronary bypass surgery or medical management for
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angina pectoris. Although the presence of incidental periph-
eral vascular disease was associated with reductions in the
8-year survival rates for either surgical or medical manage-
ment of CAD, its influence was especially unfavorable in
patients who received medical therapy alone; that is, the
long-term survival rate was 85% after coronary bypass
surgery compared with 57% for nonsurgical treatment
(P0.02). Rihal and colleagues (296) have reported similar
findings in more than 2000 patients enrolled in the CASS
study. Compared with coronary bypass surgery in patients
with both CHD and peripheral vascular disease, surgically
treated patients with 3-vessel disease had significantly better
long-term survival than those treated medically after adjust-
ment for all covariates, including clinical measures of disease
stability, stress test results, and LV function. In a study at the
Cleveland Clinic Foundation, the cumulative 5-year survival
rate for the 216 patients who received coronary bypass was
72% (81% in men without diabetes mellitus) compared with
43% (P0.001) for 35 patients in whom coronary bypass was
indicated but never performed (294,297). Fatal cardiac events
occurred within a mean of 4.6 years in 12% and 26% of these
2 subsets, respectively (P0.033). These later studies illus-
trate the importance of both perioperative and long-term
cardiac risk when one considers whether to recommend
coronary bypass surgery before noncardiac surgery.
A study by Fleisher et al (298) of a cohort of Medicare
beneficiaries undergoing infrainguinal or abdominal aortic
reconstructive surgery found that preoperative stress testing
followed by revascularization was associated with improved
short- and long-term survival with the higher-risk aortic
surgery. However, this association may be confounded by the
fact that the cohorts referred for preoperative stress testing
were “healthier” patients, as evidenced by the finding that
stress testing with or without coronary revascularization was
associated with greater short- and long-term survival. On the
other hand, a number of retrospective studies have demon-
strated that patients who previously have successfully under-
gone coronary bypass have a low perioperative mortality rate
in association with noncardiac procedures and that their
mortality rate is comparable to the surgical risk for other
patients who have no clinical indications of CAD (299–302).
The first large, randomized trial (CARP) was published by
McFalls and colleagues (143), who randomly assigned 510
patients with significant coronary artery stenosis among 5859
patients scheduled for vascular operations to either coronary
artery revascularization before surgery or no revasculariza-
tion before surgery. Indications for vascular operations were
expanding aortic abdominal aneurysm in 33% or peripheral
vascular occlusive disease in 67%. Patients needing emergent
or urgent surgery were excluded, as were patients with
unstable coronary syndromes, at least 50% stenosis of the left
main coronary artery, LVEF less than 20%, or severe
aortic stenosis. One or more major coronary arteries had to
have at least 70% stenosis and be suitable for revascular-
ization. Overall, 74% of the 510 patients had 3 or more of
the Eagle clinical risk criteria for CAD (44), 2 or more
variables as defined by the Revised Cardiac Risk Index (4),
or a moderate or large reversible defect on perfusion stress
imaging. The remaining patients had angina or abnormal
results on a stress test.
Two hundred fifty-eight patients were assigned to revas-
cularization, and of the 225 who actually received preopera-
tive coronary artery revascularization and had subsequent
vascular surgery, 59% had PCI (PTCA and bare-metal stents)
and 41% had CABG, at the discretion of the local investiga-
tors. The average number of vessels revascularized was 3.0
plus or minus 0.8 in the CABG patients and 1.3 plus or minus
0.8 in the PCI group. Thirty-three patients had coronary
revascularization and did not undergo subsequent vascular
surgery. Of these 33 patients, 10 died after CABG or PCI, 18
declined vascular surgery, and 5 developed a severe coexist-
ing condition. Of those proceeding to vascular surgery, 4
deaths occurred in the revascularization group; 3 patients (2
after PCI and 1 after CABG) died after vascular surgery,
which was performed during the same admission as the
coronary revascularization procedure. Four percent of the
patients assigned to the nonrevascularization group under-
went coronary revascularization because of a change in their
cardiac status. In the revascularization group, a median of 48
days after CABG and 41 days after PCI elapsed before the
vascular operation. The types of vascular surgery procedures,
anesthesia, and adjunctive medical management were similar
between the revascularization and no-revascularization
groups. Long-term medical management was similar between
the 2 groups.
At 30 days after the vascular operation and analyzing
treatment assigned, death had occurred in 3.1% of the
revascularization group and 3.4% of the nonrevascularization
group (P0.87). Within 30 days of the vascular operation,
postoperative MI by biomarker criteria had occurred in 12%
of the revascularization group and 14% of the nonrevascu-
larization group (P0.37). At 2.7 years after randomization,
mortality was 22% in the revascularization group and 23% in
the nonrevascularization group (RR: 0.98, 95% CI: 0.70 to
1.37, P0.92). Analysis with regard to treatment received
rather than treatment assigned did not alter the long-term
mortality findings. The authors concluded that routine coro-
nary revascularization in patients with stable cardiac symp-
toms before elective vascular surgery does not significantly
alter the long-term outcome or short-term risk of death or MI.
In a subsequent publication from the CARP trial, the
authors reported on the subset of 222 patients who underwent
elective vascular surgery after coronary revascularization
(303). Prior CABG had been performed in 91 patients and
prior PCI in 131 patients. Patients were not randomized
between CABG and PCI; rather, the type of coronary revas-
cularization was left to the discretion of the local investigator.
Completeness of revascularization was defined as the number
of coronary vessels revascularized relative to the total number
of vessels with a stenosis of 70% or greater. A revascular-
ization rate of greater than 100% could be obtained by this
definition. Baseline clinical characteristics, Revised Cardiac
Risk Index, results of stress imaging, and medical treatment
were similar in the CABG and PCI groups. The CABG group
had 3.0 (standard deviation 1.3) significantly stenosed vessels
compared with 2.2 (standard deviation 1.4) in the PCI group
(P less than 0.001). Completeness of revascularization was
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117% (standard deviation 66%) in the CABG group com-
pared with 81% (standard deviation 57%) in the PCI group (P
less than 0.001). The incidence of death was not significant
between the CABG and PCI groups (2.2% versus 3.8%,
respectively; P0.497). The incidence of any MI at 30 days
and any MI after vascular surgery was higher in the PCI
group than in the CABG group (30 days, 16.8% versus 6.6%,
P0.024; after vascular surgery, 32.7% versus 9.9%,
P0.009). They also found that the longer the delay between
coronary revascularization and the vascular operation, the
higher the incidence of MI. In the entire group, MI was
inversely related to the completeness of revascularization
(P0.02) and occurred more frequently in abdominal than in
infrainguinal vascular operations (19% versus 7.5%,
P0.01). This study addressed outcomes after vascular sur-
gery in patients who received nonrandomized coronary re-
vascularization procedures and did not address the relative
benefit or risk of CABG compared with PCI for preoperative
coronary revascularization using intention-to-treat analysis.
In patients in whom coronary revascularization is indi-
cated, timing of the procedure depends on the urgency of the
noncardiac surgical procedure balanced against the stability
of the underlying CAD. The decision to perform revascular-
ization on a patient before noncardiac surgery to “get them
through” the noncardiac procedure is appropriate only in a
small subset of very-high-risk patients when long-term out-
comes are included.
The DECREASE-II trial (59) was designed to evaluate the
utility of cardiac testing in patients undergoing major vascu-
lar surgery with intermediate cardiac risk factors and ade-
quate beta-blocker therapy. A composite end point of death
and nonfatal MI was assessed at 30 days after vascular
surgery. The incidence of the primary end point in patients
with extensive ischemia was 14.7%. Extensive ischemia was
identified in 34 patients (8.8% of the population studied).
Only 12 of 34 patients with extensive ischemia were consid-
ered to be candidates for coronary revascularization. The
authors found that “in intermediate-risk patients with exten-
sive ischemia, no revascularization compared with revascu-
larization did not improve 30-day outcome (25.0% versus
9.1% events; OR 3.3, 95% CI: 0.5 to 24; p less than 0.32).”
The authors went on to state, “The effect of coronary
revascularization in intermediate-risk patients with extensive
stress-induced ischemia cannot be assessed, owing to the
insufficient number of patients studied.” This study confirms
that extensive cardiac ischemia is a risk factor for perioper-
ative cardiac events, but it was too small to assess the effect
of revascularization.
The DECREASE-V pilot study (304) screened 1880 pa-
tients scheduled for major vascular surgery and identified a
high-risk cohort by the presence of 3 or more clinical risk
factors. Of these, 101 showed extensive ischemia on DSE (5
or more ischemic segments, 88% of patients) or dobutamine
or dipyridamole perfusion scintigraphy (at least 3 ischemic
walls, 13% of patients). An LVEF of 35% or less was
observed in 43% of these 101 patients. The 101 patients were
randomized to best medical therapy and revascularization or
best medical therapy alone before vascular surgery. Best
medical therapy included tight heart rate control with beta
blockers and continuation of antiplatelet therapy. The revas-
cularization group (n49) underwent catheterization, which
revealed 2-vessel disease in 24%, 3-vessel disease in 67%,
and left main disease in 8%. Revascularization with PCI was
performed in 65% and CABG in 35%. Drug-eluting stents
(DES) were used in 94% of the PCI patients, and dual-
antiplatelet therapy was continued perioperatively. There was
no significant difference in perioperative transfusion require-
ment in patients with and without antiplatelet therapy. Vas-
cular surgery occurred a median of 29 (range 13 to 65) days
after CABG and a median of 31 (range 19 to 39) days after
PCI. Two patients died after CABG before vascular surgery
owing to ruptured aneurysms. The outcome of 30-day all-
cause death or nonfatal MI was similar between the revascu-
larization and medical therapy patients at 43% versus 33%
(OR: 1.4, 95% CI: 0.7 to 2.8, P0.30), respectively. Postop-
erative troponin elevations occurred in 38.8% of revascular-
ized patients versus 34.7% of medically treated patients. The
incidence of 1-year all-cause death or MI was high (47%) and
similar in both groups at 49% for revascularization and 44%
for medical therapy (OR: 1.2, 95% CI: 0.7 to 2.3, P0.48).
This study was not sized to definitively answer the
question as to the value of preoperative revascularization
in high-risk patients; however, the findings are consistent
with the previously published literature suggesting a lack
of benefit of preoperative coronary revascularization in
preventing death or MI.
Patients undergoing elective noncardiac procedures who
are found to have prognostic high-risk coronary anatomy and
in whom long-term outcome would likely be improved by
coronary bypass grafting (305) should generally undergo
coronary revascularization before a noncardiac elective vas-
cular surgical procedure or noncardiac operative procedures
of intermediate or high risk (Table 4). The cumulative
mortality and morbidity of both the coronary revasculariza-
tion procedure and the noncardiac surgery should be weighed
carefully in light of the individual patient’s overall health,
functional status, and prognosis. The indications for preoper-
ative surgical coronary revascularization, therefore, are es-
sentially identical to those recommended by the ACC/AHA
2004 Guideline Update for Coronary Artery Bypass Graft
Surgery and the accumulated data on which those conclusions
were based (306).
7.1.3. Preoperative PCI
The role of prophylactic preoperative PCI in reducing
untoward perioperative cardiac complications appears limited
to patients with unstable active CAD who would be appro-
priate candidates for emergent or urgent revascularization
under the published ACC/AHA PCI and CABG guidelines
(306,307). Patients with ST-elevation MI, unstable angina,
and non–ST-elevation MI benefit from early invasive man-
agement, as outlined in the current ACC/AHA/SCAI (Society
for Cardiovascular Angiography & Interventions) 2005
guideline update for PCI (307). Additionally, in such patients
in whom noncardiac surgery is imminent, despite an in-
creased risk in the peri-MI period, a strategy of balloon
angioplasty or bare-metal stenting should be considered, as
discussed below.
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Patients with asymptomatic ischemia or stable Canadian
Cardiovascular Society class I or II angina do not appear to be
candidates for prophylactic preoperative coronary revascular-
ization unless cardiac catheterization reveals high-risk surgi-
cal anatomy, as discussed above. The evidence for the use and
timing of PCI discussed below is summarized in Table 10.
It is unclear from the literature whether patients with stable
but severe Canadian Cardiovascular Society class III angina
Table 10. Studies Reporting the Clinical Outcome (Death or Nonfatal MI) of Patients Undergoing Noncardiac Surgery After PCI
Study, Year
No. of Patients
Who
Underwent PCI
Time From PCI
to Surgery
Perioperative
Mortality, %
Perioperative
Infarction, % Comments
PCI without stents (coronary balloon
angioplasty)
Allen et al (308), 1991 148 338 days
(mean)
2.7 0.7 No increase in events if surgery performed within
90 days of PTCA
Huber et al (309), 1992 50 9 days (mean) 1.9 5.6 CABG needed after balloon angioplasty in 10% of
patients; no control group for comparison
Elmore et al (310), 1993 14 10 days
(mean)
0 0% Very small study. Event rate in patients treated
with CABG or balloon angioplasty less than in
control group. Angioplasty patients had fewer risk
factors than patients undergoing CABG
Gottlieb et al (311), 1998 194 11 days
(median)
0.5 0.5 Only vascular surgeries included
Posner et al (312), 1999 686 1 year
(median)
2.6 2.2 Patients who had undergone PCI had a similar
frequency of death and MI but half the angina
and HF as matched patients with CAD who had
not undergone PCI. Event rates were much
higher if PCI had been performed within 90 days
Brilakis et al (313), 2005 350 Within 2
months
0.3 0.6 All events occurred in patients who underwent
surgery within 2 weeks of PTCA
Leibowitz et al (314), 2006 216 Early (0 to 14
days)
19 4.7 56% had balloon angioplasty. 44% had stents.
No outcome difference between balloon
angioplasty and stent groups
Late (15 to 62
days)
11 7.2
PCI with coronary stents
Kaluza et al (315), 2000 40 13 days
(mean)
20 16.8 Mortality was 32% among patients operated on
less than 12 days after stent placement vs 0 in
patients operated on 12 to 30 days after PCI
Hassan et al (316), 2001 251 29 months
(median)
0.8 0.8 Among patients who received PCI in BARI,
outcome after noncardiac surgery was equivalent
to that of BARI patients who had received CABG
McFalls et al (143), 2004 225 54 days
(median)
3.1
(revascularization)
vs 3.4% (control)
11.6
(revascularization)
vs 14.3%
(control)
Patients randomized to coronary revascularization
(PCI in 59%, CABG in 41%) or not before
vascular surgery. No difference in short- or
long-term risk of MI or death
Godet et al (317), 2005 78 5 to 8 weeks 4 9 Propensity analysis showed no benefit for
preoperative revascularization
Vicenzi et al (318), 2006 103 12 months 5 12 Mix of bare-metal and drug-eluting stents. Cardiac
risk within 35 days of stent implantation was
increased 2.1-fold compared with after 35 days
Schouten et al (319), 2007 192 Early 13.3 0 Early surgery: 13.3% had MACE; late surgery:
0.6% had MACE. Early surgery and no
thienopyridine: 30.7% had MACE
Late 0.6 0
Poldermans et al (304), 2007 32 PCI
17 CABG
31 days 22.5 at 30 days 34.7 at 30 days High-risk patients with significant CAD
randomized to revascularization vs medical
therapy. No advantage to revascularization in
primary end point at 30 days or 1 year
BARI indicates Bypass Angioplasty Revascularization Investigation; CAD, coronary artery disease; CABG, coronary artery bypass surgery; HF, heart failure; MACE,
major adverse cardiovascular event(s); MI, myocardial infarction; PCI, percutaneous coronary intervention; PTCA, percutaneous transluminal coronary angioplasty.
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would benefit from prophylactic preoperative coronary inter-
vention. Indications for PCI for patients with this clinical
presentation are outlined in the current ACC/AHA/SCAI
2005 guideline update for PCI (307). The balance of the
evidence to date suggests that routine preoperative coronary
revascularization in patients with stable class III angina will
not alter perioperative risk. High-risk unprotected left main
disease in a noncardiac surgical candidate presents a special
case for consideration. The reported high rates of restenosis
and acute events after balloon angioplasty, atherectomy, and
bare-metal stenting in the left main artery suggest that these
procedures would be a poor preoperative strategy before
noncardiac surgery (320). There have been reports of suc-
cessful unprotected left main PCI with DES in this group of
patients (321), but the need for prolonged and perhaps
lifelong dual-antiplatelet therapy to prevent catastrophic sub-
acute thrombosis suggests that this strategy would have
limited utility in the preoperative setting as well. Coronary
artery bypass grafting should be considered in suitable
patients with significant left main stenoses.
Percutaneous intervention as a prophylactic preopera-
tive coronary intervention in stable patients with prior
coronary bypass surgery before noncardiac surgery is of
unknown value. However, recurrent symptomatic ischemia
early after CABG is a class I indication for percutaneous
revascularization.
In summary, the present review of the literature suggests
that PCI before noncardiac surgery is of no value in prevent-
ing perioperative cardiac events, except in those patients in
whom PCI is independently indicated for an acute coronary
syndrome. However, unscheduled noncardiac surgery in a
patient who has undergone a prior PCI presents special
challenges, particularly with regard to management of the
dual-antiplatelet agents required in those who have received
coronary stents.
7.1.4. PCI Without Stents: Coronary Balloon
Angioplasty
Several retrospective series of coronary balloon angioplasty
before noncardiac surgery have been reported (Table 10). In
a 50-patient series reported from Mayo Clinic (309), PTCA
using balloons without stents was performed before noncar-
diac surgery (52% vascular procedures) in patients at high
risk for perioperative complications (62% with greater than
Canadian Cardiovascular Society class III angina, 76% with
multivessel disease, and all with positive functional tests).
Urgent CABG was required in 10% of patients after PTCA.
The noncardiac operation was performed a median of 9 days
after PCI, and the perioperative MI rate was 5.6%, whereas
the mortality rate was 1.9%. Whether this result differs from
what might have occurred without PTCA is uncertain.
Elmore et al (310) analyzed a cohort of 2452 patients who
had abdominal aortic aneurysm surgery between 1980 and
1990, of whom 100 patients (4.1%) required perioperative
coronary revascularization (86 had CABG, and 14 had
PTCA). No deaths occurred in either group, and the periop-
erative mortality rate for the 2452 patients was 2.9%. The
median number of days between the coronary revasculariza-
tion and surgery was 10 days for PTCA and 68 days for
CABG. At 3 years, no statistical difference in survival was
seen between the groups (82.8% for CABG and 92.3% for
PTCA). The 3-year cardiac event rates were 27.3% for the
CABG group and 56.5% for the PTCA group. The small
numbers of patients in the PTCA group and the retrospective
analysis over a long period of time make interpretation of the
results of this study difficult. It appears, however, that
candidates for elective abdominal aortic aneurysm surgery
who have symptomatic disease (CAD) have a low operative
mortality when revascularization is performed before surgery
by either PTCA or CABG.
Allen et al (308) performed a retrospective analysis of 148
patients who underwent angioplasty before noncardiac sur-
gery (35% abdominal, 33% vascular, and 13% orthopedic
surgery). Surgery occurred within 90 days after angioplasty in
72 patients. There were 4 operative deaths (1 cardiac), and 16
patients experienced cardiac complications during the non-
cardiac surgery. Cardiac complications were more common
in patients older than 60 years. Little information can be
gleaned from this small retrospective study except to note the
low incidence of cardiac death in patients who had coronary
angioplasty sometime before their noncardiac surgery.
Gottlieb et al (311) studied 194 patients with CAD who
underwent PTCA before vascular surgery (abdominal aortic,
carotid endarterectomy, or peripheral vascular surgery). The
median interval between PTCA and surgery was 11 days
(interquartile range 3 to 49 days) (311). Twenty-six (13.4%)
of the patients had a cardiac complication, but only 1 patient
died, and 1 had a nonfatal MI. The variable time interval
over which PTCA was performed before surgery and the
inability to know whether the clinical outcome of these
patients would have been different had a prior PTCA
procedure not been performed limit the conclusions that
can be drawn from this study.
Massie et al performed a case-control study of 140 patients
with abnormal dipyridamole myocardial perfusion imaging
scans in 2 or more segments; 70 underwent coronary angiog-
raphy (of whom 25 were referred for revascularization), and
70 (matched for age, gender, type of vascular surgery, and
number of myocardial segments that were suggestive of
ischemia on myocardial perfusion imaging scanning) did not
(322). A trend toward late benefit associated with preopera-
tive revascularization was offset by a trend toward an early
hazard from the risk of the preoperative invasive cardiac
evaluation and treatment. There were no significant differ-
ences between the angiography group and matched control
subjects with respect to the frequency of perioperative non-
fatal MI (13% versus 9%) or fatal MI (4% versus 3%) or the
frequency of late nonfatal MI (16% versus 19%) or late
cardiac death (10% versus 13%).
In a retrospective cohort study by Posner et al (312),
adverse events in the 30 days after noncardiac surgery were
compared among patients who had undergone preoperative
PTCA at any time, patients with nonrevascularized CAD, and
patients without known coronary disease (“normal controls”).
Patients with CAD had twice the risk of an adverse outcome
as normal controls (OR: 1.98, P less than 0.001); however,
the risk of an adverse outcome among patients who had
undergone PTCA was half that of patients with nonrevascu-
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larized CAD. The benefit was limited to a reduction in angina
and HF; there was no reduction in early postoperative MI or
death associated with prior PTCA. The investigators did not
control for the severity of coronary disease, comorbid
illness, or the medical management used in the PTCA and
nonrevascularized CAD groups. No benefit was seen in
patients who had a PTCA 90 days or less before noncardiac
surgery. The long time frame in which PTCA had been
performed preoperatively limits the conclusions that can
be drawn from this study.
Leibowitz et al (314) performed a retrospective review of
216 patients who had PCI with balloon angioplasty alone or
PCI with stenting within 3 months of noncardiac surgery.
Adverse clinical events included acute MI, major bleeding,
and death less than 6 months after noncardiac surgery.
Overall, 11% of patients died, 12% in the balloon-only group
(13/122) versus 14% in the stent group (13/94; PNS). There
was no significant difference in either acute MI or bleeding
between the balloon-only group (6% and 13%, respectively)
and the stent group (7% and 16%, respectively). More deaths
occurred in both the balloon-only and stent groups if noncar-
diac surgery was performed on days 0 to 14 after PCI (19%)
than on days 15 to 62 after PCI (11%). However, the
retrospective nature of the study did not allow for standard-
ization of medical therapy after PCI, and 46% of patients who
died had an ejection fraction less than 30%.
A retrospective analysis by Brilakis et al (313) of 350
patients who underwent balloon angioplasty between 1988
and 2001 in the 2 months before noncardiac surgery found 3
(1.6%) had perioperative MI or death, and all these events
occurred in the patients who underwent noncardiac surgery
within 2 weeks of balloon angioplasty. The authors concluded
that the risk of perioperative death or MI in patients who
undergo PCI before noncardiac surgery is low, and PTCA
balloon angioplasty should be performed at least 2 weeks
before noncardiac surgery.
There are data that permit comparison of the protective
effects of revascularization with CABG and balloon angio-
plasty before noncardiac surgery. In the Bypass Angioplasty
Revascularization Investigation, patients with multivessel
coronary disease were randomly assigned to undergo balloon
angioplasty or CABG (323). In an ancillary study, the results
of 1049 surgeries performed in 501 patients subsequent to
randomization were analyzed; 250 patients had undergone
CABG, and 251 had balloon angioplasty (316). The median
time from the most recent coronary revascularization proce-
dure to noncardiac surgery was 29 months. The results of the
study revealed that the frequency of death or MI was low in
patients with multivessel disease who had undergone either
procedure (1.6% in both groups), and there was no difference
in the length of hospitalization or hospital cost. The risk of
death or MI was lower when the noncardiac surgery was
performed less than 4 years after coronary revascularization
(0.8% versus 3.6% in patients undergoing surgery 4 or more
years after coronary revascularization). These data do not
provide insight into which patients require preoperative
coronary revascularization, but they do suggest that the risk
of perioperative infarction or death is approximately equal in
patients who have undergone balloon angioplasty or CABG if
they had been appropriate for and amenable to either type of
coronary revascularization procedure.
After balloon angioplasty, delaying noncardiac surgery for
more than 8 weeks increases the chance that restenosis at the
angioplasty site will have occurred and theoretically increases
the chances of perioperative ischemia or MI. However,
performing the surgical procedure too soon after the PCI
procedure might also be hazardous. Arterial recoil or acute
thrombosis at the site of balloon angioplasty is most likely to
occur within hours to days after balloon coronary angioplasty.
Delaying surgery for at least 2 to 4 weeks after balloon
angioplasty to allow for healing of the vessel injury at the
balloon treatment site is supported by the study by Brilakis et
al (313). Daily aspirin antiplatelet therapy should be contin-
ued perioperatively. The risk of stopping the aspirin should be
weighed against the benefit of reduction in bleeding compli-
cations from the planned surgery.
7.1.5. PCI: Bare-Metal Coronary Stents
Table 10 also provides data on several studies of PCI with
coronary stenting before noncardiac surgery. Godet et al(317)
performed an analysis of 1152 patients after abdominal aortic
surgery, 308 of whom underwent preoperative coronary
angiography and 78 of whom underwent PCI (bare-metal
stents in 96%). Patients who underwent coronary angiogra-
phy without PCI fell into 2 groups: those with minor coronary
lesions (n13) and those with untreatable severe CAD
(n123). This latter group had a high cardiac risk, with
severe postoperative coronary events occurring in 14.5% and
death in 8.1%. After aortic surgery, compared with a control
group of patients without preoperative PCI, the preoperative
bare-metal coronary stent group showed no significant dif-
ferences in death (4% in the control group and 5% in the stent
group) or in severe postoperative coronary events (defined as
new Q waves, prolonged ST-T changes, or positive troponin
I; 6% in the control group and 9% in the stent group).
Propensity analysis provided a similar conclusion, with a
predicted rate of severe postoperative coronary events of
8.2% versus an observed rate in the bare-metal coronary stent
group of 9.0% (nonsignificant) and a predicted rate of death
of 6.9% versus an observed rate of 5.1% (nonsignificant).
A retrospective study by Kaluza et al (315) indicated that
the frequency of bare-metal stent thrombosis when elective
noncardiac surgery is performed within 2 weeks of stent
placement is very high, as is the frequency of MI and death.
In that study, there were 8 deaths, 7 MIs, and 11 major
bleeding episodes in 40 patients who underwent coronary
bare-metal stent placement less than 6 weeks (1 to 39 days,
average 13 days) before noncardiac surgery. All deaths and
MIs occurred in patients who were subjected to surgery less
than 14 days after bare-metal stenting, and stent thrombosis
accounted for most of the fatal events.
Another retrospective analysis by Wilson et al (324) of
patients who underwent major noncardiac surgery in the 2
months after bare-metal coronary stent placement showed
death, MI, or stent thrombosis in 8 (4%) of 207 patients, with
death occurring in 6 patients (3%). Examination of the
interval between coronary stenting and cardiac events re-
vealed that all adverse events occurred in patients who
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underwent noncardiac surgery within 6 weeks of coronary
stenting. Neither bleeding complications nor transfusion rate
appeared related to the antiplatelet regimen (324).
Reddy and Vaitkus (325) published a retrospective analysis
of 56 patients who received bare-metal coronary stents before
noncardiac surgery that showed that 38% of patients who
underwent surgery within 14 days of coronary stenting
experienced a stent-related MI or cardiovascular death. No
patients who underwent noncardiac surgery more than 6
weeks after coronary stenting had stent-related MI or cardio-
vascular death.
Sharma et al (326) retrospectively reviewed 47 patients
who underwent noncardiac surgery within 90 days of bare-
metal coronary stent implantation. They noted a 26% mortal-
ity rate in patients who had noncardiac surgery within 3
weeks of stent implantation compared with a 5% mortality
rate in those in whom noncardiac surgery occurred more than
3 weeks after stent implantation. More importantly, in the
early-surgery group, death occurred in 1 (5%) of 20 patients
who continued taking thienopyridines perioperatively com-
pared with 6 (85.7%) of 7 patients in whom thienopyridines
were discontinued. There were no significant differences in
bleeding between those taking or not taking thienopyridines.
If a coronary stent is used in the revascularization proce-
dure, as in the majority of percutaneous revascularization
procedures, further delay of noncardiac surgery may be
beneficial. Bare-metal stent thrombosis is most common in
the first 2 weeks after stent placement and is exceedingly rare
(less than 0.1% of most case series) more than 4 weeks after
stent placement (327,328). Given that stent thrombosis will
result in Q-wave MI or death in the majority of patients in
whom it occurs, and given that the risk of bare-metal stent
thrombosis diminishes after endothelialization of the stent has
occurred (which generally takes 4 to 6 weeks), it appears
reasonable to delay elective noncardiac surgery for 4 to 6
weeks to allow for at least partial endothelialization of the
stent, but not for more than 12 weeks, when restenosis may
begin to occur.
A thienopyridine (ticlopidine or clopidogrel) is generally
administered with aspirin for 4 weeks after bare-metal stent
placement. The thienopyridines and aspirin inhibit platelet
aggregation and reduce stent thrombosis but increase the risk
of bleeding. Rapid endothelialization of bare-metal stents
makes late thrombosis rare, and thienopyridines are rarely
needed for more than 4 weeks after implantation of bare-
metal stents. For this reason, delaying surgery 4 to 6 weeks
after bare-metal stent placement allows proper thienopyridine
use to reduce the risk of coronary stent thrombosis; then, after
the thienopyridine has been discontinued, the noncardiac
surgery can be performed. However, once the thienopyridine
is stopped, its effects do not diminish immediately. It is for
this reason that some surgical teams request a 1-week delay
after thienopyridines are discontinued before the patient
proceeds to surgery. In patients with bare-metal stents, daily
aspirin antiplatelet therapy should be continued periopera-
tively. The risk of stopping the aspirin should be weighed
against the benefit of reduction in bleeding complications
from the planned surgery. In the setting of noncardiac surgery
in patients who have recently received a bare-metal stent, the
risk of stopping dual-antiplatelet agents prematurely (within 4
weeks of implantation) is significant compared with the risk
of major bleeding from most commonly performed surgeries.
7.1.6. PCI: DES
Drug-eluting stents are designed to reduce neointimal forma-
tion, thus leading to lower restenosis rates. The currently
available DES are coated with either sirolimus or paclitaxel.
Several additional agents are in clinical testing. However, the
action of these drugs will delay endothelialization and healing
and possibly induce hypersensitivity to the drug or polymer
and lead to an increased risk of thrombosis (329,330).
Thrombosis of DES may occur late and has been reported up
to 1.5 years after implantation, particularly in the context of
discontinuation of antiplatelet agents before noncardiac sur-
gery (331,332).
Vicenzi et al (318) reported a prospective observational
study of 103 patients who underwent noncardiac surgery
within 12 months of stent implantation. A mix of bare-metal
stents and DES was reported, but in a significant number of
patients, the type of stent could not be identified. Antiplatelet
agents were either continued perioperatively or discontinued
for fewer than 3 days preoperatively. All patients received
therapeutic unfractionated heparin or enoxaparin. The main
outcome variable was the combined perioperative complica-
tion rate at 30 days, which included cardiac complications,
bleeding, surgical complications, and sepsis. Cardiac compli-
cations included death, MI, repeat revascularization, conges-
tive HF, new unstable angina, new significant arrhythmias, or
myocardial cell injury, defined as a positive troponin T
without ECG signs or symptoms. Fully 45% of the patients
experienced complications, and 4.9% died. The majority
(333,334) of complications were cardiac (5% cardiac death,
12% MI, and 22% myocardial cell injury). Only 4% had
bleeding complications despite the use of an anticoagulation
regimen. Recently implanted stents (less than 35 days before
surgery) resulted in a 2.1-fold increase in adverse events
compared with those implanted more than 90 days before
surgery. Outcomes stratified by type of anticoagulation
regimen, type of stent, and type of operation were not
reported. The authors estimated that 5% of stented patients
from their institutions underwent subsequent noncardiac
surgery. This study raises concern that noncardiac surgery,
even with continued antiplatelet or anticoagulation regi-
mens, presents a substantial risk of cardiac events in the
year after stent implantation.
The CARP trial (143) and DECREASE-V pilot trial (304)
used bare-metal stents and DES, respectively, in some of the
patients randomized to revascularization in those trials, and
neither trial showed an advantage of preoperative PCI with
stents in preventing perioperative death or MI. See Section
7.1.2 for details.
Schouten et al (319) reported a single-center registry
experience of 192 patients who had noncardiac surgery
between 1999 and 2005 who also had a successful PCI for
unstable coronary disease within the preceding 2 years.
Patients with bare-metal stents received lifelong aspirin and
at least 1 month of clopidogrel, and patients with DES
received lifelong aspirin and clopidogrel for at least 3 months
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(sirolimus) or 6 months (paclitaxel), according to the existing
guidelines. No protocol for continuation or withholding of
antiplatelet agents before noncardiac surgery was in force,
and this decision was left to the care providers. The compos-
ite end point of major adverse cardiac events (MACE, defined
as nonfatal MI or death) at 30 days after noncardiac surgery
was analyzed. There was a Revised Cardiac Risk Index of 1
in 34%, 2 in 39%, and 3 or more in 28% of the patients. Beta
blockers were being taken preoperatively by 68% of patients.
Bare-metal stents were used in 48% and DES in 54% of the
patients. The early-surgery group was defined as those whose
noncardiac surgery occurred within the time frame when
clopidogrel was required (bare-metal stent, 1 month; siroli-
mus stent, 3 months; and paclitaxel stent, 6 months). Late
surgery was defined as noncardiac surgery that occurred after
this time. A total of 2.6% of all patients experienced MACE
(all fatal), with a 13.3% rate of MACE in the early-surgery
group and 0.6% in the late-surgery group. Interruption of
antiplatelet therapy was associated with a significantly higher
rate of MACE (5.5% versus 0%, P0.0023) in the entire
group of patients undergoing noncardiac surgery. Discontin-
uation of antiplatelet therapy in the early-surgery group
resulted in a 30.7% incidence of MACE (all fatal) versus a
0% incidence in early-surgery patients who continued dual-
antiplatelet therapy perioperatively. Overall, there was no
difference in MACE between patients with bare-metal stents
and those with DES. The study reported that all patients with
MACE had discontinued antiplatelet therapy before surgery,
whereas only 46% without MACE had done so. The study
also stated there was no difference in surgical risk between
patients in whom antiplatelet agents were discontinued and
those in whom they were not. Excessive blood loss occurred
in 2 patients, 1 of whom was receiving antiplatelet agents and
1 of whom was not. Transfusions were required in 24% of
patients taking antiplatelet therapy and in 20% of those in
whom antiplatelet therapy was discontinued (P0.50). The
authors concluded that there was an increased rate of MACE
in patients undergoing early surgery and that discontinuation
of antiplatelet agents may be a major cause of this MACE.
This study was reported as research correspondence, and the
authors cited the limitation of small numbers in interpretation
of the results. Nonetheless, these findings are concordant with
other small series and support the conclusion that early
surgery and discontinuation of antiplatelet agents are risk
factors for cardiac events at the time of noncardiac surgery
after stent placement.
7.1.7. Stent Thrombosis and DES
Several reports of stent thrombosis after discontinuation of
antiplatelet therapy before noncardiac surgery have been
published and raise concern. Iakovou et al (333) followed up
2229 patients after DES implantation. Overall, 1.3% had stent
thrombosis, with a case fatality rate of 45%. Subacute
thrombosis within 30 days of implantation occurred in 0.6%
of patients, and late thrombosis, more than 30 days after
implantation, occurred in 0.7%. Independent predictors of
stent thrombosis were premature discontinuation of antiplate-
let therapy (hazard ratio [HR]: 90, P less than 0.001), renal
failure (HR: 6.49, P less than 0.001), bifurcation lesions
(HR: 6.42, P less than 0.001), diabetes mellitus (HR:
3.71, P0.001), and lower ejection fraction (HR: 1.09 for
each 10% decrease, P less than 0.001). Thrombosis occurred
in 29% of patients who prematurely discontinued dual-
antiplatelet therapy. Moreno et al (335) performed a meta-
analysis of DES trials and found no significant difference
in the rate of stent thrombosis between DES (0.58%)
and bare-metal stents (0.54%); however, they noted the
absence of thienopyridine therapy to be associated with
DES thrombosis.
Ong et al (336) reported on late angiographic DES throm-
bosis, defined as occurring at least 1 month after stent
implantation. They reported an incidence of late stent throm-
bosis of 0.35% in patients treated with DES; however, of the
8 angiographically confirmed cases of late stent thrombosis in
their cohort of 2006 patients, 3 were related to complete
cessation of antiplatelet therapy, and 2 additional cases
occurred within 1 month of cessation of clopidogrel therapy.
McFadden et al (331) reported 4 cases of stent thrombosis
that occurred 343 to 442 days after stent implantation shortly
after discontinuation of antiplatelet agents. Nasser et al
(332) reported 2 cases in which aspirin was stopped for
noncardiac surgery 4 and 21 months after DES implanta-
tion; both patients suffered acute stent thrombosis and a
large MI, and 1 died.
Spertus et al (337) reported a 19-center study of 500
patients with acute MI designed to examine the prevalence
and predictors of thienopyridine discontinuation 30 days after
DES treatment. They found that 13.6% stopped thienopyri-
dine therapy within 30 days, and these patients were more
likely to die (7.5% versus 0.7%, P less than 0.0001) and to be
rehospitalized (23% versus 14%, P0.08) by 12 months than
those who continued thienopyridine therapy.
The BASKET-LATE study (Basel Stent Cost-
Effectiveness Trial–Late Thrombotic Events) (338) reported
a significantly greater incidence of death and nonfatal MI in
patients who had received DES than in those who received
bare-metal stents after clopidogrel had been discontinued at 6
months. A consecutive series of 746 patients with 1133
stented lesions randomly assigned in a 2:1 fashion to DES or
bare-metal stents and without events at 6 months were
followed up for 12 months after the discontinuation of
clopidogrel. Groups were well matched with regard to base-
line clinical characteristics, and the cohort included consec-
utive patients with indications for the procedure of ST-
elevation MI in 21.1% and unstable angina in 36.7%. Overall,
the 18-month rate of death or MI was not different between
the DES and bare-metal stent groups. The rate of death or MI
after clopidogrel discontinuation at 6 months was 4.9% in the
DES group and 1.3% in the bare-metal stent group (HR: 2.2,
P0.03). Documented late stent thrombosis was twice as
frequent in the DES group as in the bare-metal stent group
(2.6% versus 1.3%), and occurred between 15 and 362 days
(median 116 days, interquartile range 53 to 313 days) after
discontinuation of clopidogrel. Stent thrombosis was associ-
ated with an 88% risk of death or nonfatal MI. Target-vessel
revascularization was less frequent in the DES group than in
the bare-metal stent group (7.5% versus 11.6%, P0.04). The
authors concluded that after the discontinuation of clopi-
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dogrel, there is an increased incidence of cardiac death and
nonfatal MI in patients receiving DES compared with bare-
metal stents, possibly related to stent thrombosis.
A long-term observational study of 24-month clinical
outcomes in patients with stents and varying duration of
clopidogrel therapy was reported by Eisenstein et al (339). A
total of 4666 patients who received bare-metal stents
(n3165) or DES (n1501) were followed up at 6, 12, and
24 months. Patients were stratified with regard to type of stent
and clopidogrel use. Landmark analysis was performed on
those patients who were event-free at 6 and 12 months of
follow-up and stratified as to clopidogrel use at that time.
Adjusted 24-month outcomes based on 6-month clopidogrel
use showed that DES patients without clopidogrel at 6
months had significantly higher rates of death (5.3% versus
2.0%, P0.03) and death or MI (7.2% versus 3.1%, P0.02)
than patients in the DES group given clopidogrel. The
adjusted HR for death in the DES group without clopidogrel
was 2.43 (P0.03) compared with the DES with clopidogrel
group. There were no significant differences in death or death
and MI in patients with bare-metal stents with or without
clopidogrel at 6 months. There were fewer events in patients
with DES plus clopidogrel at 6 months (death or MI 3.1%
versus 6.0%, P0.02) than in patients with bare-metal stents
without clopidogrel at 6 months. Adjusted 24-month out-
comes based on 12-month clopidogrel use similarly showed
that DES patients who did not take clopidogrel had signifi-
cantly higher rates of death (3.5% versus 0%, P0.004) and
death or MI (4.5% versus 0%, P less than 0.001) than DES
patients who did take clopidogrel at 12 months. There were
no significant differences in death or death and MI in patients
with bare-metal stents with or without clopidogrel use at 12
months. There were fewer events in patients with DES plus
clopidogrel (death or MI 0%, P less than 0.001) than in
patients with bare-metal stents with (4.7%) or without (3.6%)
clopidogrel treatment at 12 months. The authors concluded
that the extended use of clopidogrel (up to 12 months) in
patients with DES is associated with a reduced risk of death
and death or MI at 24 months. They noted that the optimal
duration of clopidogrel use beyond 12 months after DES
implantation is not currently known.
On December 7 and 8, 2006, the US Food and Drug
Administration held advisory panel meetings in Washington,
DC, to discuss the safety and stent thrombosis rates associ-
ated with DES (340). At the time of this writing, the panel
report is yet to be published, but initial conclusions were that
1) there appears to be a numerical excess of late stent
thrombosis with DES, but the magnitude is uncertain; 2) there
does not appear to be an increase in rates of death or MI when
the products are used in accordance with indications listed on
the label; 3) the off-label use of DES, like bare-metal stents,
is associated with increased risk compared with on-label use;
and 4) more data are needed, which will entail studying
outcomes in more patients for longer periods of time. The
panel concurred with the AHA/ACC guideline recommenda-
tion for 12 months of dual-antiplatelet therapy after DES
implantation in patients who are not at high risk for bleeding.
The Swedish Coronary Angiography and Angioplasty Reg-
istry (SCAAR) study group published a registry study of
6033 patients treated with DES and 13 738 patients treated
with bare-metal stents and followed up for 3 years (341).
Over the entire follow-up period, the 2 groups did not differ
in the composite outcomes of death or MI. At 6 months, there
was a trend toward a lower unadjusted event rate in the DES
group. However, after 6 months, patients with DES had a
higher event rate, with 12.7 more events per 1000 patients per
year than among patients given bare-metal stents (adjusted
relative risk 1.2%; 95% CI: 1.05 to 1.37). At 3 years,
mortality was higher in patients with DES (adjusted relative
risk 1.18%; 95% CI: 1.04 to 1.35). The relative rate of clinical
restenosis was 60% lower in the DES patients. This analysis
suggests an 18% increase in the relative risk of death in the
long term with DES compared with bare-metal stents, which
equates to an incremental absolute risk of death of 0.5% per
year and an incremental absolute risk of death or MI of 0.5%
to 1.0% per year after the initial 6 months.
In January 2007, an AHA/ACC/SCAI/American College
of Surgeons (ACS)/American Diabetes Association (ADA)
science advisory was issued regarding the prevention of
premature discontinuation of dual-antiplatelet therapy in pa-
tients with coronary artery stents (342). The advisory notes
that the current recommendations of duration of dual-
antiplatelet regimens after bare-metal, sirolimus-eluting, and
paclitaxel-eluting stent implantation were formulated from
trials designed to obtain Food and Drug Administration
approval and the anticipated time required for the stent struts
to become adequately endothelialized. These trials included
low-risk lesions in low-risk patients. It has been observed that
only approximately 30% to 40% of DES are implanted in
such low-risk lesions in low-risk patients (on-label indica-
tions). Approximately 60% to 70% of patients receiving DES
in most large contemporary series of coronary intervention
are in off-label populations that include patients with mul-
tivessel coronary disease, left main disease, aorto-coronary
vein grafts, bifurcation lesions, previously stented lesions
with in-stent restenosis, prior brachytherapy, small vessels,
very long lesions, multiple or overlapping stents, chronic total
occlusions, and infarct-related lesions in acute MI. Addition-
ally, reports have suggested that delayed or absent endothe-
lialization (343), localized hypersensitivity (330,344), and
late stent thrombosis (see above) may occur with increased
frequency in patients with DES.
Several analyses of the randomized trials and postmarket-
ing registries of sirolimus and paclitaxel DES have been
published recently. Kastrati et al (345) reported that 4958
patients randomized to DES or bare-metal stents and fol-
lowed up for 12 to 59 months had no significant difference in
the incidence of death or MI, but there was a sustained
reduction in the need for reintervention with DES. There was
a slight increase in the risk of stent thrombosis with
sirolimus-eluting stents after the first year. Mauri et al (346)
analyzed 878 patients treated with sirolimus-eluting stents,
1400 treated with paclitaxel-eluting stents, and 2267 patients
treated with bare-metal stents over 4 years of follow-up
according to a hierarchical classification of stent thrombosis.
The incidence of stent thrombosis by any criterion was 3%
and did not differ between DES and bare-metal stent patients.
Stone et al (347) analyzed randomized trials of DES versus
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bare-metal stents and found that stent thrombosis occurred in
1.2% of sirolimus-eluting stent patients and 1.3% of
paclitaxel-eluting stent patients, neither of which was signif-
icantly different from the bare-metal stent control group.
Rates of death and MI were similar between the DES and
bare-metal stent groups over 4 years. After 1 year, stent
thrombosis was more common with DES patients. Spaulding
et al (348) analyzed data from 1748 patients in 4 randomized
trials of sirolimus-eluting stents compared with bare-metal
stents with regard to survival at 4 years. The survival rate was
93.3% in the DES group compared with 94.6% in the
bare-metal stent group (P  NS). In patients with diabetes
mellitus, the survival rate was better in the bare-metal stent
group (95.6% versus 87.8%; HR for death, sirolimus group
2.9, P0.008). Rates of MI and stent thrombosis were similar
between the 2 groups.
Stent thrombosis is usually a significant clinical event. The
incidence of death or MI was 64.4% in patients with angio-
graphically documented bare-metal stent thrombosis (349).
Mortality rates due to presumed or documented DES throm-
bosis range from 20% to 45% (337–339).
The average reported incidence of subacute (within 1
month of implantation) stent thrombosis is approximately
0.5% to 1.0%. Late stent thrombosis at 1 to 12 months was
not seen with bare-metal stents but was reported to occur in
0.19% of patients in a large DES registry (350). In October
2006, an independent patient-level meta-analysis of DES
trials was presented that demonstrated an increased rate of
DES thrombosis of approximately 0.2% per year between
years 1 and 4 after stent implantation compared with bare-
metal stents (351). Another meta-analysis (352) of all the
published DES trials that examined very late stent thrombosis
at more than 1 year after implantation found a rate of 5.0 per
1000 patients (0.5%) compared with 0% in patients with
bare-metal stents (relative risk 5.02, P0.02). The incidence
of early stent thrombosis (within 30 days of implantation)
was 4.4 per 1000 (0.44%) in DES patients compared with 5.0
per 1000 (0.5%) in bare-metal stent patients (P0.74). The
incidence of late stent thrombosis (more than 30 days after
implantation) was 5.0 per 1000 DES patients compared with
2.8 per 1000 bare-metal stent patients (P0.22). The median
time to late sirolimus-eluting stent thrombosis was 15.5
months (range 173 to 773 days), and the median time to
paclitaxel-eluting stent thrombosis was 18 months (range 40
to 548 days), whereas the median time to bare-metal stent
thrombosis was 3.5 to 4.0 months. Very late stent thrombosis
appears to be a phenomenon restricted to DES. These
findings have clear implications for the duration of antiplate-
let therapy.
Predictors of late stent thrombosis include the clinical
factors of advanced age, acute coronary syndrome, diabetes
mellitus, low ejection fraction, renal failure, and prior brachy-
therapy and the angiographic factors of long stents, multiple
lesions, overlapping stents, ostial or bifurcation lesions, small
vessels, and suboptimal stent results (underexpansion, malap-
position, or residual dissection). The optimal duration of
clopidogrel therapy after 1 year has not been established and
should depend on the physician’s judgment of the risk/benefit
ratio for the individual patient. Current expert opinion sug-
gests that continuation of thienopyridine (clopidogrel) ther-
apy beyond 1 year may be considered in patients undergoing
DES placement.
A 2007 AHA/ACC/SCAI/ACS/ADA science advisory re-
port (342) concludes that premature discontinuation of dual-
antiplatelet therapy markedly increases the risk of cata-
strophic stent thrombosis and death or MI. To eliminate the
premature discontinuation of thienopyridine therapy, the
advisory group recommends the following:
1. Before implantation of a stent, the physician should discuss the
need for dual-antiplatelet therapy. In patients not expected to
comply with 12 months of thienopyridine therapy, whether for
economic or other reasons, strong consideration should be given
to avoiding a DES.
2. In patients who are undergoing preparation for PCI and who are
likely to require invasive or surgical procedures within the next 12
months, consideration should be given to implantation of a bare-
metal stent or performance of balloon angioplasty with provi-
sional stent implantation instead of the routine use of a DES.
3. A greater effort by healthcare professionals must be made before
patient discharge to ensure that patients are properly and thor-
oughly educated about the reasons they are prescribed thienopy-
ridines and the significant risks associated with prematurely
discontinuing such therapy.
4. Patients should be specifically instructed before hospital dis-
charge to contact their treating cardiologist before stopping any
antiplatelet therapy, even if instructed to stop such therapy by
another healthcare provider.
5. Healthcare providers who perform invasive or surgical procedures
and who are concerned about periprocedural and postprocedural
bleeding must be made aware of the potentially catastrophic risks
of premature discontinuation of thienopyridine therapy. Such
professionals who perform these procedures should contact the
patient’s cardiologist if issues regarding the patient’s antiplatelet
therapy are unclear, to discuss optimal patient management
strategy.
6. Elective procedures for which there is significant risk of perioper-
ative or postoperative bleeding should be deferred until patients
have completed an appropriate course of thienopyridine therapy
(12 months after DES implantation if they are not at high risk of
bleeding and a minimum of 1 month for bare-metal stent
implantation).
7. For patients treated with DES who are to undergo subsequent
procedures that mandate discontinuation of thienopyridine ther-
apy, aspirin should be continued if at all possible and the thien-
opyridine restarted as soon as possible after the procedure be-
cause of concerns about late stent thrombosis.
Similar conclusions and recommendations were published
online in a clinical alert by the SCAI in January 2007 (351).
Given the above reports and recommendations, use of a DES
for coronary revascularization before imminent or planned
noncardiac surgery that will necessitate the discontinuation of
dual-antiplatelet agents is not recommended.
In conclusion, in patients with stable CAD, the indica-
tions for PCI in the preoperative setting should be identical
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to those developed by the joint ACC/AHA Task Force that
provided guidelines for the use of PCI in patients with
stable angina and asymptomatic ischemia (307). There is
no evidence to support prophylactic preoperative percuta-
neous revascularization in patients with asymptomatic
ischemia or stable angina.
Similarly, there is little evidence to show how long a more
distant PCI (ie, months to years before noncardiac surgery)
protects against perioperative MI or death. Because additional
coronary restenosis is unlikely to occur more than 8 to 12
months after PCI (whether or not a stent is used), it is reasonable
to expect ongoing protection against untoward perioperative
ischemic complications in currently asymptomatic, active pa-
tients who had been symptomatic before complete percutaneous
coronary revascularization more than 8 to 12 months previously.
7.1.8. Perioperative Management of Patients With Prior
PCI Undergoing Noncardiac Surgery
According to the 2005 PCI guidelines, “In patients who have
undergone PCI, clopidogrel 75 mg daily should be given for
at least 1 month after bare-metal stent implantation (unless
the patient is at increased risk for bleeding, then it should be
given for a minimum of 2 weeks), 3 months after sirolimus
stent implantation, and 6 months after paclitaxel stent implan-
tation, and ideally up to 12 months in patients who are not at
high risk of bleeding. (Level of Evidence: B)” (307). The
newer recommendation by the AHA/ACC/SCAI/ACS/ADA
Science Advisory Committee cited above (342) is for 12
months of dual-antiplatelet therapy in patients who have
undergone PCI with DES. If there is a contraindication to 12
months of dual-antiplatelet therapy, such as planned noncar-
diac surgery, then DES should not be implanted.
For patients who have undergone successful coronary
intervention with or without stent placement before planned
or unplanned noncardiac surgery, there is uncertainty regard-
ing how much time should pass before the noncardiac
procedure is performed. One approach is outlined in Figure 2,
which is based on expert opinion. Given the reports of late
DES thrombosis and the current recommendations discussed
above, clinicians should remain vigilant even beyond 365
days after DES placement. The times of 14, 30 to 45, and 365
days for balloon angioplasty, bare-metal stents, and DES,
respectively, recommended in Figure 2 are somewhat arbi-
trary because of a lack of high-quality evidence.
Consideration should be given to continuing dual-
antiplatelet therapy in the perioperative period for any patient
needing noncardiac surgery that falls within the time frame
that requires dual-antiplatelet therapy, particularly those who
have received DES. In addition, consideration should be
given to continuing dual-antiplatelet therapy perioperatively
beyond the recommended time frame in any patient at high
risk for the consequences of stent thrombosis, such as patients
in whom previous stent thrombosis has occurred, after left
main stenting, after multivessel stenting, and after stent
placement in the only remaining coronary artery or graft
conduit. Even after thienopyridines have been discontinued,
serious consideration should be given to continuation of
aspirin antiplatelet therapy perioperatively in any patient with
previous placement of a DES. The risk of stopping antiplate-
let therapy should be weighed against the benefit of reduction
in bleeding complications from the planned surgery. If
thienopyridines must be discontinued before major surgery,
aspirin should be continued and the thienopyridine restarted
as soon as possible. There is no evidence that warfarin,
antithrombotics, or glycoprotein IIb/IIIa agents will reduce
the risk of stent thrombosis after discontinuation of oral
antiplatelet agents (342).
7.1.9. Perioperative Management in Patients Who Have
Received Intracoronary Brachytherapy
Intracoronary radiation with gamma or beta brachytherapy
has been used in the past to treat recurrent in-stent restenosis.
Brachytherapy delays the healing response and inhibits en-
dothelialization of the irradiated coronary segment. Late total
occlusion and thrombosis of the irradiated coronary segment
occurs at a rate of 6% to 15%, especially after the placement
of additional new bare-metal stents. Prolonged antiplatelet
therapy is effective in preventing late thrombosis of the
Balloon 
angioplasty
Bare-metal 
stent
Drug-eluting 
stent
Delay for elective or 
nonurgent surgery
<14 days >14 days
Proceed to the 
operation room 
with aspirin
Delay for elective or 
nonurgent surgery
>30-45 days <30-45 days
Proceed to the 
operating room 
with aspirin
<365 days
>365 days
Previous PCI
Time since PCI
Figure 2. Proposed approach to the management of patients with previous percutaneous coronary intervention (PCI) who require non-
cardiac surgery, based on expert opinion.
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irradiated coronary segment, in 1 study reducing the late
thrombosis rate to 2.5% with 6 months of therapy versus
9.6% with 1 month of dual-antiplatelet therapy. Additional
benefit was demonstrated with 12 months of dual-antiplatelet
therapy (late thrombosis rate of 3.3%) (353,354). It is unclear
when, if ever, antiplatelet therapy can be safely discontinued
in these patients.
Given the considerations above, antiplatelet therapy should
be continued as per the ACC/AHA/SCAI 2005 Guideline
Update for Percutaneous Coronary Intervention, with a class
IIa recommendation: “It is reasonable that patients undergo-
ing brachytherapy be given daily chronic clopidogrel 75 mg
indefinitely and daily chronic aspirin 75 mg to 325 mg
indefinitely unless there is significant risk for bleeding. (Level
of Evidence: C)” (307). Therefore, serious consideration
should be given to continuing dual-antiplatelet therapy in the
perioperative period for any patient who has received brachy-
therapy for restenosis or in-stent restenosis, particularly those
in whom additional stents (bare-metal or drug-eluting) were
placed at the time of or subsequent to the administration of
brachytherapy. The risk of stopping antiplatelet therapy
should be weighed against the benefit of reduction in bleed-
ing complications from the planned surgery.
7.1.10. Risks Associated With Perioperative
Antiplatelet Agents
Dual-antiplatelet therapy with aspirin and clopidogrel carries a
0.4% to 1.0% increased absolute risk of major bleeding com-
pared with aspirin alone (355). Some procedures carry a low risk
of bleeding; for example, there is no indication to interrupt
dual-antiplatelet therapy for dental procedures (356). The risk of
surgical bleeding after administration of aspirin, thienopyridines,
and glycoprotein IIb/IIIa inhibitors has been reviewed (334,357).
Increased blood loss in patients taking aspirin has been reported
in noncardiac surgery, including general surgical, gynecologic,
and urologic operations, and in dermatologic surgery in those
patients whose bleeding time was prolonged. One study
reported that patients taking aspirin who were undergoing
emergency general surgery operations did not demonstrate
an increased risk of bleeding complications (358). Preop-
erative aspirin use may not increase the risk of neuraxial
anesthesia or analgesia (359).
The authors of a review of this subject (334) concluded
that monotherapy with aspirin need not be routinely
discontinued for elective noncardiac surgery. Burger et al
(360) reviewed the surgical literature with regard to the
risks of stopping low-dose aspirin versus the risks of
bleeding and found that in the majority of surgeries,
low-dose aspirin may result in increased frequency of
procedural bleeding (relative risk 1.5) but not an increase
in the severity of bleeding complications or perioperative
mortality due to bleeding complications. Possible excep-
tions were intracranial surgery and prostatectomy. They
recommended that aspirin should only be discontinued if
the known bleeding risks are similar or more severe than
the observed cardiovascular risks of aspirin withdrawal.
In cardiac surgery, perioperative aspirin use results in
increased blood loss and need for reoperation but no increase
in mortality and is associated with improved saphenous vein
bypass graft patency. The ACC/AHA 2004 Guideline Update
for Coronary Artery Bypass Graft Surgery reviewed this issue
and stated: “In summary, aspirin is the drug of choice for
prophylaxis against early saphenous graft thrombotic closure.
Perioperative use and/or administration of aspirin within 48
hours of operation should be the standard of care and should
be continued indefinitely, given its benefit in the secondary
prevention of subsequent clinical events” (306). In non-
cardiac vascular surgery, preoperative aspirin is routinely
used and is associated with improved peripheral bypass
graft patency. Few data exist regarding the risks and
benefits of the use of aspirin perioperatively in other
noncardiovascular surgery.
Likewise, monotherapy with clopidogrel or ticlopidine
may not need to be discontinued in elective noncardiac
surgery; however, there is conflicting information about the
risks of bleeding in patients taking perioperative clopidogrel.
Hongo et al reported that a significant increased risk of major
perioperative bleeding was found in patients undergoing
CABG (361). Another study suggested no increased risk of
bleeding complications and mortality in patients taking clo-
pidogrel who were undergoing emergency CABG compared
with those treated with aspirin and heparin alone (362). In the
Clopidogrel in Unstable angina to prevent Recurrent Events
(CURE) trial (363), patients in whom clopidogrel was
stopped fewer than 5 days before CABG surgery had a
significantly increased (9.6% versus 6.3% in the placebo arm)
rate of major bleeding but no significant difference in
perioperative mortality. Kapetanakis et al reported that pa-
tients receiving clopidogrel before off-pump coronary artery
bypass surgery had an OR of 5.1 (95% CI: 2.47 to 10.47, P
less than 0.01) with regard to the need for hemostatic
reoperation and a significant increase in the need for packed
red blood cell and platelet transfusions but no difference in
surgical mortality (364). In a series of patients undergoing
carotid endarterectomy, a reduction in transcranial Doppler–
determined emboli was seen with pretreatment with aspirin
and clopidogrel, but no increase in bleeding complications or
blood transfusions was seen (365).
Cannon et al (366) suggest that for patients receiving
clopidogrel, a 5-day interval between stopping the drug and
elective surgery is optimal. This is reflected in the ACC/AHA
recommendation that clopidogrel should be withheld for at
least 5 to 7 days in patients scheduled for elective CABG
surgery (306). For urgent and emergent surgery, a delay of
surgery until platelet function has recovered is usually not a
feasible option. Under these circumstances, some experts
recommend platelet transfusions for treatment of hemorrhage
that continues despite usual hemostatic techniques, even if
platelet count is normal. However, no data demonstrate that
transfused platelets reverse the clopidogrel effect. For this
reason, it may be more appropriate to reserve platelet trans-
fusion for patients with significant clinical bleeding after
usual hemostatic methods are applied. A comprehensive
approach for patients taking clopidogrel and aspirin who are
undergoing emergent CABG surgery might include the use of
aprotinin, aminocaproic acid, or tranexamic acid to promote
hemostasis during the early reperfusion period. Early clinical
experience suggested that the intraoperative use of aprotinin
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or tranexamic acid may permit surgery to be conducted safely
on patients presenting while taking aspirin and clopidogrel
(367,368); however, there is controversy regarding the safety
of aprotinin in cardiac surgery (369). Although this result is
debated, Mangano and colleagues found that aprotinin used in
cardiac surgery was associated with a doubling in the risk of
renal failure requiring dialysis among patients undergoing
complex coronary artery surgery compared with controls
(369). Similarly, the use of aprotinin in the primary surgery
group was associated with a 55% increase in the risk of MI or
HF (P less than 0.001) and a 181% increase in the risk of
stroke or encephalopathy (P0.001). Neither aminocaproic
acid nor tranexamic acid was associated with an increased
risk of renal, cardiac, or cerebral events compared with
controls. A later study found that the use of aprotinin was
associated with a significant reduction in long-term survival
(5-year mortality 20.8% with aprotinin versus 12.7% for
controls, OR: 1.48, P0.005) that was not seen in CABG
patients treated with aminocaproic acid or tranexamic acid
(370). The applicability of this information to other types of
surgery is unknown.
7.1.11. Strategy of Percutaneous Revascularization in
Patients Needing Urgent Noncardiac Surgery
Patients who require percutaneous coronary revascularization
in whom near-term noncardiac surgery is necessary require
special consideration (342,371). A potential strategy is out-
lined in Figure 3. Percutaneous coronary revascularization
should not be routinely performed in patients who need
noncardiac surgery unless clearly indicated for high-risk
coronary anatomy, unstable angina, MI, or hemodynamically
or rhythmically unstable active CAD amenable to percutane-
ous intervention. If PCI is necessary, then the urgency of the
noncardiac surgery and the risk of bleeding associated with
the surgery in a patient taking dual-antiplatelet agents need to
be considered. If there is little risk of bleeding or if the
noncardiac surgery can be delayed 12 months or more, then
PCI with DES and prolonged aspirin and thienopyridine
therapy could be considered if the patient meets the criteria
outlined in the AHA/ACC/SCAI/ACS/ADA science advisory
group recommendations outlined above (342). If the noncar-
diac surgery is likely to occur within 1 to 12 months, then a
strategy of bare-metal stenting and 4 to 6 weeks of aspirin and
thienopyridine therapy with continuation of aspirin perioper-
atively should be considered. Although the risk of restenosis
with this strategy is higher than with DES, restenotic lesions
are usually not life-threatening, even though they may present
as an acute coronary syndrome (372), and can usually be dealt
with by repeat PCI if necessary. If the noncardiac surgery is
imminent (within 2 to 6 weeks) and the risk of bleeding is
high, then consideration should be given to balloon angio-
plasty and provisional bare-metal stenting plus continued
aspirin antiplatelet monotherapy, with restenosis dealt with
by repeat PCI if necessary. If the noncardiac surgery is urgent
or emergent, then cardiac risks, the risk of bleeding, and the
long-term benefit of coronary revascularization must be
weighed, and if coronary revascularization is absolutely
necessary, CABG combined with the noncardiac surgery
could be considered.
7.2. Perioperative Medical Therapy
7.2.1. Perioperative Beta-Blocker Therapy
Recommendations for Beta-Blocker Medical Therapy
CLASS I
1. Beta blockers should be continued in patients undergoing surgery
who are receiving beta blockers to treat angina, symptomatic
Care should be taken in applying recommendations on beta-blocker
therapy to patients with decompensated HF, nonischemic cardiomyopa-
thy, or severe valvular heart disease in the absence of CHD.
Balloon 
angioplasty
Bare-metal 
stent
Drug-eluting 
stent
14 to 29 days 30 to 365 days Greater than 365 days
Acute MI, high-risk 
ACS,  or high-risk 
cardiac anatomy
Timing of Surgery
Bleeding risk of surgery Stent and continued dual antiplatelet therapyLow
Not low
Figure 3. Proposed treatment for patients requiring percutaneous coronary intervention (PCI) who need subsequent surgery. ACS indi-
cates acute coronary syndrome; and MI, myocardial infarction.
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arrhythmias, hypertension, or other ACC/AHA class I guideline
indications. (Level of Evidence: C)
2. Beta blockers should be given to patients undergoing vascular
surgery who are at high cardiac risk owing to the finding of
ischemia on preoperative testing. (Level of Evidence: B)
CLASS IIa
1. Beta blockers are probably recommended for patients undergoing
vascular surgery in whom preoperative assessment identifies
CHD. (Level of Evidence: B)
2. Beta blockers are probably recommended for patients in whom
preoperative assessment for vascular surgery identifies high car-
diac risk, as defined by the presence of more than 1 clinical risk
factor.* (Level of Evidence: B)
3. Beta blockers are probably recommended for patients in whom
preoperative assessment identifies CHD or high cardiac risk, as
defined by the presence of more than 1 clinical risk factor,* who
are undergoing intermediate-risk or vascular surgery. (Level of
Evidence: B)
CLASS IIb
1. The usefulness of beta blockers is uncertain for patients who are
undergoing either intermediate-risk procedures or vascular sur-
gery, in whom preoperative assessment identifies a single clinical
risk factor.* (Level of Evidence: C)
2. The usefulness of beta blockers is uncertain in patients undergo-
ing vascular surgery with no clinical risk factors who are not
currently taking beta blockers. (Level of Evidence: B)
CLASS III
1. Beta blockers should not be given to patients undergoing surgery
who have absolute contraindications to beta blockade. (Level of
Evidence: C)
Since publication of the ACC/AHA focused update on
perioperative beta-blocker therapy, several randomized trials
have been published that have not demonstrated the efficacy
of these agents. Despite several meta-analyses, some of
which reached conflicting conclusions, there are still very few
randomized trials of this issue.
Few studies have compared different beta-blocker agents.
Studies to determine the ideal target population, duration of
preoperative titration, and route of administration are lacking.
In addition, practical concerns, such as how, when, how long,
and by whom perioperative beta-blocker therapy should
ideally or practically be implemented, remain unaddressed.
Randomized controlled trials are still needed to explore the
observation that there may be some harm associated with
beta-blocker therapy in low-risk patients (373). Moreover,
there is currently a lack of data regarding which beta blocker
to use perioperatively, although longer-acting agents appear
superior to shorter-acting agents. In fact, studies involving the
shorter-acting agent metoprolol have shown lower or no
efficacy (374,375). In summary, the best approach on how to
medically protect patients from cardiovascular complications
during noncardiac surgery is still unknown. Limitations in the
perioperative beta-blocker literature include the following:
● Most trials are inadequately powered.
● Few randomized trials of medical therapy to prevent
perioperative MACE have been performed.
● Few randomized trials have examined the role of periop-
erative beta-blocker therapy, and there is particularly a lack
of trials that focus on high-risk patients.
● Studies to determine the role of beta blockers in
intermediate- and low-risk populations are lacking.
● Studies to determine the optimal type of beta blockers are
lacking.
● No studies have addressed care-delivery mechanisms in the
perioperative setting, identifying how, when, and by whom
perioperative beta-blocker therapy should be implemented
and monitored.
Although many of the randomized controlled trials of
beta-blocker therapy are small, the weight of evidence—
especially in aggregate—suggests a benefit to perioperative
beta blockade during noncardiac surgery, particularly in
high-risk patients (Table 11). Current studies suggest that
beta blockers reduce perioperative ischemia and may reduce
the risk of MI and death in high-risk patients. Available
Table 11. Recommendations for Perioperative Beta-Blocker Therapy Based on Published Randomized Clinical Trials
Surgery
No Clinical Risk
Factors
1 or More Clinical
Risk Factors CHD or High Cardiac Risk
Patients Currently
Taking Beta Blockers
Vascular Class IIb, Level of
Evidence: B
Class IIa, Level of
Evidence: B
Patients found to have
myocardial ischemia on
preoperative testing: Class I,
Level of Evidence: B*
Class I, Level of
Evidence: B
Patients without ischemia or
no previous test: Class IIa,
Level of Evidence: B
Intermediate risk    Class IIb, Level of
Evidence: C
Class IIa, Level of
Evidence: B
Class I, Level of
Evidence: C
Low risk          Class I, Level of
Evidence: C
See Table 4 for definition of procedures. Ellipses (  ) indicate that data were insufficient to determine a class of recommendation or level of evidence. See
text for further discussion. CHD indicates coronary heart disease.
*Applies to patients found to have coronary ischemia on preoperative testing.
†Applies to patients found to have coronary heart disease.
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evidence strongly suggests but does not definitively prove
that when possible, beta blockers should be started days to
weeks before elective surgery. The dose should be titrated to
achieve a resting heart rate of 60 beats per min (bpm) to
increase the likelihood the patient will receive the benefit of
beta blockade. Rate control with beta blockers should con-
tinue during the intraoperative and postoperative period to
maintain a heart rate of 60 to 65 bpm, because this regimen
has demonstrated efficacy (59,89). Prospective randomized
trials are either under way or soon to be presented. These will
hopefully shed light on some of the questions regarding
perioperative beta-blocker therapy. Per ACC/AHA Task
Force on Practice Guidelines methodology, unpublished data
cannot be used to formulate guideline recommendations.
7.2.1.1. Evidence on Efficacy of Beta-Blocker Therapy
Several randomized trials examined the effect of periopera-
tive beta blockers on cardiac events surrounding surgery.
Poldermans et al examined the effect of bisoprolol on patients
undergoing vascular surgery and in patients at high risk for
perioperative cardiac complications who were scheduled for
vascular surgery (89). Of 846 patients with risk factors for
cardiac disease, 173 were found to have new regional
wall-motion abnormalities on DSE. Of these patients, 61
were excluded from further study owing to large areas
(greater than or equal to 5 segments) of regional wall-motion
abnormalities on DSE or because they were already taking
beta blockers. The remaining 112 high-risk patients were
randomized to standard care or bisoprolol started at least 7
days before surgery and titrated to maintain heart rate less
than 60 bpm preoperatively and less than 80 bpm intraoper-
atively and postoperatively. The rates of cardiac death (3.4%
versus 17%; P0.02) and nonfatal MI (0% versus 17%; P
less than or equal to 0.001) were lower for the bisoprolol
groups than for the placebo groups, respectively. Importantly,
owing to the unblinded design and the inclusion of only
high-risk patients in this study, the results cannot be gener-
alized to all patients undergoing noncardiac surgery.
Boersma et al subsequently reanalyzed the total cohort of
1351 consecutive patients considered for enrollment in the
aforementioned randomized trial of bisoprolol (248). Forty-
five patients had perioperative cardiac death or nonfatal MI.
Eighty-three percent of the patients had fewer than 3 clinical
risk factors. Among this subgroup, patients taking beta
blockers had a lower risk of cardiac complications (0.8%
[2/263]) than those not taking beta blockers (2.3% [20/855]).
In patients with 3 or more risk factors (17%), those taking
beta blockers who had a DSE who demonstrated 4 or fewer
segments of new wall-motion abnormalities had a signifi-
cantly lower incidence of cardiac complications (2.3% [2/86])
than those not receiving beta-blocker therapy (9.9% [12/
121]). However, among the small group of patients with more
extensive ischemia on DSE (5 or more segments), there was
no difference in the incidence of cardiac events (4 of 11 for
those taking beta blockers versus 5 of 15 for those not taking
beta blockers). Therefore, beta-blocker therapy was benefi-
cial in all but the subset of patients with more extensive
ischemia. Nevertheless, one must be cautious about inferring
a class effect from this observation about bisoprolol and the
treatment protocol.
The Multicenter Study of Perioperative Ischemia Research
Group (88,376) reported on 200 patients undergoing general
surgery randomized to a combination of intravenous and oral
atenolol versus placebo for 7 days. Although they found no
difference in perioperative MI or death, they reported signif-
icantly fewer episodes of ischemia by Holter monitoring in
the atenolol versus placebo groups (24% versus 39%, respec-
tively; P0.03). They then conducted follow-up on these
patients after discharge and documented fewer deaths in the
atenolol group over the subsequent 6 months (1% versus
10%; P less than 0.001). It is not clear why such a brief course
of therapy could exert such a delayed effect, and the study did
not control for other medications given either before or after
surgery. Use of ACE inhibitors and beta blockers postoper-
atively differed significantly between the study groups.
Additional studies have examined the use of perioperative
beta blockers but were limited in power to detect cardiac
events or were not randomized. More recent randomized
trials have looked at beta blockade for the prevention of
perioperative cardiac complications during noncardiac sur-
gery. Juul et al (375) randomized 921 diabetic subjects
undergoing a range of noncardiac operations to either 100 mg
of extended-release metoprolol or placebo in the DIPOM
(Diabetic Postoperative Mortality and Morbidity) study. They
excluded patients with “conditions indicating beta-blocker
treatment,” which was not elaborated on. Of those random-
ized, an equal number of deaths (16%) were observed in both
groups. Myocardial infarction rates were not reported sepa-
rately, and it is unclear at what time point the mortality was
compared. Yang et al (377) report a study of 496 subjects
undergoing major vascular surgery who were randomized to
dose-adjusted metoprolol or placebo. Exclusions in that study
included those already taking a beta blocker. They reported
similar MI rates (7.7% versus 8.4%) and death rates (0%
versus 1.6%) at 30 days in the beta-blocker and placebo
groups, respectively. These were not noninferiority analyses
but rather simply negative study results. Most importantly for
the purposes of these guidelines, the patients included (al-
though diabetic in 1 study and undergoing major vascular
surgery in the other) undoubtedly represent a heterogenous
risk group without documented CAD. These studies suggest
no identifiable benefit for these beta-blocker regimens in this
lower-risk group.
Stone et al (76) randomized a group of patients with mild
hypertension who underwent predominantly (58%) vascular
surgery to oral beta blockers 2 hours before surgery or
standard care. Control subjects had a higher frequency (28%)
of ST-segment depression (on intraoperative monitoring, as
reported by the authors) than treated patients (2%). In a
nonrandomized study, Pasternack et al (378) gave oral
metoprolol immediately before surgery, followed postopera-
tively by intravenous metoprolol during abdominal aortic
aneurysm repair. Only 3% suffered an acute MI compared
with 18% for matched control subjects. Pasternack et al (79)
subsequently reported fewer episodes of intraoperative ische-
mia in patients treated with oral metoprolol before peripheral
vascular surgery than in untreated patients. Yeager et al (379)
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reported a case-control analysis of their experience with
perioperative MI during vascular surgery, comparing 53
index cases of perioperative MI with 106 matched control
subjects. They found a strong association of beta-blocker use
with a decreased likelihood of MI (OR: 0.43; P0.01). In 26
vascular surgery patients with documented preoperative is-
chemia who were randomized to a protocol of heart rate
suppression with intravenous esmolol compared with stan-
dard care, Raby et al (380) demonstrated that the esmolol
group had fewer episodes of ischemia than control subjects
(33% versus 72%; P0.055). Zaugg et al (381) randomized
elderly noncardiac surgery patients to preoperative and post-
operative atenolol titrated to heart rate, intraoperative atenolol
titrated to heart rate, or no beta blockers and detected no
episodes of intraoperative myocardial ischemia, ECG
changes consistent with MI, or death in any group. Three of
19 patients in the no-beta-blocker group developed signifi-
cant elevations of cardiac troponin I (cTnI) consistent with a
perioperative MI compared with none of 40 patients who
received 1 of the atenolol regimens. Brady et al randomized
patients undergoing elective vascular surgery to either meto-
prolol 50 mg twice a day or placebo, from admission to the
hospital until 7 days after surgery (382). They found no
difference in cardiovascular events, which included MI,
unstable angina, ventricular tachycardia, and stroke. This trial
may have been underpowered (n103) to identify a differ-
ence in outcomes, particularly hard outcomes of death and
MI. Also, by trial design, therapy was initiated the day before
vascular surgery, and it is quite possible that those random-
ized to metoprolol received incomplete beta blockade in the
early perioperative period.
Perioperative beta-blocker therapy has been reviewed in
several meta-analyses and in a very large cohort population
study. Auerbach and Goldman (383) undertook a review of
this topic in 2002. They reported on a MEDLINE search and
literature review of only 5 studies (all 5 studies are included
in Table 12). They calculated a number needed to treat, on the
basis of these studies, of only 2.5 to 6.7 to see improvement
in measures of myocardial ischemia and only 3.2 to 8.3 in
studies reporting a significant impact of beta blockers on
cardiac or all-cause mortality. They concluded that the
literature supports a benefit of beta blockers on cardiac
morbidity and mortality.
A systematic review of the perioperative medical therapy
literature by Stevens et al (385) for noncardiac surgery
included the results of 11 trials using beta blockers for
perioperative therapy. These authors concluded that beta
blockers significantly decreased ischemic episodes during
and after surgery. Beta blockers significantly reduced the risk
of nonfatal MI; however, the results became nonsignificant if
the 2 most positive trials were eliminated. Likewise, the risk
of cardiac death was significantly decreased with beta-
blocker usage. These authors incorporated studies not con-
sidered in other meta-analyses, including studies that were
not blinded. Results to be quantified were limited to those in
the 30-day perioperative period. The authors also reported a
direct relationship between the prevalence of prior MI and the
magnitude of risk reduction observed with beta-blocker
therapy, suggesting that higher risk confers greater benefit.
The number needed to prevent perioperative ischemia was 8
subjects, the number needed to prevent MI was 23, and 32
patients had to be treated to prevent cardiac death. These
authors pointed out that given the observation that high-risk
patients seemed to receive all the benefit, the target popula-
tion for beta-blocker therapy is not clear. They also high-
lighted that schedules of beta-blocker administration varied
significantly among the reported studies and acknowledged
the potential for a single large, strongly positive study to skew
the results of this meta-analysis (385).
In contrast, Devereaux et al (386) published their opinion
paper on the clinical evidence regarding the use of beta-
blocker therapy in patients undergoing noncardiac surgery for
the purpose of preventing perioperative cardiac complica-
tions. They expressed the opinion that the literature support-
ing the use of beta blockers during noncardiac surgery is
modest at best and is based on a few small, unblinded studies
with a focused patient population. In a review of the literature
in 2005, Devereaux et al (387) discussed 22 studies random-
izing 2437 patients undergoing noncardiac surgery to beta-
blocker therapy or placebo. The Perioperative Beta Blockade
(POBBLE) study was not included in this review (382). They
found no statistically significant benefit with regard to any of
the individual outcomes and a “nominally” statistically sig-
nificant benefit (RR: 0.44, 99% CI 0.16 to 1.24) for the
composite outcome of cardiovascular mortality, nonfatal MI,
and nonfatal cardiac arrest. The authors believed that these
data were inadequate to draw conclusions without a larger,
controlled study. This review, however, included a wide
variety of studies, patient populations, and beta-blocker
regimens. Many of the studies described only a single or
double dose of beta blockers preoperatively or at induction of
anesthesia. Many of the data, therefore, do not pertain to
perioperative beta blockade for the purpose of cardiac risk
reduction or are focused on a low-risk population. Addition-
ally, the largest studies included, those reported by Miller et
al (388) and preliminary data from Yang et al (377), which
together account for almost as many subjects as all the other
studies combined, may not have been appropriate to include
in this analysis. The first, by Miller et al, was a study of a
single intravenous dose of beta blocker for the purpose of
blood pressure control during intubation, not reduction of
perioperative events. It included follow-up only to the point
of discharge from the recovery room. The second, that of
Yang et al, was based on an abstract, whereas the full
manuscript has now been published. The studies included in
this review also varied widely in length of follow-up.
McGory et al (389) performed a meta-analysis of 6
randomized trials of perioperative beta blockade and con-
cluded that therapy was associated with significant reductions
in perioperative myocardial ischemia (33% to 15%), MI,
cardiac mortality, and long-term cardiac mortality (12% to
2%). These authors used the combined data to derive ORs and
CIs for several outcomes. For perioperative overall mortality,
the OR for beta-blocker therapy was 0.52 (95% CI: 0.20 to
1.35), and for perioperative cardiac mortality, the OR was
0.25 (95% CI: 0.07 to 0.87). Neither the POBBLE study nor
the unpublished findings included in the Devereaux article
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were included, which explains the marked difference in
findings from the other meta-analysis.
A cohort study by Lindenauer et al (373) reviewed records
from more than 700 000 patients undergoing noncardiac
surgery at 329 hospitals in the United States. Participant
hospitals in this cohort study were members of a consortium
database measuring quality of care and healthcare use. These
authors evaluated all noncardiac surgical cases and compared
those who received beta blockers within the first 2 days of
hospitalization with those who did not. The authors used
propensity score matching techniques in an attempt to reduce
confounding. These authors found that for a Revised Cardiac
Risk Index score(4) of 3 or more (based on the presence of
history of ischemic heart disease, cerebrovascular disease,
renal insufficiency, diabetes mellitus, or a patient undergoing
high-risk surgery), patients who received beta blockers were
significantly less likely to die while in the hospital. This was
not true for those with a revised risk index of 2, l, or 0. Those
with a risk index of 0 were more likely to die in the hospital
if given a beta blocker on day 1 or day 2 of hospitalization.
This study was retrospective and not randomized and is
therefore subject to potential bias. This is particularly true in
terms of reporting bias, because the documentation was based
entirely on administrative data sets, using arbitrary definitions
of “on” or “off” perioperative beta blockers that were based
solely on hospital day of use. Nonetheless, there appears to be
Table 12. Perioperative Prophylactic Beta Blockers and Anti-Ischemic Medications
Myocardial Ischemia MI Death
Study, Year Procedure n Control Drug and Dosage Control Drug Control Drug Control Drug
Studies of beta blockers
Pasternack et al (378), 1987 Abdominal aortic
aneurysmorrhaphy
83 Case-control Metoprolol 50 mg PO
preoperatively
17.6%
(9/51)
3.1%
(1/32)*
Pasternack et al (379), 1989 Vascular 200 Unblinded Metoprolol 50 mg PO
preoperatively
1.83.2
episodes
0.81.6
episodes*
Noncardiac 128 Placebo Labetalol 28.2%
(11/39)
2.2%
(2/89)*
0%
(0/39)
0%
(0/89)
Stone et al (76), 1988 Atenolol
Alprenolol
PO preoperatively
Poldermans et al (89), 1999 Vascular 112 Unblinded Bisoprolol 5 to 10 mg
PO
17%
(9/53)
0%
(0/59)*
17%
(9/53)
3.4%
(2/59)*
Raby et al (380), 1999 Vascular 26 Placebo IV esmolol 72.7%
(8/11)
33.3%
(5/15)*
Wallace et al (376), 1998, and
Mangano et al (88), 1996
Noncardiac 200 Placebo Atenolol 10 to 20 mg IV
or 50 to 100 mg PO
39/101
(38.6%)
24/99
(24.2%)*
(At 6
months)
10/101
1/99
(9.9%)
(1.0%)*
Urban et al (384), 2000 Noncardiac 107 Placebo IV esmolol on the day
of surgery, followed by
metoprolol starting at
25 mg PO BID and
increased to maintain
an HR less than 80
bpm, and continued for
the next 48 hours
14.5%
(8/55)
5.8%
(3/52)
5.4%
(3/55)
1.9%
(1/52)
Brady et al (382), 2005 Vascular 103 Placebo Metoprolol 50 mg PO
BID preoperatively until
7 days after surgery
9% (4/44) 9.4%
(5/53)
11.3%
(5/44)
5.6%
(3/53)
2.2%
(1/44)
5.6%
(3/53)
Juul et al (375), 2006 Noncardiac 921 Placebo Metoprolol 100 mg
sustained release 1 day
preoperatively, until up
to 8 days
postoperatively
16%
72/459)
16%
(74/462)
Yang et al (377), 2006 Vascular 496 Placebo Weight-adjusted
metoprolol, 50, 75, or
100 mg
21/250
(8.4%)
19/246
(7.7%)
4/250
(1.6%)
0/246
(0%)
BID indicates twice per day; bpm, beats per minute; HR, heart rate; IV, intravenous; McSPI, Multicenter Study of Perioperative Ischemia; MI, myocardial infarction;
n, number of patients; NTG, nitroglycerin; and PO, by mouth.
*P0.05 for drug vs control.
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an association between improved outcomes and the use of
beta blockers in clinically high-risk patients.
Finally, 1 observational cohort study examined the ques-
tion of which beta blocker may be best for perioperative
medical therapy. Redelmeier and colleagues (374) reviewed
administrative data related to elective surgery in Ontario,
Canada, and documented perioperative beta-blocker usage
from April 1992 to April 2002 (10 years). They limited their
analysis to patients over 65 years of age who were receiving
either atenolol or metoprolol before and after surgery and
identified 37 151 subjects. A total of 1038 either had a
perioperative MI or died, and the rate of MI or death was
significantly lower among those patients receiving atenolol
than among those given metoprolol (2.5% versus 3.2%, P less
than 0.001). This difference persisted even after adjustment
for demographic, clinical, and surgical factors. The inclusion
of other long-acting beta blockers in the analysis yielded an
identical risk reduction. These data suggest that long-acting
beta blockade (when therapy is initiated before surgery), may
be superior to short-acting beta blockade. These observations
await clinical trial evaluation.
7.2.1.2. Titration of Beta Blockers
Feringa and colleagues performed an observational cohort
study of 272 vascular surgery patients (390). Beta-blocker
dose was converted to a percentage of the maximum recom-
mended therapeutic dose. In multivariable analysis, higher
beta-blocker doses (per 10% increase) were significantly
associated with a lower incidence of myocardial ischemia
(HR: 0.62, 95% CI: 0.51 to 0.75), troponin T release (HR:
0.63, 95% CI: 0.49 to 0.80), and long-term mortality (HR:
0.86, 95% CI: 0.76 to 0.97). Higher heart rates during ECG
monitoring (per 10-bpm increase) were significantly associ-
ated with an increased incidence of myocardial ischemia
(HR: 2.49, 95% CI: 1.79 to 3.48), troponin T release (HR:
1.53, 95% CI: 1.16 to 2.03), and long-term mortality (HR: 1.42,
95% CI: 1.14 to 1.76). An absolute mean perioperative heart rate
less than 70 bpm was associated with the best outcome.
Poldermans and colleagues (59) randomly assigned 770
intermediate-risk patients to cardiac stress testing (n386) or
no testing (n384). All patients received beta blockers, and
the beta-blocker dose was adjusted preoperatively to achieve
a resting heart rate of 60 to 65 bpm. In patients with ischemia,
physicians aimed to control heart rate below the ischemic
threshold. Patients assigned to no testing had a similar
incidence of the cardiac events as those assigned to testing.
Patients with a heart rate less than 65 bpm had lower risk than
the remaining patients (1.3% versus 5.2%; OR 0.24, 95% CI:
0.09 to 0.66, P0.003). The authors concluded that cardiac
testing can safely be omitted in intermediate-risk patients,
provided that beta blockers aimed at tight heart rate control
are prescribed.
The importance of tight heart rate control in reducing
perioperative myocardial ischemia is further supported by a
study by Raby et al (380). The lack of tight heart rate control
is a potential explanation for the lack of efficacy in some of
the randomized trials. Accumulating evidence suggests that
effective heart rate control with beta blockers should be
targeted at less than 65 bpm.
7.2.1.3. Withdrawal of Beta Blockers
Concerns regarding the discontinuation of beta-blocker ther-
apy in the perioperative period have existed for several
decades (391). Shammash and colleagues (392) studied a
total of 140 patients who received beta blockers preopera-
tively. Mortality in the 8 patients who had beta blockers
discontinued postoperatively (50%) was significantly greater
than in the 132 patients in whom beta blockers were contin-
ued (1.5%; OR 65.0, P less than 0.001). Hoeks and colleagues
(393) studied 711 consecutive peripheral vascular surgery
patients. After adjustment for potential confounders and the
propensity of its use, continuous beta-blocker use remained
significantly associated with a lower 1-year mortality than
among nonusers (HR: 0.4, 95% CI: 0.2 to 0.7). In contrast,
beta-blocker withdrawal was associated with an increased risk of
1-year mortality compared with nonusers (HR: 2.7, 95% CI: 1.2
to 5.9).
As noted in the recommendations, continuation of beta-
blocker therapy in the perioperative period is a class I
indication, and accumulating evidence suggests that titration
to maintain tight heart rate control should be the goal.
7.2.2. Perioperative Statin Therapy
Recommendations for Statin Therapy
CLASS I
1. For patients currently taking statins and scheduled for noncardiac
surgery, statins should be continued. (Level of Evidence: B)
CLASS IIa
1. For patients undergoing vascular surgery with or without clinical
risk factors, statin use is reasonable. (Level of Evidence: B)
CLASS IIb
1. For patients with at least 1 clinical risk factor who are undergoing
intermediate-risk procedures,
statins may be considered. (Level of Evidence: C)
Lipid lowering has proven to be highly effective in the
secondary prevention of cardiac events. Numerous studies
have demonstrated that many patient groups (high-risk pa-
tients with a history of MI, high-risk patients without a
history of MI, and patients who are simply at high risk) have
a lower incidence of MI, stroke, and death when treated with
lipid-lowering agents. Specifically, the bulk of this evidence
applies to hydroxymethylglutaryl coenzyme A (HMG-CoA)
reductase inhibitors, or statin therapy (394,395).
The effectiveness of this class of medications in preventing
cardiovascular events among high-risk patients has suggested
to many that these agents might similarly improve perioper-
ative cardiac risk. Certainly, the growing evidence that statin
therapy improves endothelial function, reduces vascular in-
flammation, and stabilizes atherosclerotic plaque all supports
the concept that these agents may reduce the incidence of
cardiovascular events brought on by the stress of surgery in
the setting of known atherosclerotic disease.
The evidence relating to statin use in the perioperative
period to date is primarily in the form of observational studies
(Table 13) (253,396–399,401–404). Hindler and colleagues
conducted a meta-analysis to evaluate the overall effect of
preoperative statin therapy on postoperative outcomes (405).
Preoperative statin therapy was associated with 59% reduc-
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tion in the risk of mortality after vascular (1.7% versus 6.1%;
P0.0001) surgery. When including noncardiac surgery, a
44% reduction in mortality (2.2% versus 3.2%; P0.0001)
was observed.
One randomized controlled trial has been performed to
evaluate the effectiveness of statin therapy for perioperative
cardiovascular risk protection. Durazzo and colleagues ran-
domized 100 patients who were to undergo vascular surgery
to atorvastatin 20 mg per day or placebo (406). Subjects in the
study received atorvastatin for an average of 30 days before
undergoing vascular surgery. The end point studied was a
composite of death due to a cardiac cause, MI, unstable
angina, and stroke. Cardiac events occurred in 13 patients
(26%) in the placebo group at 6-month follow-up compared
with only 4 (8%) in the atorvastatin group (P0.31). Al-
though this study was small, with few end points, and
included a composite end point, the investigators did have
complete follow-up, and the difference in event rates between
the 2 groups was statistically significant.
Poldermans and colleagues evaluated the association be-
tween perioperative death and statin use in a case-control
study (397). They identified all patients who died during
hospitalization for vascular surgery from among 2816 pa-
tients who underwent vascular surgery at Erasmus University
between 1991 and 2000 (397). For each of the 160 cases of
in-hospital death, they matched 2 control subjects based on
similar year and type of surgery. Statin use was significantly
less in those who died during hospitalization for vascular
surgery, with an adjusted OR of 0.22 (95% CI: 0.10 to 0.47).
Only 65% of the cases in this study died of vascular causes,
although the authors point out that there was no association
between statin use and death among those patients who died
of bleeding complications. The authors did adjust for medi-
cation use, including beta blockers and statins. Although
retrospective and observational, these data certainly argue for
an association between a lack of statin use and increased
mortality after major vascular surgery.
In another similar study, O’Neil-Callahan and colleagues
evaluated the association between statin use and cardiac
complications during noncardiac surgery (398). They col-
lected information on all patients undergoing major vascular
surgery (carotid endarterectomy, aortic surgery, or lower-
extremity revascularization) between January 1999 and De-
cember 2000 at a single tertiary referral center. The compos-
ite end point for this study included death, MI, ischemia,
congestive HF, and ventricular tachyarrhythmias. The pri-
mary end point occurred in 157 of 1163 patients, significantly
more frequently in patients not receiving statin therapy
(16.5%) than in those receiving statins (9.9%, P0.001).
After adjustment for other predictors of perioperative cardiac
events, statin use remained associated with a decreased risk
(OR: 0.52, 95% CI: 0.35 to 0.76, P0.001). These authors
found that statin use was associated with beta-blocker use, but
a propensity score analysis suggested that the effect of statins
was independent of that association.
A large administrative database combining patient infor-
mation from 4 western Canadian provinces was used to
examine the relationship between statin use and outcomes in
patients undergoing carotid endarterectomy (401). In this
study, the authors identified all patients undergoing open
surgical treatment for symptomatic carotid disease, examin-
ing the association between statin use and perioperative
death, perioperative stroke or death, or perioperative cardio-
vascular outcomes. They found a significant inverse correla-
tion between statin use and perioperative death (OR: 0.25,
95% CI: 0.07 to 0.90) and between statin use and perioper-
ative stroke or death (OR: 0.55, 95% CI: 0.32 to 0.95) but not
cardiovascular outcomes (OR: 0.87, 95% CI: 0.49 to 1.54).
Interestingly, this group showed no benefit for any of these
outcomes in asymptomatic patients undergoing carotid end-
Table 13. Published Studies of Perioperative Statin Use and Outcomes in Noncardiac Surgery
Adjusted OR (95% CI)
Study, Year Design n (Statin/Total) Surgery
Perioperative
Complications
Perioperative
Mortality
Lindenauer et al (396), 2004 Retrospective/
administrative
77 082/
780 591
Major noncardiac 0.62 (0.58 to 0.67)
Poldermans et al (397), 2003 Case-control 160 Cases,
320 controls
Major vascular 0.22 (0.10 to 0.47)
O’Neil-Callahan et al (398), 2005 Retrospective 526/1163 Major vascular 0.52 (0.35 to 0.77)
Kertai et al (399), 2004 Retrospective 162/570 AAA surgery 0.24 (0.10 to 0.70)
(Death or MI)
Landesberg et al (400), 2003 Retrospective 502 Major vascular 0.54 (0.26 to 1.11)
Kennedy et al (401), 2005 Retrospective/
administrative
815/2031
Symptomatic
Carotid
endarterectomy
0.55 (0.32 to 0.95)
(Stroke or death)
0.25 (0.07 to 0.90)
665/1252
Asymptomatic
Carotid
endarterectomy
0.54 (0.13 to 2.24)
(Stroke or death)
1.34 (0.61 to 2.93)
Ward et al (402), 2005 Retrospective 72/446 Infrainguinal vascular
surgery
0.36 (0.14 to 0.93)
McGirt et al (403), 2005 Retrospective 657/1566 Carotid
endarterectomy
0.35 (0.15 to 0.85)
(Stroke)
0.20 (0.04 to 0.99)
AAA indicates abdominal aortic aneurysm; CI, confidence interval; MI, myocardial infarction; n, number of patients; and OR, odds ratio.
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arterectomy, which suggests that benefit, as expected, is
proportional to risk. Similarly, McGirt et al (403) reviewed
the results of carotid endarterectomy in 1566 patients at a
major academic medical center, documenting a reduced rate
of perioperative stroke (OR: 0.35, 95% CI: 0.15 to 0.85) and
death (OR: 0.20, 95% CI: 0.04 to 0.99).
Le Manach prospectively collected data in patients under-
going infrarenal aortic surgery and compared a cohort when
there were no guidelines for perioperative continuation of
statins (discontinuation group, n491) compared with when
guidelines were instituted whereby statin therapy was contin-
ued starting as soon as possible after surgery (continuation
group, n178) (407). Postoperative statin withdrawal (more
than 4 days) was an independent predictor of postoperative
myonecrosis (OR: 2.9, 95% CI: 1.6 to 5.5).
Finally, in the largest such observational study, Lindenauer
and colleagues reviewed the hospital and pharmacy records
of 780 591 patients over 18 years of age who were undergo-
ing noncardiac surgery (396). These data came from admin-
istrative databases in 329 hospitals participating in a quality
and benchmarking program. The authors defined statin use as
recorded use of statin therapy during the first 2 days of
hospitalization. Use after the first 2 days was coded as nonuse
of statins. These authors used propensity matching to adjust
for baseline demographic and risk factor differences. Hospital
mortality was the primary end point and was analyzed in
association with statin use, stratified by each patient’s calcu-
lated Revised Cardiac Risk Index score based on Lee et al (4).
Patients who received statins had a lower crude mortality rate
(2.13% versus 3.05%, P less than 0.001) and a lower
mortality rate with matching by propensity score (2.18%
versus 3.15%, P less than 0.001). Mortality remained lower
after adjustment for differences with conditional logistic
regression (adjusted OR 0.62, 95% CI: 0.58 to 0.67). The
authors estimated that the number needed to treat with statin
therapy to prevent in-hospital death was 85 (95% CI: 77 to
98), varying from 186 in the lowest-risk group to 30 in the
highest-risk group.
Several other reports also lend support to the association
between perioperative statin use and perioperative outcomes.
Some of these studies are analyses of reports that included
statin use among the independent variables associated with
outcomes after noncardiac surgery (404) or are reanalyses of
data already discussed (408,409) Additionally, Schouten and
colleagues (409) studied 981 patients undergoing major
vascular surgery and did not find an association between
perioperative statin use and an increased risk of myopathy or
any cases of rhabdomyolysis.
In summary, the evidence so far accumulated suggests a
protective effect of perioperative statin use on cardiac com-
plications during noncardiac surgery. Most of these data are
observational and identify patients in whom time of initiation
of statin therapy and duration of statin therapy are unclear.
Furthermore, statin dose, target or achieved low-density
lipoprotein levels, and indications for statin therapy are also
largely unclear. Sufficiently powered randomized trials are
needed to determine whether these observed associations
translate into a benefit for statin therapy prescribed peri-
operatively for the purpose of lowering cardiac event rates
surrounding noncardiac surgery. Utilizing the periopera-
tive period as an opportunity to impact long-term health,
consideration should be given to starting statin therapy in
patients who meet National Cholesterol Education Pro-
gram criteria (395,410).
7.2.3. Alpha-2 Agonists
CLASS IIb
1. Alpha-2 agonists for perioperative control of hypertension may be
considered for patients with known CAD or at least 1 clinical risk
factor who are undergoing surgery. (Level of Evidence: B)
CLASS III
1. Alpha-2 agonists should not be given to patients undergoing
surgery who have contraindications to this medication. (Level of
Evidence: C)
Several studies examined the role of alpha-agonists
(clonidine and mivazerol) for perioperative cardiac protec-
tion. Oliver et al (411) reported a large, randomized, placebo-
controlled, multicenter trial of the alpha-2 agonist mivazerol
in perioperative use. They randomized 2854 patients with
known CAD or significant risk factors who were undergoing
noncardiac surgery to a 1.5 mcg per kg per hour infusion of
mivazerol or placebo. Among patients with an established
history of CAD who were undergoing general surgical
procedures, the rate of MI was no different between the
mivazerol and placebo groups, but the cardiac death rate was
reduced (13 of 946 versus 25 of 941; P0.04). Among
patients undergoing vascular procedures, both cardiac death
rate (6 of 454 versus 18 of 450; P0.017) and the combined
end point of death or MI (44 of 454 versus 64 of 450;
P0.037) were significantly reduced. The Multicenter Study
of Perioperative Ischemia Research Group (412) also re-
ported the results of a placebo-controlled, randomized,
double-blind study of perioperative mivazerol. Three hundred
patients with known CAD undergoing noncardiac surgery
were randomized to high-dose (1.5 mcg per kg per hour) or
low-dose (0.75 mcg per kg per hour) mivazerol or placebo.
No differences in perioperative death or MI were observed,
but the high-dose group had significantly less myocardial
ischemia than the placebo group (20 of 98 versus 35 of 103;
P0.026). Two randomized, placebo-controlled studies of
clonidine for perioperative myocardial protection were per-
formed in 297 patients undergoing vascular surgery (413) and
61 patients undergoing general surgery (414). Both demon-
strated a significant decrease in the incidence of myocardial
ischemia (35 of 145 versus 59 of 152, P less than 0.01, and 1
of 28 versus 5 of 24, P0.05, respectively).
Wijeysundera and colleagues (415) performed a meta-
analysis of perioperative alpha-2 agonist administration
through 2002 comprising 23 trials enrolling 3395 patients.
Alpha-2 agonists reduced mortality (RR: 0.76, 95% CI: 0.63
to 0.91) and MI (RR: 0.66, 95% CI: 0.46 to 0.94) during
vascular surgery.
More recently, Wallace et al (416) conducted a prospec-
tive, double-blinded, clinical trial on patients with or at risk
for CAD to investigate whether prophylactic clonidine re-
duced perioperative myocardial ischemia and long-term death
in patients undergoing noncardiac surgery. Patients were
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randomized to clonidine (n125) or placebo (n65).
Clonidine (0.2 mg orally and by patch) or placebo (tablet and
patch) were administered the night before surgery, and
clonidine (0.2 mg orally) or placebo (tablet) was administered
on the morning of surgery. Patches were left on for 4 days.
Prophylactic clonidine administered perioperatively signifi-
cantly reduced myocardial ischemia during the intraoperative
and postoperative period (clonidine 18 of 125 or 14% versus
placebo 20 of 65 or 31%; P0.01). Moreover, administration
of clonidine had minimal hemodynamic effects and reduced
postoperative mortality for up to 2 years (clonidine 19 of 125
or 15% versus placebo 19 of 65 or 29%; RR: 0.43, 95% CI:
0.21 to 0.89, P0.035).
7.2.4. Perioperative Calcium Channel Blockers
A meta-analysis of perioperative calcium channel blockers in
noncardiac surgery that was published in 2003 identified 11
studies involving 1007 patients (417). Calcium channel
blockers significantly reduced ischemia (RR: 0.49, 95% CI:
0.30 to 0.80, P0.004) and supraventricular tachycardia (RR:
0.52, 95% CI: 0.37 to 0.72, P less than 0.0001). Calcium
channel blockers were associated with trends toward reduced
death and MI. In post hoc analyses, calcium channel blockers
significantly reduced death/MI (RR: 0.35, 95% CI: 0.15 to
0.86, P0.02). The majority of these benefits were attribut-
able to diltiazem. Dihydropyridines and verapamil did not
decrease the incidence of myocardial ischemia, although
verapamil decreased the incidence of supraventricular
tachycardia. The authors concluded that a large-scale trial
was needed to define the value of these agents.
7.3. Prophylactic Valvular Intervention Before
Noncardiac Surgery
There is little information about the appropriateness of
valvular repair or replacement before a noncardiac surgical
procedure is undertaken. Clinical experience indicates that
patients with valvular heart disease severe enough to warrant
surgical treatment should have valve surgery before elective
noncardiac surgery. It has been suggested that patients with
severe mitral or aortic stenosis who require urgent noncardiac
surgery, such as intestinal resection for lesions causing
serious gastrointestinal bleeding, may benefit from catheter
balloon valvuloplasty at least as a temporizing step to reduce
the operative risk of noncardiac surgery (418–421). Unfor-
tunately, there are no controlled studies, and the risks of
balloon aortic valvuloplasty in older patients are significant
(418), although mitral valvuloplasty performed by experi-
enced operators has been shown to be safe and effective.
Experience with managing valvular heart disease during labor
and delivery provides insights into the approach to manage-
ment of the patient for noncardiac surgery. The vast majority
of women with regurgitant valvular heart disease can be
managed medically during the course of pregnancy, including
labor and delivery, because the decrease in peripheral vascu-
lar resistance that occurs with pregnancy tends to decrease
regurgitant lesions (422). Increased arterial afterload is not
well tolerated in patients with aortic and mitral regurgitation.
Therefore, increases in blood pressure should be prevented,
and LV afterload should be optimized with vasodilators. In
contrast, patients with significant aortic or mitral stenosis
often do not do well with the increased hemodynamic burden
of pregnancy. If the stenosis is severe, percutaneous catheter
balloon valvotomy should be considered as definitive therapy
or as a bridge to care for the patient through pregnancy, labor,
and surgical delivery. Excessive changes in intravascular
volume should be avoided (see also Section 3.5, Valvular
Heart Disease).
7.4. Perioperative Arrhythmias and
Conduction Disturbances
In the perioperative setting, cardiac arrhythmias or conduc-
tion disturbances often reflect the presence of underlying
cardiopulmonary disease, drug toxicity, or metabolic de-
rangements. In patients with documented hemodynamically
significant or symptomatic arrhythmias, electrophysiologic
testing and catheter ablation, particularly for supraventricular
arrhythmias, may be indicated to prevent arrhythmia recur-
rence (423–425). In patients with documented hemodynam-
ically significant or symptomatic arrhythmias, acute treat-
ment is indicated. Sustained supraventricular arrhythmias
may require electrical or pharmacological cardioversion.
Alternatively, in atrial fibrillation or atrial flutter, a rate-
control strategy can be accomplished with beta-adrenergic
blockers, calcium channel blockers, or digoxin (oral or
intravenous). Of these 3 types of medications, digitalis is the
least effective agent and beta blockers are the most effective
agent for controlling the ventricular response during atrial
fibrillation (426). An additional benefit of beta blockers is
that they have been shown to accelerate the conversion of
postoperative supraventricular arrhythmias to sinus rhythm
compared with diltiazem (427). In select cases, electrophysi-
ologic testing and catheter ablation, particularly for supraven-
tricular arrhythmias, may be indicated.
Patients with chronic atrial fibrillation or a history of
paroxysmal atrial fibrillation before surgery often take
chronic oral anticoagulants. It may be necessary to discon-
tinue this anticoagulation from a few to several days before
surgery. Bridging anticoagulation with either low-molecular-
weight or unfractionated heparin may be indicated if the
thromboembolic risk assessment warrants. If time does not
allow and it is important that the patient not be taking
anticoagulants, the effect of warfarin can be reversed by
parenteral vitamin K or fresh frozen plasma (428).
Ventricular arrhythmias, whether simple premature ven-
tricular contractions, complex ventricular ectopy, or nonsus-
tained tachycardia, usually do not require therapy unless they
are associated with hemodynamic compromise or occur in the
presence of ongoing or threatened myocardial ischemia or LV
dysfunction. Studies have shown that although nearly half of
all high-risk patients undergoing noncardiac surgery have
frequent premature ventricular contractions or asymptomatic
nonsustained ventricular tachycardia, the presence of these
ventricular arrhythmias is not associated with an increase in
nonfatal MI or cardiac death (36,37). Nevertheless, the
presence of an arrhythmia in the preoperative setting should
provoke a search for underlying cardiopulmonary disease,
ongoing myocardial ischemia or infarction, drug toxicity, or
metabolic derangements. Physicians should also have a low
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threshold at which they institute prophylactic beta-blocker
therapy in patients at increased risk of developing a periop-
erative or postoperative arrhythmia (including those in whom
arrhythmias are present during the preoperative evaluation).
Several studies have demonstrated that beta-blocker ther-
apy can reduce the incidence of arrhythmias during the
perioperative period (87,117). Sustained or symptomatic
ventricular tachycardia should be suppressed preoperatively
with intravenous lidocaine, procainamide, or amiodarone, and
a thorough search should be conducted for underlying causes
and appropriate short- and long-term therapy.
The indications for temporary pacemakers are almost
identical to those previously stated for long-term permanent
cardiac pacing (429). Patients with intraventricular conduc-
tion delays, bifascicular block (right bundle-branch block
with left anterior or posterior hemiblock), or left bundle-
branch block with or without first-degree atrioventricular
block do not require temporary pacemaker implantation in the
absence of a history of syncope or more advanced atrioven-
tricular block (118).
7.5. Intraoperative Electromagnetic
Interference With Implanted Pacemakers
and ICDs
It is important to be aware of the potential for adverse
interactions between electrical/magnetic activity and pace-
maker or ICD function that may occur during the operative
period. These interactions result from electrical current gen-
erated by electrocautery or cardioversion, as well as the
impact of metabolic derangements, antiarrhythmic agents,
and anesthetic agents on pacing and sensing thresholds. The
probability of these adverse interactions can be minimized if
certain precautions are taken. Although this topic has been
analyzed in a number of review articles and book chapters
(430–433), no formal guidelines have been developed by the
ACC, the AHA, or the Heart Rhythm Society. Of note,
however, is a practice advisory that has been published by the
American Society of Anesthesiology (434).
Electrocautery involves the use of radiofrequency current
to cut or coagulate tissues. It is usually applied in a unipolar
fashion between the cautery device and an indifferent plate
attached to the patient’s skin. The indifferent plate is often
placed on the patient’s thigh. Although bipolar cautery
systems are available, they are not widely used. The potential
for electromagnetic interference with an implanted device is
related to the amount of current generated in the vicinity of
the pacemaker or ICD device. In general, high current is
generated if the cautery device is close to the pacemaker,
particularly if the current path of the cautery lies along the
axis of the pacemaker or ICD lead. The electrical current
generated by electrocautery can cause a variety of responses
by the implanted device, including the following: 1) tempo-
rary or permanent resetting to a backup, reset, or noise-
reversion pacing mode (eg, a dual-chamber pacemaker may
be reset to VVI pacing at a fixed rate); 2) temporary or
permanent inhibition of pacemaker output; 3) an increase in
pacing rate due to activation of the rate-responsive sensor; 4)
ICD firing due to activation by electrical noise; or 5)
myocardial injury at the lead tip that may cause failure to
sense and/or capture. Cardioversion can have similar effects
on pacemaker or ICD function. Although the probability of
any of these adverse interactions occurring has fallen dramat-
ically owing to the almost universal use of bipolar leads
(which greatly reduces the probability of electromagnetic
interference) and improved pacemaker and ICD design, they
still may occur (430–433,435).
The likelihood and potential clinical impact of adverse
interactions occurring in patients with ICDs and pacemaker
devices will be influenced by a number of factors, including
whether the patient is pacemaker dependent, whether the
pacemaker has unipolar or bipolar leads, whether the electro-
cautery is bipolar or unipolar, and the relative distance from
and orientation of the electrocautery relative to the pacemaker
and pacemaker lead. These factors, combined with the ur-
gency and type of surgery (interactions are far more likely to
occur with surgical procedures that involve the chest or
abdomen) and the availability of expertise in pacing and/or
ICDs, will ultimately determine the type and extent of
evaluation that is performed in a particular institution. Pa-
tients with pacemakers must be assessed as to whether they
are pacer dependent. This may be determined by a chart
review and examination of the ECG, as opposed to requiring
the interrogation of the device. When the patient is not pacer
dependent and/or the cautery is remote and will be adminis-
tered in brief bursts, and the operative team can monitor the
ECG and pulse oximeter (which allows pulse determination
even when electrical interference by cautery interferes with the
ECG), it may be unnecessary to interrogate the pacer at all.
Several general recommendations can be made concerning
the preoperative and operative management of patients with
implanted devices who are undergoing surgical procedures
(436). Patients with implanted ICDs or pacemakers need to be
identified before surgery so that appropriate records from the
device clinic that is monitoring the patient’s device can be
obtained. In addition, the original indication for device
placement should be identified before surgery. Patients with
permanent pacemakers, who are pacemaker dependent,
should have their device evaluated within 3 to 6 months
before significant surgical procedures, and also after surgery.
Significant surgical procedures include major abdominal or
thoracic surgery, particularly when the surgery involves large
amounts of electrocautery. This evaluation should include 1)
determining the type of device, 2) determining whether the
patient is pacemaker dependent for antibradycardia pacing,
and 3) determining device programmed settings and battery
status. If a patient is pacemaker dependent, the device should
be reprogrammed to an asynchronous mode during surgery
(VOO or DOO), or a magnet should be placed over the device
during surgery. Implantable cardioverter defibrillator devices
should have their tachyarrhythmia treatment algorithms pro-
grammed off before surgery and turned on after surgery to
prevent unwanted shocks due to spurious signals that the
device might interpret as ventricular tachycardia or fibrilla-
tion. During the period of time when device therapy has been
inactivated, the patient should be monitored continuously for
a life-threatening arrhythmia. All patients with implanted
devices should have both continuous ECG monitoring and
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continuous pulse monitoring during surgery. This reflects the
fact that electrocautery may interfere with ECG monitoring
and make it difficult or impossible to determine the patient’s
rhythm. Efforts should be made to minimize the chance for
interactions by careful management of potential sources of
electromagnetic interference. These include 1) the use of a
bipolar electrocautery system if possible, 2) the use of short
and intermittent bursts of electrocautery at the lowest possible
energy levels, 3) maximization of the distance between the
electrocautery and the device, and 4) if a unipolar cautery is
to be used, placement of the ground patch in a position so as
to minimize current flow through the pacemaker or ICD
device. Finally, if emergency cardioversion is required, the
paddles should be placed as far from the implanted device as
possible and in an orientation likely to be perpendicular to the
orientation of the device leads (anterior-posterior paddle
position is preferred). After the surgery, the function of the
implanted device should be assessed and in some cases
formally evaluated. If the pacemaker or ICD was repro-
grammed before surgery, it should be programmed back to its
original settings after surgery. In the case of an ICD, an
interrogated programmer printout should be produced to
verify that its antitachycardia function has been restored to its
active status.
Placement of a magnet over an implanted device has
variable effects depending on the type of device, its manu-
facturer, and its model. Most bradycardia pacemakers will
respond to magnet application with asynchronous pacing at a
pre-prescribed rate. However, this magnet function can, in a
minority of pacemaker models, be programmed off, and
therefore, a magnet may not elicit a response from those
models. If a magnet will be used during surgery in a patient
with a pacemaker who is pacemaker dependent, it should be
applied before surgery to be certain that appropriate asyn-
chronous pacing is triggered by the magnet. Unlike bradycar-
dia pacemakers, a magnet will not change the pacing function
of an ICD. Magnet application will affect only the
antitachycardia function of an ICD. With some models of
ICDs, the magnet will first suspend the antitachycardia
(shocking) function and then actually turn the therapy off.
With other ICD models, the magnet will only temporarily
disable the shock function (while the magnet is in place), and
the therapy will then become active again on its removal
(either intentional or unintentional). Programming the shock
function off with an ICD programmer (and turning it back on
after the surgery) is the preferred method of addressing these
issues. Because some patients with ICDs are also pacemaker
dependent, the pacing function of the ICD may need to be
programmed to an asynchronous mode (eg, VOO or DOO)
during surgery to prevent electromagnetic interference–
induced inhibition. Communication of the status of the
pacemaker or ICD to the anesthesiologist, surgeon, and
intensivist is imperative.
7.6. Preoperative Intensive Care
CLASS IIb
1. Preoperative intensive care monitoring with a pulmonary artery
catheter for optimization of hemodynamic status might be con-
sidered; however, it is rarely required and should be restricted to a
very small number of highly selected patients whose presentation
is unstable and complex and who have multiple comorbid condi-
tions. (Level of Evidence: B)
Preoperative invasive monitoring in an intensive care
setting can be used to optimize and even augment oxygen
delivery in patients at high risk. It has been proposed that
indexes derived from the pulmonary artery catheter (PAC)
and invasive blood pressure monitoring can be used to
maximize hemodynamic function which may lead to a reduc-
tion in organ dysfunction or morbidity.
There are limited numbers of studies evaluating intensive
care monitoring before noncardiac surgery. Two prospective
randomized trials evaluating the use of PACs and hemody-
namic optimization arrived at different conclusions regarding
its impact on morbidity and mortality (437,438). A meta-
analysis of hemodynamic optimization by Poeze et al (439)
found an overall decreased mortality rate (RR: 0.75, 95% CI:
0.54 to 0.81) in all studies. Kavarana et al (440) performed a
retrospective analysis investigating preoperative optimization
of cardiovascular function using a PAC in elderly patients
(greater than 65 years) undergoing elective colon resection
and found reduced mortality (5% versus 15.8%) only in
patients with a cardiac risk index greater than 10. Kern and
Shoemaker’s (441) meta-analysis of 21 randomized con-
trolled trials with various approaches found reduced mortality
with hemodynamic optimization.
7.7. Venothromboembolism/Peripheral
Arterial Disease
Two peripheral vascular disorders that merit attention preop-
eratively are venous thromboembolism and, in the elderly,
chronic occlusive peripheral arterial disease. Prophylactic
measures need to be planned and in some cases started
preoperatively for persons with clinical circumstances asso-
ciated with postoperative venous thromboembolism. These
correlates of thromboembolic risk include advanced age;
prolonged immobility or paralysis; prior venous thromboem-
bolism; malignancy; major surgery, particularly operations
involving the abdomen, pelvis, or lower extremities; obesity;
varicose veins; HF; MI; stroke; fractures of the pelvis, hip, or
leg; congenital or acquired aberrations in hemostatic mecha-
nisms (hypercoagulable states); and, possibly, high-dose es-
trogen use as suggested by the American College of Chest
Physicians (114). The choice of prophylactic measure or
agent—graded-compression elastic stockings, low-dose sub-
cutaneous heparin, low-molecular-weight heparin, warfarin,
or intermittent pneumatic compression—will depend on the
risk of venous thromboembolism and the type of surgery
planned. Table 14 provides published recommendations for
various types of surgical procedures (442).
The noninvasive techniques—impedance plethysmography
and real-time compression ultrasonography—are effective
objective tests to exclude clinically suspected deep venous
thrombosis and are best used for this purpose (443,444).
Routine screening of all postoperative patients with a nonin-
vasive technique is not as cost-effective or efficient as
appropriate antithrombotic prophylaxis for moderate- and
high-risk patients (445,446).
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The prevalence of chronic occlusive peripheral arterial
disease rises with increasing age, affecting more than 10% of
the general population older than 65 years (447) and as many
as half of all persons with CAD (448). Patients with this
condition may be at increased risk of perioperative cardiac
complications, even for a given degree of coronary disease
(449). This may warrant particular attention to the preopera-
tive evaluation and intraoperative therapy of such patients.
Protection of the limbs from trauma during and after surgery
is as important for those with asymptomatic arterial disease as
for those with claudication.
8. Anesthetic Considerations and
Intraoperative Management
The pathophysiological events that occur with the trauma of
surgery and the perioperative administration of anesthetic and
pain-relieving drugs often affect the physiology of cardiac
function and dysfunction to great degrees. Specific integra-
tion of these changes with the consultative evaluation is a
field unto itself and beyond the scope of these guidelines. The
information provided by the cardiovascular consultant needs
to be integrated by the anesthesiologist, surgeon, and postop-
erative caregivers in preparing an individualized periopera-
tive management plan. The diagnosis of an MI has been
redefined by the Joint European Society of Cardiology/ACC
Committee for the Redefinition of MI, but the definition of a
perioperative MI in noncardiac surgery was not specifically
addressed (450).
There are many different approaches to the details of the
anesthetic care of the cardiac patient, including the use of
specific anesthetic agents (Table 15) or anesthetic techniques
(eg, general, regional, or monitored anesthesia care). Each
has implications regarding anesthetic and intraoperative mon-
itoring. In addition, no study has clearly demonstrated a
change in outcome from the routine use of the following
techniques: a PAC, ST-segment monitor, transesophageal
echocardiography (TEE), or intravenous nitroglycerin. There-
fore, the choice of anesthetic technique and intraoperative
monitors is best left to the discretion of the anesthesia care
team. Intraoperative management may be influenced by the
perioperative plan, including the need for postoperative
monitoring, ventilation, analgesia, and the perioperative use
of anticoagulants or antiplatelet agents. Therefore, a discus-
sion of these issues before the planned surgery will allow for
a smooth transition through the perioperative period.
8.1. Choice of Anesthetic Technique and
Agent
Recommendations for Use of Volatile Anesthetic Agents
CLASS IIa
1. It can be beneficial to use volatile anesthetic agents during
noncardiac surgery for the maintenance of general anesthesia in
hemodynamically stable patients at risk for myocardial ischemia.
(Level of Evidence: B)
Multiple studies have examined the influence of anesthetic
drugs and techniques on cardiac morbidity. In a large-scale
Table 14. Levels of Thromboembolism Risk in Surgical Patients Without Prophylaxis
Deep Vein
Thrombosis, %
Pulmonary
Embolism, %
Level of Risk Calf Proximal Clinical Events Fatal Events Successful Prevention Strategies
Low 2 0.4 0.2 Less than 0.01 No specific prophylaxis; early and aggressive
mobilization
Minor surgery in patients less than 40 years old
with no additional risk factors
Moderate 10 to 20 2 to 4 1 to 2 0.1 to 0.4 LDUH (every 12 hours), LMWH (less than or
equal to 3400 U daily), GCS, or IPC
Minor surgery in patients with additional risk
factors
Surgery in patients aged 40 to 60 years with no
additional risk factors
High 20 to 40 4 to 8 2 to 4 0.4 to 1.0 LDUH (every 8 hours), LMWH (more than 3400
U daily), or IPC
Surgery in patients more than 60 years old or aged
40 to 60 years with additional risk factors (prior
VTE, cancer, molecular hypercoagulability)
Highest 40 to 80 10 to 20 4 to 10 0.2 to 5.0 LMWH (more than 3400 U daily), fondaparinux,
oral VKAs (INR 2 to 3), or IPC/GCS plus
LDUH/LMWH
Surgery in patients with multiple risk factors (age
greater than 40 years, cancer, prior VTE)
Hip or knee arthroplasty, HFS
Major trauma; SCI
GCS indicates graduated compression stocking; HFS, hip fracture surgery; INR, international normalized ratio; IPC, intermittent pneumatic compression; LDUH,
low-dose unfractionated heparin; LMWH, low-molecular-weight heparin; SCI, spinal cord injury; U, unit; VKA, vitamin K antagonist; and VTE, venous thromboembolism.
Adapted with permission from Geerts et al (114).
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study of unselected patients, coexisting disease and surgical
procedure were important determinants of outcome (466). All
anesthetic techniques and drugs are associated with known
effects that should be considered in the perioperative plan.
Opioid-based anesthetics were previously popularized be-
cause of the cardiovascular stability associated with their use.
The use of high doses of opioids, however, is associated with
the need for prolonged postoperative mechanical ventilation,
and their use may increase length of stay in the intensive care
unit (ICU).
All inhaled volatile anesthetic agents have cardiovascular
effects, including depression of myocardial contractility and
afterload reduction. The similarities between the agents are
greater than their differences. Early studies demonstrated that
volatile anesthetic agents did not influence outcome com-
pared with high-dose opioid techniques (451–453). However,
as summarized in Table 15, randomized clinical trials in
patients undergoing CABG surgery indicate that volatile
anesthetics decrease troponin release and enhance LV func-
tion compared with propofol, midazolam, or balanced anes-
thesia techniques with opioids. These data can likely be
generalized to patients with CAD who are undergoing non-
cardiac surgery. Of the 15 trials performed (451–465), the
use compared with the nonuse of volatile anesthetics was
associated with a decrease in troponin release in 6 trials,
preservation of early LV function in 5, decreased ICU length
of stay in 1, and decreased late cardiac events in 1. Although
decreases in troponin levels reflect the cardioprotective ac-
tions of volatile anesthetics, none of the trials were powered
to evaluate MI or death as an outcome. Volatile anesthetics
have been shown in animal studies to precondition and
postcondition the heart against infarction by activating spe-
cific intracellular signal transduction pathways (467). De-
creased troponin levels in cardiac surgery patients receiving
volatile anesthetics may reflect this preconditioning or post-
conditioning effect. De Hert et al (468) demonstrated that
sevoflurane administered throughout surgery decreased tro-
ponin and ICU length of stay compared with patients who
received propofol, whereas no differences in troponin levels
were observed in patients receiving sevoflurane when this
volatile anesthetic was administered solely as either a pre-
conditioning or postconditioning agent. Similarly, low
doses (0.25 to 0.5 minimum alveolar concentration
[MAC]) of sevoflurane and isoflurane have been demon-
strated to provide cardioprotection in animal models;
however, the dose dependence or class effect of volatile
anesthetics to produce cardioprotection in humans has not
been specifically investigated.
Neuraxial anesthetic techniques include spinal and epidural
approaches. Both techniques can result in sympathetic block-
ade, resulting in decreases in both preload and afterload. The
decision to use neuraxial anesthesia for the high-risk cardiac
Table 15. Randomized Clinical Trials of Volatile Anesthetics in Patients Undergoing Coronary Artery Surgery
Study, Year n Anesthetic Control
Surgical
Technique End Point
Slogoff and Keats (451),
1989
1012 Enflurane
Halothane
Isoflurane
High-dose sufentanil CPB No difference in ischemia, MI, or death
Leung et al (452), 1991 186 Isoflurane High-dose sufentanil CPB No difference in ischemia
Helman et al (453), 1992 200 Desflurane High-dose sufentanil CPB Increased ischemia during induction of anesthesia
Belhomme et al (454), 1999 20 Isoflurane before aortic
cross-clamping
No volatile anesthetic CPB No difference in TnI activation of PKC
Penta de Peppo et al (455),
1999
22 Enflurane before CPB No volatile anesthetic CPB Improved LV function
Tomai et al (456), 1999 40 Isoflurane before CPB No volatile anesthetic CPB Decreased TnI in subset of patients with EF less
than 50%
Haroun-Bizri et al (457),
2001
49 Isoflurane before CPB No volatile anesthetic CPB Improved LV function
De Hert et al (458), 2002 20 Sevoflurane Propofol CPB Decreased TnI; improved LV function
De Hert et al (459), 2003 45 Sevoflurane Propofol CPB; elderly; EF
less than 50%
Decreased TnI; improved LV function
Desflurane
Julier et al (460), 2003, and
Garcia et al (461), 2005
72 Sevoflurane before aortic
cross-clamping
No volatile anesthetic CPB No difference in TnI at 72 hours; decreased BNP;
decreased late cardiac events in the same study
population
Conzen et al (462), 2003 20 Sevoflurane Propofol OPCAB Decreased TnI
De Hert et al (463), 2004 320 Sevoflurane or
desflurane
Propofol or
midazolam
CPB Decreased TnI; decreased ICU and hospital LOS
Forlani et al (464), 2004 60 Isoflurane before CPB No volatile anesthetic CPB Decreased TnI and CK-MB
Bein et al (465), 2005 52 Sevoflurane Propofol MIDCAB Improved LV function
BNP indicates brain natriuretic peptide; CK-MB, MB isoenzyme of creatine kinase; CPB, cardiopulmonary bypass; EF, ejection fraction; ICU, intensive care unit; LOS,
length of stay; LV, left ventricle; MI, myocardial infarction; MIDCAB, minimally invasive direct coronary artery bypass; OPCAB, off-pump coronary bypass; n, number
of patients; PKC, protein kinase C; and TnI, troponin I.
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patient may be influenced by the dermatomal level of the
surgical procedure. Infrainguinal procedures can be per-
formed under spinal or epidural anesthesia with minimal
hemodynamic changes if neuraxial blockade is limited to
those dermatomes. Abdominal procedures can also be per-
formed with neuraxial techniques; however, high dermatomal
levels of anesthesia may be required and may be associated
with significant hemodynamic effects. High dermatomal
levels can potentially result in hypotension if preload be-
comes compromised or blockade of the cardioaccelerators
occurs. A meta-analysis reviewed the impact of central
neuraxial analgesia on outcome after coronary artery bypass
surgery (469). The use of thoracic epidural analgesia de-
creased postoperative pulmonary complications but did not
influence the incidence of MI or overall mortality. Seven
randomized clinical trials conducted in patients undergoing
vascular surgery demonstrated no differences in outcome
when regional and general anesthesia techniques were com-
pared (470–476). One trial of 168 patients undergoing
abdominal aortic surgery specifically examined the relative
importance of intraoperative versus postoperative epidural
anesthesia and analgesia compared with general anesthesia on
outcomes (475). No differences in major morbidity, length of
stay, or mortality rate were observed. There was no overall
difference in death or major complications in 1021 patients
randomized to receive general anesthesia/opioid analgesia or
combined general/epidural anesthesia and analgesia for intra-
abdominal aortic, gastric, biliary, or colon surgery (477). In
the subgroup of patients undergoing aortic surgery, the
incidence of MI was decreased (P0.05) from 7.9% in the
general anesthesia/opioid analgesia group to 2.7% in the
general/epidural anesthesia group; however, the use of beta
blockers in the 2 groups was not reported. The MASTER
(Multicenter Australian Study of Epidural Anesthesia) trial
randomized 915 patients undergoing major abdominal sur-
gery to receive either combined general and epidural anes-
thesia/epidural analgesia or general anesthesia with opioid
analgesia (478). Epidural anesthesia/analgesia did not de-
crease death or cardiovascular outcomes but modestly im-
proved pulmonary outcomes compared with the general
anesthesia group. In a subgroup analysis of patients undergo-
ing aortic surgery, there was no effect of perioperative
epidural analgesia on major outcomes (476).
“Monitored anesthesia care” by an anesthesia caregiver
includes the use of local anesthesia supplemented with
intravenous sedation/analgesia. In a large-scale study, moni-
tored anesthesia care was associated with the highest inci-
dence of 30-day mortality (466). This finding may reflect a
strong selection bias in which patients with significant coex-
isting disease were selected for surgery with monitored
anesthesia care rather than other anesthetic techniques. Al-
though this technique can eliminate some of the undesirable
effects of general or neuraxial anesthesia, it provides poor
blockade of the stress response unless the local anesthetic
provides profound anesthesia of the affected area. If the local
anesthetic block is less than satisfactory or cannot be used at
all, monitored anesthesia care could result in an increased
incidence of myocardial ischemia and cardiac dysfunction
compared with general or regional anesthesia. To achieve the
desired effect, excess sedation can occur. Therefore, there
may be no significant difference in overall safety with
monitored anesthesia care, and general or regional anesthesia
may be preferable. In general, the cardiovascular consultant
should be aware of these issues, but it is the role of the
anesthesiologist to select the best approach with integration
and consideration of all medical perspectives and sometimes
even patient preference.
8.2. Perioperative Pain Management
From the cardiac perspective, pain management may be a
crucial aspect of perioperative care. Because the majority of
cardiac events in noncardiac surgical patients occur postop-
eratively, the postoperative period may be the time during
which ablation of stress, adverse hemodynamics, and hyper-
coagulable responses are most critical. Although no random-
ized controlled study specifically addressing analgesic regi-
mens has demonstrated improvement in outcome, patient-
controlled analgesia techniques are associated with greater
patient satisfaction and lower pain scores. Epidural or spinal
opiates are becoming more popular and have several theoret-
ical advantages. Several studies have evaluated differing
combinations of general and epidural anesthesia and intrave-
nous and epidural analgesia (470,471,473,474,479). Patients
having epidural anesthesia/analgesia have demonstrated
lower opiate dosages, better ablation of the catecholamine
response, and a less hypercoagulable state (480,481). In 1
study of patients undergoing lower-extremity vascular bypass
procedures (471), the use of epidural anesthesia/analgesia
was associated with a lower incidence of cardiac morbidity;
however, this finding was not confirmed in 2 other studies
(474,479). In a study of 124 patients undergoing aortic
surgery, there was no difference in the incidence of myocar-
dial ischemia in patients randomized to postoperative intra-
venous analgesia versus epidural analgesia (473). An effec-
tive analgesic regimen must be included in the perioperative
plan and should be based on issues unique to a given patient
undergoing a specific procedure at a specific institution.
8.3. Prophylactic Intraoperative Nitroglycerin
CLASS IIb
1. The usefulness of intraoperative nitroglycerin as a prophylactic
agent to prevent myocardial ischemia and cardiac morbidity is
unclear for high-risk patients undergoing noncardiac surgery, par-
ticularly those who have required nitrate therapy to control angina.
The recommendation for prophylactic use of nitroglycerin must
take into account the anesthetic plan and patient hemodynamics
and must recognize that vasodilation and hypovolemia can readily
occur during anesthesia and surgery. (Level of Evidence: C)
Nitroglycerin has been shown to reverse myocardial ische-
mia intraoperatively; however, the intraoperative prophylac-
tic use of nitroglycerin in patients at high risk may have no
effects or may actually lead to cardiovascular decompensa-
tion through decreases in preload. Topical nitroglycerin may
have uneven absorption intraoperatively, so when clinically
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indicated, it is reasonable to administer nitroglycerin intrave-
nously. The venodilating and arterial dilating effects of
nitroglycerin are mimicked by some anesthetic agents, so
that the combination of agents may lead to significant
hypotension and myocardial ischemia. Therefore, nitro-
glycerin should be used only when the hemodynamic
effects of other agents being used and intravascular vol-
ume status have been considered.
Four controlled studies have evaluated prophylactic nitro-
glycerin infusions for high-risk patients, including 2 studies
in noncardiac surgery patients (482–485). Only 1 study,
performed in patients with stable angina undergoing carotid
endarterectomy, demonstrated a reduced incidence of intra-
operative myocardial ischemia in the group receiving 1 mcg
of nitroglycerin per kilogram of weight per minute. Neither of
the 2 small studies demonstrated any reduction in the inci-
dence of MI or cardiac death. In a retrospective analysis of
patients with rest anginal symptoms who were undergoing
CABG surgery, preoperative use of intravenous nitroglycerin
had no effect on outcomes such as MI, death, or use of an
intra-aortic balloon pump (486).
8.4. Use of TEE
CLASS IIa
1. The emergency use of intraoperative or perioperative TEE is
reasonable to determine the cause of an acute, persistent, and
life-threatening hemodynamic abnormality. (Level of Evidence: C)
Transesophageal echocardiography has become increas-
ingly common in the operating room for cardiac surgery but
is less frequently used in noncardiac surgery. Multiple inves-
tigations have documented the improved sensitivity of TEE
for detection of myocardial ischemia compared with ECG or
pulmonary capillary wedge pressure measurements. Most
studies have used offline analysis of the TEE images, how-
ever, and automated, online detection may increase its value.
There are few data regarding the value of TEE-detected
wall-motion abnormalities to predict cardiac morbidity in
noncardiac surgical patients. In 2 studies from the same
group, intraoperative wall-motion abnormalities were poor
predictors of cardiac morbidity (487,488). In 1 study involv-
ing 322 men undergoing noncardiac surgeries, TEE demon-
strated an OR of 2.6 (95% CI: 1.2 to 5.7) for predicting
perioperative cardiac events (487). Although regional wall-
motion abnormalities in a high-risk patient suggest myocar-
dial ischemia, resolution of myocardial ischemia may not
result in improvement of wall motion.
There is emerging evidence demonstrating the utility of
TEE to alter the management of patients undergoing cardiac
surgery; however, interpretation of TEE requires additional
education. Many anesthesiologists are expert in this tech-
nique, but others have limited or no training. Currently, there
is insufficient evidence to determine the cost-effectiveness of
TEE for its use as a diagnostic monitor or to guide therapy
during noncardiac surgery; therefore, the routine use of TEE
in noncardiac surgery does not appear warranted. In contrast,
emergent use of intraoperative or perioperative TEE to
determine the cause of an acute, persistent, and life-
threatening hemodynamic abnormality is indicated. Guide-
lines for the appropriate use of TEE have been developed by
the American Society of Anesthesiologists and the Society of
Cardiovascular Anesthesiologists (489).
8.5. Maintenance of Body Temperature
Recommendations for Maintenance of Body
Temperature
CLASS I
1. Maintenance of body temperature in a normothermic range is
recommended for most procedures other than during periods in
which mild hypothermia is intended to provide organ protection
(eg, during high aortic cross-clamping). (Level of Evidence: B)
Hypothermia is common during the perioperative period in
the absence of active warming of patients. In a retrospective
analysis of a prospective randomized trial comparing 2
different anesthetic techniques for infrainguinal revascular-
ization surgery, hypothermia (temperature less than 35 de-
grees Celsius) was associated with an increased risk of
myocardial ischemia compared with patients who had a
core temperature greater than or equal to 35 degrees
Celsius (normothermic group) in the postanesthesia care
unit (490). Several methods of maintaining normothermia
are available in clinical practice, the most widely studied
being forced-air warming.
One randomized clinical trial was performed in 300 high-
risk patients undergoing noncardiac surgery in which patients
were randomized to active warming via forced air (normo-
thermic group) or routine care (hypothermic group) (491).
Perioperative morbid cardiac events (unstable angina/ische-
mia, cardiac arrest, and MI) occurred less frequently in the
normothermic group than in the hypothermic group (1.4%
versus 6.3%; P0.02). In addition, ventricular tachycardia
occurred less frequently in the normothermic group (2.4%
versus 7.9%; P0.04) (491). Hypothermia was an indepen-
dent predictor of morbid cardiac events by multivariable
analysis (RR: 2.2, 95% CI: 1.1 to 4.7, P0.04), indicating a
55% reduction in risk when normothermia was maintained.
8.6. Intra-Aortic Balloon Counterpulsation
Device
Placement of an intra-aortic balloon counterpulsation device
has been suggested as a means of reducing perioperative
cardiac risk in noncardiac surgery. Several case reports have
documented its use in patients with unstable coronary syn-
dromes or severe CAD who are undergoing urgent noncar-
diac surgery (492–495). Although the rate of cardiac com-
plications is low compared with other series of patients at
similarly high risk, there are no randomized trials to assess its
true effectiveness. Additionally, the use of intra-aortic bal-
loon counterpulsation is associated with complications, par-
ticularly in patients with peripheral vascular disease. There is
currently insufficient evidence to determine the benefits
versus risks of prophylactic placement of an intra-aortic
balloon counterpulsation device for high-risk noncardiac
surgery.
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8.7. Perioperative Control of Blood Glucose
Concentration
Recommendations for Perioperative Control of Blood
Glucose Concentration
CLASS IIa
1. It is reasonable that blood glucose concentration be con-
trolled¶ during the perioperative period in patients with diabe-
tes mellitus or acute hyperglycemia who are at high risk for
myocardial ischemia or who are undergoing vascular and major
noncardiac surgical procedures with planned ICU admission.
(Level of Evidence: B)
CLASS IIb
1. The usefulness of strict control of blood glucose concentration¶
during the perioperative period is uncertain in patients with dia-
betes mellitus or acute hyperglycemia who are undergoing non-
cardiac surgical procedures without planned ICU admission. (Level
of Evidence: C)
Hyperglycemia is an independent predictor of cardiovas-
cular risk, and severity of hyperglycemia is directly related to
mortality rate during MI. The impact of perioperative control
of blood glucose concentration on morbidity and mortality
has been investigated recently. Table 16 summarizes the
results of 13 clinical trials evaluating the relationship between
blood glucose concentration and outcome in critically ill
patients with and without diabetes mellitus (496–499,501–
509). Eight retrospective analyses conducted in patients
undergoing coronary artery surgery and in patients admitted
to a medical-surgical ICU for a variety of surgical and
nonsurgical conditions indicated that increased blood glucose
concentration was an important predictor of morbidity and
mortality. These results were confirmed by a randomized
clinical trial of critically ill patients (63% cardiac surgical
patients) admitted to a surgical ICU who received intensive
treatment with intravenous insulin to control blood glucose
concentrations between 80 and 110 mg per dL, who were
compared with conventionally treated patients who received
insulin only if blood glucose exceeded 215 mg per dL (496).
Aggressively treated patients with a prolonged length of stay
in the ICU demonstrated significant decreases in morbidity
and mortality. Glucose-insulin-potassium was also shown to
improve outcomes in cardiac surgery patients when blood
glucose concentrations were well controlled (497) but not
when blood glucose concentrations were inadequately con-
trolled (498). The benefit of glucose-insulin-potassium to
produce cardioprotection in nonhyperglycemic cardiac sur-
gery patients is controversial and may not be similar to the
use of insulin to specifically control blood glucose concen-
tration (506). The role of intraoperative glycemic control with
a standardized insulin protocol to modulate outcomes was
investigated in a prospective observational study of patients
with diabetes mellitus undergoing CABG surgery. Although
postoperative blood glucose concentrations were similar,
those patients who achieved tight control of blood glucose
concentrations intraoperatively demonstrated decreased mor-
bidity and mortality compared with patients whose blood
glucose was poorly controlled (4 consecutive blood glucose
measurements exceeding 200 mg per dL despite insulin
therapy) (500). A retrospective analysis similarly identified
intraoperative blood glucose concentration as an independent
predictor of adverse outcome in cardiac surgery patients
(502). The risks of stroke, MI, and death were also shown to
be independently increased 3- to 4-fold by preoperative
hyperglycemia (glucose concentration in excess of 200 mg
per dL) in patients undergoing carotid endarterectomy (501).
Although clinical trials demonstrated the deleterious effects
of perioperative hyperglycemia, the ideal target for and
cardiovascular benefit of intraoperative and postoperative
glycemic control are not entirely clear. Results of regression
analyses (499) suggest that blood glucose concentrations
controlled to less than 150 mg per dL in the perioperative
period may improve outcome and minimize the risk of severe
hypoglycemia in anesthetized patients (510,511). The Amer-
ican College of Endocrinology recently published a position
statement recommending that preprandial glucose concentra-
tion should be less than 110 mg per dL, with maximal glucose
not to exceed 180 mg per dL in hospitalized patients and that
blood glucose concentration should be controlled to less than
110 mg per dL in the ICU (511). The use of intravenous
insulin therapy to maintain glycemic control in the perioper-
ative period was recommended.
9. Perioperative Surveillance
Although much attention has been focused on the preopera-
tive preparation of the high-risk patient, intraoperative and
postoperative surveillance for myocardial ischemia and in-
farction, arrhythmias, and venous thrombosis should also lead
to reductions in morbidity. Postoperative myocardial ische-
mia has been shown to be the strongest predictor of periop-
erative cardiac morbidity and is rarely accompanied by pain
(1). Therefore, it may go untreated until overt symptoms of
cardiac failure develop.
The diagnosis of a perioperative MI has both short- and
long-term prognostic value. Traditionally, a perioperative MI
has been associated with a 30% to 50% perioperative mor-
tality and reduced long-term survival (42,512–514). There-
fore, it is important to identify patients who sustain a
perioperative MI and to treat them aggressively, because it
may reduce both short- and long-term risk.
9.1. Intraoperative and Postoperative Use of
PACs
Recommendations for Perioperative Use of PACs
CLASS IIb
1. Use of a PAC may be reasonable in patients at risk for major
hemodynamic disturbances that are easily detected by a PAC.
However, the decision must be based on 3 parameters: patient
disease, surgical procedure (ie, intraoperative and postoperative
fluid shifts), and practice setting (experience in PAC use and
interpretation of results), because incorrect interpretation of the
data from a PAC may cause harm. (Level of Evidence: B)¶Blood glucose less than 150 mg per dL appears to be beneficial.
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Table 16. Impact of Perioperative Blood Glucose Concentration on Outcomes
Study, Year Study Type No. of Patients Study Design
Mean Glucose,
mg/dL
% of Patients
With Diabetes Major Findings
van den Berghe et al
(496), 2001
RCT 1548 Surgical
ICU pts
Intensive intravenous
insulin vs
conventional
treatment
Intensive
10319 vs
conventional
15333
13 vs 13 Intensive insulin compared with
conventional treatment decreased
mortality (8.0% to 4.6%) and major
morbidity.
Lazar et al (497),
2004
RCT 141 On-pump
CABG pts
GIK vs SQ insulin GIK 1344 vs
SQ insulin
2676
100 GIK improved 5-year survival and
decreased major morbidity.
Lell et al (498), 2002 RCT 46 Off-pump
CABG pts
GIK vs saline GIK 386152 vs
saline
21175
28 vs 45 No differences were seen in TnI or
CK-MB between groups; study terminated
because of concerns of persistent
hyperglycemia in the GIK group.
Finney et al (499),
2003
Prospective
observational
531 ICU pts Intravenous insulin N/A 16 Increased administration of insulin was an
independent predictor of ICU mortality;
regression models demonstrated a
mortality benefit if blood glucose was
maintained less than 144 to 200 mg/dL.
Ouattara et al (500),
2005
Prospective
observational
200 On-pump
CABG pts
Insulin by
standardized
protocol
Tightly controlled
14742 vs
poorly controlled
20854
100 Poor intraoperative control of blood
glucose was an independent predictor of
severe morbidity; mortality rate was
increased in patients with poorly
controlled glucose (11.4%) vs those with
tightly controlled glucose (2.4%).
McGirt et al (501),
2006
Retrospective 1201 Pts
undergoing CEA
Postoperative insulin
use was
nonstandardized
N/A 27 Multivariate analysis demonstrated that
preoperative glucose greater than 200
mg/dL was an independent predictor of
2.8-, 4.3-, and 3.3-fold increases in risk
of stroke/TIA, MI, or death.
Gandhi et al (502),
2005
Retrospective 409 Cardiac
surgery pts
Nonstandardized
intraoperative use of
insulin in 6%
Any adverse
event 14137
vs no events
12725
28.6 vs 18 Multivariate analysis demonstrated that
mean and maximal intraoperative glucose
predicted increased mortality. A 20-mg/dL
increase in mean intraoperative glucose
was associated with a 30% increase in
adverse events.
Krinsley (503), 2004 Retrospective 1600 Med-Surg
ICU pts
Historical control vs
standardized glucose
control protocol
Historical
15293 vs
protocol
13155
16 vs 18 Decreased mortality, renal insufficiency,
and ICU length of stay were observed in
the standardized insulin protocol
compared with the historical group.
Hill et al (504), 2000 Retrospective 2862 CABG pts Nonstandardized
glucose
management
79-653 31 Univariate analysis showed no association
between maximum blood glucose
concentration and mortality.
Krinsley (505), 2003 Retrospective 1826 Med-Surg
ICU pts
Nonstandardized
glucose
management
Survivors 138 vs
nonsurvivors 172
22 Progressive increase in in-hospital
mortality rate as blood glucose
concentration increased, up to 42.5%
among patients with mean glucose values
in excess of 300 mg/dL.
Furnary et al (506),
2003
Retrospective 3554 CABG pts SQ insulin vs
continuous
intravenous insulin
SQ 21341 vs
intravenous
17730
100 Continuous intravenous insulin was an
independent predictor of survival.
Estrada et al (507),
2003
Retrospective 1574 CABG pts Nonstandardized
glucose
management
Diabetes
21447 vs no
diabetes
15737
35 Hyperglycemia did not predict increased
mortality but was associated with
increased resource utilization.
McAlister et al (508),
2003
Retrospective 1574 CABG pts 92% received
intravenous insulin
by protocol
164–209 100 Hyperglycemia was an independent
predictor of adverse outcomes.
CABG indicates coronary artery bypass graft; CEA, carotid endarterectomy; CK-MB, creatine kinase MB fraction; GIK, glucose insulin potassium; ICU, intensive care
unit; Med-Sur, medical-surgical; MI, myocardial infarction; N/A, not available; pts, patients; RCT, randomized, controlled trial; SQ, subcutaneous; TIA, transient
ischemic attack; and TnI, troponin I.
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CLASS III
1. Routine use of a PAC perioperatively, especially in patients at low
risk of developing hemodynamic disturbances, is not recom-
mended. (Level of Evidence: A)
Use of a PAC may provide significant information critical
to the care of the cardiac patient; however, the potential risk
of complications and cost associated with catheter insertion
and use must be considered. Practice guidelines for PAC, as
well as methods to perform perioperative optimization of the
high-risk surgical patient, have been developed and reported
elsewhere (515,516). Several studies have evaluated the
benefit of PAC use in both randomized trials and those using
historical controls. In patients with prior MI, when perioper-
ative care included PAC and intensive care monitoring for 3
days postoperatively, there was a lower incidence of reinfarc-
tion than in historical controls (512). Other changes in
management occurred during the period under study, how-
ever, including the increased use of beta-adrenergic sympa-
thetic blockade. In particular, patients with signs and symp-
toms of HF preoperatively, who have a very high (35%)
postoperative incidence of HF, might benefit from invasive
hemodynamic monitoring (116).
Although a great deal of literature has evaluated the utility
of the PAC during the perioperative period in noncardiac
surgery, relatively few controlled studies have evaluated PAC
use in relation to clinical outcomes. Evidence of benefit of
PAC use from controlled trials is equivocal, and a large-scale
cohort study demonstrated potential harm (517). Neverthe-
less, PAC use may benefit high-risk patients. Berlauk et al
(437), in comparing outcomes associated with PAC insertion
12 hours before surgery, 3 hours before surgery, or no
planned insertion, found the PAC group had fewer adverse
intraoperative events and less postoperative cardiac morbidity
(P less than 0.05 for both). However, Bender et al (438) found
no decrease in morbidity or mortality with routine PAC use in
elective surgery. In studies using appropriate patient selec-
tion, no differences in cardiac morbidity (MI or cardiac death)
were detected (438,518–521). A meta-analysis by Poeze et al
(439) found that hemodynamic optimization of critically ill
patients decreased mortality (RR: 0.75, 95% CI: 0.62 to 0.90)
when all studies were combined, and this effect was attributed
to the decreased mortality observed in studies specifically
conducted to evaluate the benefit of perioperative interven-
tions (RR: 0.66, 95% CI: 0.54 to 0.81).
Polanczyk et al performed an observational study of 4059
patients aged 50 years or older who underwent major elective
noncardiac procedures with an expected length of stay of 2 or
more days (522). Major cardiac events occurred in 171
patients (4.2%); those who underwent right heart catheteriza-
tion had a 4-fold increased incidence of major postoperative
cardiac events (34 [15.4%] versus 137 [3.6%]; P less than
0.001). In a case-control analysis of a subset of 215 matched
pairs of patients in this trial who did and did not undergo right
heart catheterization, adjusted for propensity of right heart
catheterization and type of procedure, patients who under-
went perioperative right heart catheterization also had in-
creased risk of postoperative congestive HF (OR: 2.9, 95%
CI: 1.4 to 6.2) and major noncardiac events (OR: 2.2, 95% CI:
1.4 to 4.9) (522).
A randomized, multicenter clinical trial of goal-directed
therapy with a PAC in 1994 elderly patients (American
Society of Anesthesiologists class 3 or 4) who underwent
major noncardiac surgery demonstrated no differences in
survival or cardiovascular morbidity compared with a stan-
dard care group (77% had a central venous catheter placed)
(523). Although mortality and hospital length of stay were
similar in both groups, the PAC group demonstrated higher
rates of pulmonary embolism (0 events in the standard care
group versus 8 events in the PAC group; P0.004) (523).
Several surveys have shown physician and nurse under-
standing of PAC catheterization data are extremely variable,
which may account for the higher rate of postoperative
congestive HF and greater perioperative net fluid intake
observed in some studies. This finding led some to recom-
mend re-evaluation of current accreditation and teaching
practices (524–527). The American Society of Anesthesiol-
ogists Task Force on Pulmonary Artery Catheterization has
recently provided an update to the practice guidelines for
pulmonary artery catheterization (515). Given the above-
described studies and the accumulating data from the nonsur-
gical arena, in which the use of a PAC has not shown benefit,
the decision to place a PAC should carefully weigh the
potential for harm with any potential benefit from the
information obtained from the monitor.
9.2. Intraoperative and Postoperative Use of
ST-Segment Monitoring
CLASS IIa
1. Intraoperative and postoperative ST-segment monitoring can be
useful to monitor patients with known CAD or those undergoing
vascular surgery, with computerized ST-segment analysis, when
available, used to detect myocardial ischemia during the periop-
erative period. (Level of Evidence: B)
CLASS IIb
1. Intraoperative and postoperative ST-segment monitoring may be
considered in patients with single or multiple risk factors for CAD
who are undergoing noncardiac surgery. (Level of Evidence: B)
The presence of intraoperative and postoperative ST-
segment changes has been associated with cardiac morbidity
and mortality in high-risk patients undergoing noncardiac
surgery. Most contemporary operating rooms and ICU mon-
itors incorporate algorithms that perform real-time analysis of
the ST segment. Numerous studies have demonstrated the
limited ability of physicians to detect significant ST-segment
changes compared with computerized or offline analysis.
Computerized ST-segment trending is superior to visual
interpretation in the identification of ST-segment changes.
Because the algorithms used to measure ST-segment shifts
are proprietary, variability in accuracy between the different
monitors has been evaluated in several studies compared with
offline analysis of standard Holter recordings (528–530).
ST-segment trending monitors were found to have an average
sensitivity and specificity of 74% (range 60% to 78%) and
73% (range 69% to 89%), respectively, compared with Holter
ECG recordings (529). Several factors have been identified
that decreased the accuracy of the monitors and have been
discussed in detail elsewhere. Additionally, the lead system
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used affects the incidence of ischemia detected, with leads II
and V5 detecting only 80% of all episodes detected by a
12-lead ECG in 1 study (531), whereas another study found
that V4 was the most sensitive lead (83.3%) (532).
Virtually all studies examining the predictive value of
intraoperative and postoperative ST-segment changes have
been performed with ambulatory ECG recorders. Using
retrospective analysis, investigators have found postoperative
ST-segment changes indicative of myocardial ischemia, pri-
marily ST-segment depression, to be an independent predic-
tor of perioperative cardiac events in high-risk noncardiac
surgery patients in multiple studies, with changes of pro-
longed duration (greater than 30 minutes per episode or
greater than 2 hours cumulative duration in different studies)
being particularly associated with increased risk
(42,72,290,533,534). In a review of studies involving more
than 2400 patients between the years 1990 and 2003, Land-
esberg reported a sensitivity of perioperative ischemia in
predicting postoperative cardiac events of 55% to 100%; the
specificity was 37% to 85%, the positive predictive value was
7% to 57%, the negative predictive value was 89% to 100%,
and the relative risk of suffering a postoperative cardiac
event, including cardiac death, in patients with ischemia
ranged between 2.2% and 73% (535). Postoperative ST-
segment changes, particularly of a prolonged duration, have
been shown to predict worse long-term survival in high-risk
patients (290,513).
In a cohort of patients older than 45 years with 1 risk factor
but without known CAD, the presence of intraoperative and
postoperative ST-segment changes was not associated with
either ischemia on an exercise stress test or cardiac events
within 1 year (536). The total cohort of patients was small,
which may limit the ability to generalize these findings.
Intraoperative ST-segment changes may also occur in
low-risk populations. ST-segment depression has been
shown to occur during elective cesarean sections in healthy
patients (537,538). Because these changes were not asso-
ciated with regional wall-motion abnormalities on prec-
ordial echocardiography, in this low-risk population, such
ST-segment changes may not be indicative of myocardial
ischemia and CAD.
Thus, although there are data to support the contention that
ST-segment monitoring detects ischemia, no studies have
addressed the issue of the effect on outcome when therapy is
based on the results of ST-segment monitoring. However,
general consensus is that early treatment, such as control of
tachycardia, could lead to a reduction in cardiac morbidity.
9.3. Surveillance for Perioperative MI
CLASS I
1. Postoperative troponinmeasurement is recommended in patients
with ECG changes or chest pain typical of acute coronary syn-
drome. (Level of Evidence: C)
CLASS IIb
1. The use of postoperative troponin measurement is not well estab-
lished in patients who are clinically stable and have undergone
vascular and intermediate-risk surgery. (Level of Evidence: C)
CLASS III
1. Postoperative troponin measurement is not recommended in
asymptomatic stable patients who have undergone low-risk sur-
gery. (Level of Evidence: C)
Multiple studies have evaluated predictive factors for a
perioperative MI. The presence of clinical evidence of coro-
nary artery or peripheral vascular disease has been associated
with an increased incidence of perioperative MI. Factors that
increase the risk of a perioperative MI have been discussed
previously. Because of the increased risk of both short- and
long-term mortality from a perioperative MI, accurate diag-
nosis is important.
Perioperative MI can be documented by assessing clinical
symptoms, serial ECGs, cardiac-specific biomarkers, com-
parative ventriculographic studies before and after surgery,
radioisotopic or magnetic resonance studies specific for
myocardial necrosis, and autopsy studies. The criteria used to
diagnose infarction in various studies differ not only in the
level of cardiac biomarkers that determine abnormality but
also in the frequency with which these biomarkers are
sampled after noncardiac surgery. The cardiac biomarker
profile after infarction exhibits a typical rise and fall that
differs among different biomarkers. Daily sampling may miss
detection of a cardiac biomarker rise (such as the MB
isoenzyme of creatine kinase [CK-MB]), thus underestimat-
ing the incidence of perioperative infarction. The ECG
criteria used to define infarction may also differ not only in
the definition of a Q wave but also with respect to the
magnitude of ST-T wave shifts that determine an abnormal
response. In the analysis of cardiac biomarker criteria,
numerous assays are available to measure CK-MB, cTnI,
and, to a lesser extent, cardiac troponin T. Creatine
kinase–MB may be released from noncardiac sources in
patients with ischemic limbs or those undergoing aortic
surgery, the group at highest risk for a perioperative MI.
Additionally, other tissues may release CK-MB into the
circulation, such as many from the gastrointestinal tract.
Renal insufficiency may affect the ability to clear these
enzymes and therefore decrease the specificity of an
abnormal result. The use of cTnI or cardiac troponin T
offers the potential for enhanced specificity (539 –544).
An increasing number of studies have examined the out-
come using protocol-specific criteria for perioperative MI
after noncardiac surgery. The topic of surveillance for peri-
operative MI was reviewed in 2005 and a set of criteria
proposed (127). Charlson et al (545) reported on 232 patients,
most of whom were hypertensive or had diabetes mellitus,
who were undergoing elective noncardiac surgery. Serial
ECGs and CK-MB were collected for 6 days postoperatively.
The incidence of perioperative MI varied greatly depending
on the diagnostic criteria used. A strategy of using an ECG
immediately after the surgical procedure and on the first and
second days postoperatively had the highest sensitivity. Two
studies have demonstrated the prognostic significance of a
postoperative 12-lead ECG. Rinfret and colleagues, examin-
ing the same population set as described above in the study by
Lee et al (542), investigated the information provided by a
postoperative ECG performed in the recovery room after
operation (546). Of the 3750 patients evaluated, 7.5% had
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significant ECG changes. Significant changes included ST-
segment elevation, ST-segment depression, and T-wave
changes. The presence of these changes conferred a 2.2-fold
increase in major cardiac complications, increasing the rate
from 1.9% in patients who did not have these signs to 6.7%
in those who did (P less than 0.001). The increase in event
rate was maintained when stratified by the author’s Revised
Cardiac Risk Index (4). In fact, the RR of an adverse event
associated with ECG changes was higher in the lower-risk
group, increasing the events more than 4-fold compared with
2-fold in the high-risk subset. Bottiger and colleagues (547)
investigated the value of 12-lead ECGs obtained 15 minutes,
20 hours, 48 hours, 72 hours, and 84 hours after operation
in 55 patients. For study entry, patients had operations that
required more than 1 hour of anesthesia and a history of
CAD or 2 cardiovascular disease risk factors. Of the 55
patients, 19 had perioperative ischemia, and 2 required
cardiac catheterization. Electrocardiographic changes of
ischemia were noted in 24 patients, of which 88% were
noted in the first postoperative evaluation. Moreover, early
ECG changes were concordant with cardiac biomarker
evidence of myocardial damage.
Strategies that included the serial measurement of CK-MB
had higher false-positive rates (ie, lower specificity) without
higher sensitivities. In contrast, Rettke et al reported that
overall survival was associated with the degree of CK-MB
elevation in 348 patients undergoing abdominal aortic aneu-
rysm repair, with higher levels associated with worse survival
(548). Yeager et al evaluated the prognostic implications of a
perioperative MI in a series of 1561 major vascular proce-
dures (514). These authors found that the incidence of
subsequent MI and coronary artery revascularization was
significantly higher in patients who had a perioperative MI,
except in the subset who only demonstrated an elevated
CK-MB without ECG changes or cardiovascular symptoms.
Over the last decade, the diagnosis of myocardial damage
has become more sensitive with the application of cardiac
biomarkers. Measurement of troponin T or I facilitates the
recognition of myocardial damage with much smaller
amounts of injury. Because of the augmentation of sensitiv-
ity, the threshold to diagnosis of an MI is lower and the
frequency greater (290). On the basis of the increase in
sensitivity, many studies have been performed to determine
whether screening troponin measurements convey important
prognostic information.
The largest screening study by Lee and colleagues evalu-
ated troponin T measured in 1175 noncardiac surgical pa-
tients (542). Troponin T was measured in the recovery room
after operation and on the next 2 postoperative mornings. In
this population, an MI was diagnosed in 1.4% (n17) of the
patients using CK-MB fraction and ECG for diagnosis.
Troponin T was elevated in 87% of the patients with MI and
16% of the patients without MI.
Martinez and colleagues studied 467 high-risk patients requir-
ing noncardiac surgery (549). The diagnosis of myocardial
injury was determined by biomarkers combined with either
postoperative changes on 12-lead ECG or 1 of 3 clinical
symptoms consistent with MI (chest pain, dyspnea, or require-
ment for hemodynamic support). The incidence of MI was 9.0%
by the criterion of cTnI greater than or equal to 2.6 ng per mL,
19% by cTnI greater than or equal to 1.5 ng per mL, 13% by
CK-MB mass, and 2.8% by CK-MB%. If surveillance of cTnI
greater than or equal to 2.6 ng per mL was used to detect MI,
then the strategy with the highest diagnostic yield was surveil-
lance on postoperative days 1, 2, and 3.
The pattern of cardiac specific troponin elevation may also
be important. Le Manach and colleagues performed intense
cardiac cTnI surveillance after abdominal aortic surgery in
1136 consecutive patients to better evaluate the incidence and
timing of postoperative MI (cTnI greater than or equal to 1.5
ng per mL) or myocardial damage (abnormal cTnI less than
1.5 ng per mL) (550). Abnormal cTnI concentrations were
noted in 163 patients (14%), of whom 106 (9%) had myo-
cardial damage and 57 (5%) had perioperative MI. In 34
patients (3%), perioperative MI was preceded by a prolonged
(greater than 24 hours) period of increased cTnI (delayed
perioperative MI), and in 21 patients (2%), the increase in
cTnI lasted less than 24 hours (early perioperative MI). The
authors concluded that abnormal but low postoperative cTnI
is associated with increased mortality and may lead to
delayed perioperative MI.
Data like these highlight the difficulty of using cardiac
specific troponin to distinguish myocardial damage from
infarction. The variability in the rate of MI based on troponin
cutoff and other studies highlights the fact that there is a poor
relationship between cardiac specific troponin elevation and
postoperative ECG changes (551). It is already known that
one third of coronary arterial ischemic events occur distal to
areas of noncritical stenosis and that critical stenoses are
uncommon in the pathogenesis of MI (291). Although the
extent of coronary artery atherosclerosis, as determined by
the number of vessels with significant stenoses, predicts
frequency of perioperative MI, individual lesion stenosis does
not (552).
Studies regarding the predictive value of postoperative
cardiac specific troponin elevations for long-term outcome
have been inconsistent. Investigations have shown that post-
operative elevations in cardiac specific troponin are associ-
ated with increased cardiovascular morbidity and mortality at
30 days (553,554), 6 months (543,555), 1 year (556), and
beyond 1 year (554,557). However, other studies have shown
no association with intermediate or long-term cardiovascular
outcomes (558), and none of the studies above demonstrate a
relationship at the other time points.
On the basis of the available literature, routine measure-
ment of cardiac specific troponin after surgery is more likely
to identify patients without acute MI than with MI. Moreover,
studies of cardiac specific troponin elevations neither consis-
tently show associations with adverse cardiovascular out-
comes at any time point nor provide insight into the effect of
treatment on outcomes in patients with an elevated cardiac
specific troponin level. Although it is known that elevations
in cardiac specific troponin are more likely to occur in
patients with more extensive CAD, the role of revasculariza-
tion in patients with an elevated cardiac specific troponin
level but no other manifestation of MI remains unclear. Until
each of these issues has been addressed, routine cardiac
specific troponin measurement cannot be recommended.
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Perioperative surveillance for acute coronary syndromes with
routine ECG and cardiac serum biomarker measurement is
unnecessary in clinically low-risk patients undergoing low-
risk operative procedures.
Further evaluation regarding the optimal strategy for sur-
veillance and diagnosis of perioperative MI is required. On
the basis of current evidence, in patients without documented
CAD, surveillance should be restricted to those who develop
perioperative signs of cardiovascular dysfunction. In patients
with high or intermediate clinical risk who have known or
suspected CAD and who are undergoing high- or
intermediate-risk surgical procedures, the procurement of
ECGs at baseline, immediately after the surgical procedure
and daily on the first 2 days after surgery appears to be the
most cost-effective strategy. The use of cardiac specific
troponin measurements to supplement the diagnosis in these
symptomatic patients is warranted. Additional research is
needed to correlate long-term outcome results to the magni-
tude of isolated cardiac specific troponin elevations.
9.4. Postoperative Arrhythmias and
Conduction Disorders
Postoperative arrhythmias are often due to remedial noncar-
diac problems such as infection, hypotension, metabolic
derangements, and hypoxia. The approach taken to the acute
management of postoperative tachycardias varies depending
on the likely mechanism. If the patient develops a sustained,
regular, narrow-complex tachycardia, which is likely due to
atrioventricular nodal re-entrant tachycardia or atrioventricu-
lar reciprocating tachycardia, the tachycardia can almost
always be terminated with vagal maneuvers (Valsalva ma-
neuver or carotid sinus massage) or with intravenous adeno-
sine. Most antiarrhythmic agents (especially beta blockers,
calcium channel blockers, and type 1a or 1c antiarrhythmic
agents) can be used to prevent further recurrences in the
postoperative setting. A somewhat different approach is
generally recommended for atrial fibrillation and atrial flutter.
The initial approach to management generally involves the
use of intravenous digoxin, diltiazem, or a beta blocker in an
attempt to slow the ventricular response. Among these 3 types
of medications, digitalis is least effective and beta blockers
are most effective for controlling the ventricular response
during atrial fibrillation (426). An additional benefit of beta
blockers is that they have been shown to accelerate the
conversion of postoperative supraventricular arrhythmias to
sinus rhythm compared with diltiazem (427). Cardioversion
of atrial fibrillation/flutter is generally not recommended for
asymptomatic or minimally symptomatic arrhythmias until
correction of the underlying problems has occurred, which
frequently leads to a return to normal sinus rhythm. Also,
cardioversion is unlikely to result in long-term normal sinus
rhythm if the underlying problem is not corrected. The
avoidance of an electrolyte abnormality, especially hypoka-
lemia and hypomagnesemia, may reduce the perioperative
incidence and risk of arrhythmias, although acute preopera-
tive repletion of potassium in an asymptomatic individual
may be associated with greater risk than benefits (559–562).
Unifocal or multifocal premature ventricular contractions do
not merit therapy. Very frequent ventricular ectopy or pro-
longed runs of nonsustained ventricular tachycardia may
require antiarrhythmic therapy if they are symptomatic or
result in hemodynamic compromise. Patients with an ische-
mic or nonischemic cardiomyopathy, particularly those with
an ejection fraction of less than 35%, a history of HF, and
nonsustained ventricular tachycardia in the perioperative
period, may benefit from ICD therapy for primary prevention
of sudden cardiac death (evaluation by an electrophysiologist
may be indicated) (563–565). Ventricular arrhythmias may
respond to intravenous beta blockers, lidocaine, procain-
amide, or amiodarone (378,566–568). Electrical cardiover-
sion should be used for sustained supraventricular or ventric-
ular arrhythmias that cause hemodynamic compromise.
Bradyarrhythmias that occur in the postoperative period
are usually secondary to some other cause, such as certain
medications, an electrolyte disturbance, hypoxemia, or ische-
mia. On an acute basis, many will respond to intravenous
medication such as atropine, and some will respond to
intravenous aminophylline. Bradyarrhythmias due to sinus
node dysfunction and advanced conduction abnormalities
such as complete heart block will respond to temporary or
permanent transvenous pacing or permanent pacing. The
indications are the same as those for elective permanent
pacemaker implantations.
10. Postoperative and
Long-Term Management
Advances in preoperative risk assessment, surgical and anes-
thetic techniques, and better implementation of medical
therapy have served to decrease the frequency of cardiovas-
cular complications associated with noncardiac surgery. Ap-
propriate use of therapies that decrease the frequency of
cardiovascular complications in patients with CAD, including
beta-adrenergic blockers, antiplatelet therapies, statins, and
modifiers of the renin-angiotensin system (ACE inhibitors
and/or angiotensin receptor blockers), directed noninvasive
evaluations of the coronary anatomy, and selective use of
coronary artery revascularization have resulted in reduced
rates of perioperative MI and death compared with outcomes
in recent decades (569).
Despite these advances, cardiovascular complications rep-
resent the most common and most treatable adverse conse-
quences of noncardiac surgery. Those patients who have a
symptomatic MI after surgery have a marked increase in the
risk of death, reaching as high as 40% to 70% (570). Because
the consequences of infarction are so severe, management of
patients must continue after risk assessment in the postoper-
ative setting. As described in sections above, postoperative
ECG changes suggestive of MI predict poor outcome, and
postoperative management is an active process that requires
frequent intervention.
10.1. MI: Surveillance and Treatment
In contrast to clinically silent elevations in troponin, the
development of coronary artery plaque rupture that results in
thrombotic coronary artery occlusion requires rapid interven-
tion. Among eligible patients, rapid reperfusion therapy is the
cornerstone of therapy (571). Fibrinolytic therapy markedly
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reduces mortality when administered to patients who have MI
unrelated to a surgical procedure. However, because of the
substantial risk of bleeding at the surgical site, patients who
have recently undergone surgery have been excluded from all
trials of fibrinolytic therapy, and recent surgery is generally
considered a strong contraindication to fibrinolytic therapy.
Although fibrinolytic therapy has been administered to pa-
tients for life-threatening pulmonary embolus shortly after
noncardiac surgery, the fibrinolytic dosage has generally been
less and has been administered over a longer time interval
than is standard for the treatment of acute MI (572,573).
Immediate coronary angioplasty has been favorably com-
pared with fibrinolytic therapy in the treatment of acute MI
(574), but of greater importance is that the risk of bleeding at
the surgical site is believed to be less with direct angioplasty
than with fibrinolytic therapy. Only a single small study (575)
has evaluated the role of immediate angiography and angio-
plasty among 48 patients who were believed able to take
aspirin and intravenous heparin and to undergo immediate
angiography and PCI. This study suggested that such a
strategy is feasible and may be beneficial. However, time to
reperfusion is a critical determinant of outcome in acute MI,
and any hope of benefiting patients who have a perioperative
acute MI due to an acute coronary occlusion requires that
angiography and revascularization be performed rapidly (ie,
within 12 hours of symptom onset) (575,576). In addition,
these reperfusion procedures should not be performed rou-
tinely on an emergency basis in postoperative patients in
whom MI is not related to an acute coronary occlusion. For
instance, in cases of increased myocardial demand in a patient
with postoperative tachycardia or hypertension, lowering the
heart rate or blood pressure is likely to be of greater benefit
and is certain to carry less risk. Moreover, because of the
requirements for periprocedural anticoagulation and postre-
vascularization antiplatelet therapy, the benefits of revascu-
larization must be weighed against the risk of postoperative
bleeding, individualizing the decision for referral.
Although reperfusion therapy is an important therapy in acute
ST-segment elevation MI, the emphasis on reperfusion therapy
should not detract from pharmacological therapy, which is also
very important and has been shown to reduce adverse events in
such patients, as well as in patients with non–ST-elevation acute
coronary syndromes. Therapy with aspirin, a beta blocker, and
an ACE inhibitor, particularly for patients with low ejection
fractions or anterior infarctions, may be beneficial, whether or
not the patients are rapidly taken to the catheterization laboratory
(49). An extensive evidence-based review of therapy for ST-
segment elevation MI can be found in the ACC/AHA Guidelines
for the Management of Patients With ST-Segment Elevation
Myocardial Infarction (577). Although not intended specifically
for patients who have a postoperative MI, these guidelines are
nonetheless appropriate for these high-risk patients. Similarly,
the ACC/AHA Guidelines for Unstable Angina and Non–ST-
Segment Elevation Myocardial Infarction represent an important
template for management of this condition in the postoperative
setting (192).
In the approach to the long-term postoperative manage-
ment of noncardiac surgery patients, one should first appre-
ciate that the occurrence of an intraoperative nonfatal MI
carries a high risk for future cardiac events that are often
dominated by cardiovascular death (513,578). Patients who
sustain a perioperative MI should have evaluation of LV
function performed before hospital discharge, and standard
postinfarction medical therapy should be prescribed as de-
fined in the ACC/AHA Guidelines for the Management of
Patients With ST-Elevation Myocardial Infarction (49). The
ACC/AHA guidelines for post-MI evaluation in these types
of patients should be followed as soon as possible after
surgical recovery. The use of pharmacological stress (579) or
dynamic exercise (if feasible) for risk stratification should
also be a priority in patients to help determine who would
benefit from coronary revascularization. In all cases, the
appropriate evaluation and management of complications and
risk factors such as angina, HF, hypertension, hyperlipidemia,
cigarette smoking, diabetes mellitus (hyperglycemia), and
other cardiac abnormalities should commence before hospital
discharge. It is also important to communicate these new
observations and determinations of cardiac status and risk to
the physician and nonphysician providers who will be respon-
sible for arranging subsequent medical care and follow-up.
10.2. Long-Term Management
Although the occasion of noncardiac surgery brings a period
of increased cardiovascular risk, physicians should also use
the opportunity to ensure appropriate cardiovascular medical
therapy. Indeed, the requirement for vascular surgery indi-
cates a high cardiovascular risk alone. In a trial of 1404
patients with critical limb ischemia that investigated the
possible benefit of a molecular therapy to reduce bypass graft
failure, there was a 16% mortality rate at 1 year (404).
Medical therapy was lacking in many patients at study entry:
33% were not taking antiplatelet therapy, 54% were not
receiving lipid-lowering therapy, and 52% were not pre-
scribed beta-blocker medications.
Other risk factors may provide additional prognostic in-
sight. In studies of vascular surgery patients who had
follow-up for 40 to 48 months, cardiac events were signifi-
cantly more frequent in those who had a reduced LVEF of
less than 35% or 40% and who demonstrated at least a
moderate area of ischemia on dipyridamole myocardial per-
fusion imaging (578,580). Therefore, the perioperative car-
diovascular risk represents the most visible but not the largest
portion of morbidity and mortality that can be ameliorated by
the institution of recommended medical therapy.
These types of observations should encourage us to pay closer
attention to the medical outcome of patients seen for perioper-
ative evaluations, especially in the context of vascular surgery.
In the recently released ACC/AHA guidelines for the manage-
ment of patients with peripheral arterial disease, treatment with
a statin to achieve a low-density lipoprotein level of less than
100 mg per dL, control of blood pressure to less than 140/
90 mm Hg, cigarette smoking cessation, and antiplatelet therapy
all received class 1 indications (581). Institution of medical
therapy in the hospital is associated with increased compliance
(582), which makes early initiation preferable.
In other noncardiac surgical populations, it is clear that
preoperative clinical risk assessment, as determined by the
clinical criteria, LVEF, coronary angiography, dipyridamole
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myocardial perfusion imaging, and dobutamine echocardiogra-
phy, provides information concerning a patient’s long-term
cardiac risk. Cardiac mortality in the postoperative period
increases with higher clinical risk, lower LVEF (less than 35%),
multivessel CAD, abnormal myocardial perfusion imaging
scans, or multiple ischemic segments on dobutamine echocardi-
ography studies. Other studies (41,278,583) also confirm the
value of semiquantitative analysis of myocardial perfusion
imaging when these types of perioperative tests are used to
predict future cardiac events. All of these studies have the ability
to combine an assessment of myocardial ischemia and LV
function into a more useful clinical index; however, the extent of
ischemia or reduction in ventricular function achieves the best
level of prognostic utility for future cardiac events
(209,263,584). Overall, a normal or near-normal stress imaging
study suggests a relatively small risk, but the positive predictive
accuracy of abnormal studies is greatly enhanced by the estab-
lishment of a progressive gradient for that abnormality.
In general, the indications for additional screening or testing
in postoperative patients depend on individual patient character-
istics. It is important that the care team responsible for the
long-term care of the patient be provided with complete infor-
mation about any cardiovascular abnormalities or risk factors for
CAD identified during the perioperative period.
11. Conclusions
Successful perioperative evaluation and management of high-
risk cardiac patients undergoing noncardiac surgery requires
careful teamwork and communication between surgeon, an-
esthesiologist, the patient’s primary caregiver, and the con-
sultant. In general, indications for further cardiac testing and
treatments are the same as in the nonoperative setting, but
their timing is dependent on several factors, including the
urgency of noncardiac surgery, patient-specific risk factors,
and surgery-specific considerations. The use of both nonin-
vasive and invasive preoperative testing should be limited to
those circumstances in which the results of such tests will
clearly affect patient management. Finally, for many patients,
noncardiac surgery represents their first opportunity to re-
ceive an appropriate assessment of both short- and long-term
cardiac risk. Thus, the consultant best serves the patient by
making recommendations aimed at lowering the immediate
perioperative cardiac risk, as well as assessing the need for
subsequent postoperative risk stratification and interventions
directed at modifying coronary risk factors. Future research
should be directed at determining the value of routine
prophylactic medical therapy versus more extensive diagnos-
tic testing and interventions.
12. Cardiac Risk of Noncardiac Surgery:
Areas in Need of Further Research
Much progress has been made over the last few years
regarding perioperative evaluation of noncardiac surgery.
Eagle et al found that patients undergoing low-risk proce-
dures are unlikely to derive benefit from CABG before
low-risk surgery; however, patients with multivessel disease
and severe angina undergoing high-risk surgery might well
benefit from revascularization before noncardiac surgery
(60). Trials that identify specific subsets of patients in whom
preoperative coronary revascularization reduces perioperative
and long-term MI and death are needed. The most effective
method of preoperative coronary revascularization and the
value of complete revascularization are unknown at this time.
The benefit of cardiac testing and preoperative cardiac eval-
uation, especially in those patients with established CAD, has
been established (see Sections 5.2.3 and 5.3); what is unknown
is the cost-effectiveness and value of the various methods of
cardiac testing for reducing cardiac complications. Further stud-
ies in this area are welcomed. The implementation of various
strategies of beta blockade in patients undergoing major vascular
surgery is cost-effective and even cost-saving from a short-term
provider perspective (288), yet the efficacy and cost-
effectiveness of various medical therapies for specific subsets of
patients (eg, the role of beta blockers in those patients without a
positive stress test) are unknown.
Intraoperative and postoperative use of ST-segment monitor-
ing can be useful to monitor patients with known CAD or those
who are undergoing vascular surgery, with computerized ST-
segment analysis, when available, used to detect myocardial
ischemia during the perioperative period, and this type of
monitoring may be considered in patients with single or multiple
risk factors for CAD who are undergoing noncardiac surgery.
Although postoperative troponin measurement is recommended
in patients with ECG changes or chest pain typical of acute
coronary syndrome, its use is not well established in patients who
are clinically stable and have undergone vascular and intermediate-
risk surgery. The efficacy of monitoring patients for myocardial
ischemia and infarction, particularly the role of monitoring in
affecting treatment decisions and outcomes, is unknown.
Although randomized trials have examined the effect of
perioperative beta blockers on cardiac events surrounding sur-
gery, and observational studies have shown the benefit of statins
during the perioperative period, further evidence is needed with
regard to the length of time medical therapy needs to be initiated
before noncardiac surgery to be effective. This includes man-
agement of antiplatelet agents in the perioperative period.
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